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Increasing rates of antimicrobial resistance have become a worldwide problem 
predominantly caused by Gram-negative bacteria, especially by the family of 
the Enterobacteriaceae. This family falls within the phylum Proteobacteria, class 
Gammaproteobacteria and order Enterobacteriales. The Gram-negative bacteria of 
the genera Escherichia spp., Klebsiella spp., Enterobacter spp., Serratia spp., and 
Citrobacter spp., which are collectively called the coliforms, are members of the 
normal intestinal flora of humans and animals. 
As opportunistic pathogens, Enterobacteriaceae have become one of the most 
important causes of nosocomial and community acquired infections. Escherichia coli 
is a frequent cause of urinary tract infections. Klebsiella spp. and Enterobacter spp. are 
important causes of nosocomial pneumonia. All members of the Enterobacteriaceae 
can cause bloodstream infections and intra-abdominal infections.1,2 This may lead to 
secondary sepsis, a potentially fatal complication mediated by endotoxins. 
ß-Lactams (mainly cephalosporins and carbapenems), fluoroquinolones and amino-
glycosides constitute the main therapeutic choices to treat infections caused by 
these microorganisms.1 However, increasing resistance rates to these compounds 
have been reported in Europe in the past years.3,4 During the last two decades a 
worrisome trend has been the development of resistance to extended-spectrum 
cephalosporins, e.g. cefotaxime, ceftazidime and ceftriaxone.5,6 Such resistance is 
most often due to the presence of extended-spectrum ß-lactamases (ESBLs), but 
may also be due to plasmid-mediated or chromosomally hyperproduced AmpC 
ß-lactamase.7 Besides resistant to 3rd generation cephalosporins they are often 
resistant to different antibiotic families as fluoroquinolones, aminoglycosides and 
cotrimoxazole.8 As a result, more patients need antimicrobial treatment using so-
called ‘last resort’ agents. Carbapenems are considered as the best treatment 
options.4,9 The use of carbapenems has led to the rapid selection of carbapenem-
resistant Enterobacteriaceae.10 Antimicrobial treatment options for these multidrug 
resistant infections are limited. Only a few antimicrobial agents (e.g. colistin, 
tigecycline, fosfomycin and amikacin) with an uncertain in vivo efficacy and/or 
reported toxicity are left to treat these infections.
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1.2 Resistance trends in Europe
In Europe, antimicrobial resistance rates are provided by the European Antibiotic 
Resistance Surveillance System (EARS-Net). Overall, cephalosporin resistance has 
increased significantly across Europe from 2001 to 2008 with levels ranging from 
<1% up to 40% among invasive E. coli isolates. A significant increase between 2004 
and 2008 is reported for France as well as the Netherlands (Antimicrobial resistance 
surveillance in Europe 2009; www.ecdc.europa.eu). In 2008, combined resistance of 
3rd generation cephalosporins, fluoroquinolones and aminoglycosides is reported in 
2-23% of the isolates from different European countries. No data are available for 
carbapenem resistance in E. coli.
Multidrug resistance to three classes of antibiotics (3rd generation cephalosporins, 
fluoroquinolones and aminoglycosides) is demonstrated in 14% of the 
Klebsiella pneumoniae isolates from invasive infections. Data on carbapenem 
resistance is available for 84% of the K. pneumoniae isolates. Their prevalence 
as reported in 2008 varies from as high as 39% (Greece) to low (<1% in Nordic 
countries).
1.3 Resistance trends in the Leiden University Medical Center
The Leiden University Medical Center (LUMC) in the Netherlands is a teaching 
hospital and is a highly specialized national center for bone-marrow and solid organ 
transplantation and for cardiovascular surgery.
Between 2003 and 2007, similar resistance trends are observed in the LUMC with 
an increase of ESBL producing E. coli (5%) and K. pneumoniae (9%) in 2008. 
The resistance rates to ciprofloxacin of E. coli and K. pneumoniae have risen from 
8% to 14% and from < 1% to 7% respectively. Combined resistance of 3rd generation 
cephalosporins and aminoglycosides in 2008 is reported in 1.3% of the E. coli 
isolates and in 4.8% of the K. pneumoniae respectively. No carbapenem resistant 
isolates are reported.
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1.4 Origin of resistance
Antimicrobial resistance is not a new phenomenon. Resistance genes have an ancient 
origin as demonstrated by the recent discovery of genes conferring resistance to 
ß-lactams, tetracycline, and glycopeptides in permafrost sediments dating from 
30.000 years ago.11 Similarly, multidrug resistant bacteria have been recently 
cultured from soil samples of an over 4 million year old cave in New Mexico that 
had been geographically isolated from the surface of the planet.12 Resistance was 
found even to synthetic antibiotics that did not exist on earth until the 20th century. 
Although environmental reservoirs are well known as a possible source of antibiotic 
resistance genes detected in human pathogens, reports of antibiotic resistance 
genes from environmental bacteria with a high level of sequence similarity to those 
from human pathogens previously reported are limited. CTX-M-8 ß-lactamase in 
environmental bacteria of the genus Kluyvera,13 or qnrA-like genes from marine and 
freshwater bacteria of the genus Shewanella14 are examples of antibiotic resistance 
transferred from environmental bacteria to human pathogens. The environmental 
resistome is not only a reservoir of antibiotic resistance genes; it is also a generator 
of new mechanisms of resistance. The recently discovered carbapenem hydrolyzing 
New Delhi metallo-ß-lactamase is a good example of a new antibiotic resistance 
enzyme arising in the environment. Comparison of the genetic environments 
of blaNDM-1 in different bacterial species has identified the construction of the 
aphA6-blaNDM-1 chimera, which is likely to originate from Acinetobacter baumannii. 
15 
Introduction 13
1.5 Reservoirs of antimicrobial resistance 
Livestock are an important reservoir of antimicrobial-resistant Enterobacteriaceae. 
Excessive use of antibiotics in the veterinary sector has contributed to the selection 
and spread of multidrug resistant Enterobacteriacae.16 Although there is no complete 
evidence that agricultural use of antimicrobials is directly linked to development and 
dissemination of antibiotic resistance among human bacterial pathogens, different 
studies identified similarities in ESBL-producing E. coli isolates from chicken meat 
and humans according to mobile resistance elements, virulence genes and multilocus 
sequence typing.17-19 
Besides livestock, companion animals may also be a source for antimicrobial resistance 
genes. Surveys in pets, cats and dogs in particular, have identified multidrug resistant 
Enterobacteriaceae in healthy pets as well as in clinical diagnostic samples.20
In addition, many different antimicrobial resistance genes to various antimicrobial 
classes have been detected in water environments.21,22 River and lakes are examples 
of relevant putative reservoirs of multidrug resistant Enterobacteriaceae, since they 
collect surface waters from different origins, e.g. wastewater plants, water of urban or 
industrial effluents and agricultural activities, e.g. as found in Switzerland.23 Similarly, 
multidrug resistant Enterobacteriaceae have been detected in tap and drinking 
water, as well as drain and sewage water in India,24 household water supply in Dhaka, 
Bangladesh25 and in untreated drinking water in Portugal.26 These data implicate 
contaminated aquatic environments as a likely site for the exchange of antimicrobial 
resistance genes. 
Bacteria colonizing the human intestine also play a relevant role in the development 
and spread of antimicrobial resistance in the environment. Many horizontal gene 
transfers occur among the intestinal flora. This process is influenced by antibiotic 
use, altered colonization in critically ill patients and ingestion of contaminated food 
or water. 27,28 Multidrug resistant bacteria can then subsequently be transmitted via 
the hands.29 Recently, overseas travel as a risk factor for the acquisition of infections 
due to multidrug resistant Enterobacteriaceae has been described for infections 
due to quinolone-resistant Salmonella spp.,30 quinolone-resistant Shigella spp,31 and 
cotrimoxazole-resistant E. coli.32,33
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Figure 1 shows the dissemination of antibiotics and subsequent resistance within 
agriculture, aquaculture, wastewater treatment and associated environments. 
Figure 1. Dissemination of antibiotics and subsequent resistance within agriculture, aquaculture, wastewater treatment and associated 
environments. (adapted from Davies et al.) 34
Introduction 15
1.6 Genetics of resistance 
Resistance to antimicrobial agents can either be intrinsic or acquired. Intrinsic 
resistance comprises all of the inherent properties, which is located on the 
chromosome of a particular species. E. coli naturally produces a chromosomal 
non-inducible AmpC ß-lactamase expressed at a low level, which is responsible for 
resistance to penicillin.38 Other chromosomal resistance mechanisms include low 
permeability for a specific drug and/or due to the intrinsic presence of multidrug 
efflux pumps.
The second type is acquired resistance, in which a strain of an originally susceptible 
species becomes resistant. Acquired resistance mechanisms involve mutations in 
genes targeted by the antimicrobial agent or the transfer of resistance determinants 
borne on plasmids, bacteriophages, transposons and other mobile genetic 
elements.34,39 
In general this exchange is accomplished through the processes of transformation, 
transduction or conjugation (Figure 2).40
Figure 2. Acquisition of antimicrobial resistance (adapted from Aleksun and Levy)41
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Plasmids contain genes for resistance; they replicate independently of the host’s 
chromosome and can be distinguished by their origin of replication.
Multiple plasmids may be present within a single bacterium. Plasmids were and 
are the main vectors of antimicrobial resistance gene dissemination and exchange 
through ‘horizontal gene transfer’ with an extraordinary facility and lack of specificity 
between species.42
1.7 Antimicrobial drug targets
Most antimicrobial agents may be categorized according to their mechanism of 
action. The different antimicrobial drug targets in Gram-negative bacteria include 
the following:
 
Bacterial cell wall: The ß-lactam agents (the largest family of antibiotics) act on the 
bacterial cell wall. They inhibit the cell wall synthesis by binding to the penicillin 
binding proteins and interfere with structural cross linking of peptidoglycans. The 
ß-lactam family includes penicillins and derivatives, cephalosporins, carbapenems, 
monobactams and ß-lactam inhibitors.
Protein synthesis: Aminoglycosides interact with the conserved sequences of the 
16S rRNA of the 30S subunit. They cause misreading and premature termination of 
translation of mRNA. 
Nucleic acid synthesis: The fluoroquinolone classes inhibit DNA replication by 
interacting with the DNA gyrase (gyrase A and B) and topoisomerase enzymes 
(parC and parE). Cotrimoxazole is composed of two antibacterial drugs, 
sulfamethoxazole and trimethoprim, which act synergistically by inhibiting purine 
synthesis at different steps of the metabolic pathway of folic acid. Sulfonamide 
inhibits dihydropteroate synthetase (DHPS), which catalyses the formation of 
dihydrofolate from para-aminobenzoic acid. In the subsequent step of the pathway, 
trimethoprim inhibits dihydropholate reductase (DHFR), which catalyses the 
formation of tetrahydrofolate from dihydrofolate.
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Permeability of the bacterial cell membrane: Polymyxins, act on the cytoplasmic 
and outer membrane of gram negative bacteria. They bind to the phospholipids 
in the cytoplasmic membrane, causing loss of membrane integrity, leakage of 
cytoplasmic contents and finally cell death.
1.8 Main mechanisms of antimicrobial resistance in 
Enterobacteriaceae
Resistance to antimicrobial agents can be caused by four general mechanisms.35-37
1. Enzymatic modification
2. Target alteration
3. Decreased permeability of the bacterial membrane
4. Active efflux
Enterobacteriaceae are capable to combine all mechanisms mentioned above to 
achieve resistance to a single class or to multiple classes of antibiotics. 
Resistance to ß-lactam antibiotics may be due to mutations in the penicillin-binding 
proteins (PBPs) or reduced permeability of the cell wall by mutations in outer 
membrane proteins (OMPs) and increased efflux. 
The predominant mechanism of resistance to ß-lactams is the production of 
ß-lactamases. Two classification schemes exist for ß-lactamases: Ambler classes A-D, 
based on amino acid sequence homology and the Bush-Jacoby groups 1-4, based 
on substrate and susceptibility to the inhibitor clavulanic acid. Table 2 depicts and 
updated version of the functional classification scheme for ß-lactamases proposed 
initially by Bush in 1989,43 expanded in 1995 by Bush-Jacoby and Medeiros,44 and 
updated in 2009.45 A complete update and overview of the individual ß-lactamases 
is available at www.lahey.org/studies.
The mechanisms of resistance to frequently used antibiotics are listed in Table 1 
on the next page. An overview of the predominant resistance mechanisms are 














decreased outer membrane permeability
efflux








decreased outer membrane permeability
efflux
Class I AmpC ß-lactamase chromosome
Monobactams Aztreonam enzymatic modification
decreased outer membrane permeability
efflux
enzymatic modification









decreased outer membrane permeability
efflux
gyrA, gyrB, parC and parE
ompF, ompC, ompA, ompX
marAB, soxRS













decreased outer membrane permeability ompF, ompC, ompA 




enzymatic modification serine and metallo ß-lactamases** plasmid
Anti-folate 
agents
Sulfonamide target modification of enzyme 
dihydropteroate synthase (DHPS)
folP chromosome
enzymatic modification of target sul plasmid
Trimethoprim mutation in the enzyme 
dihydrofolate reductase (DHFR)
folA chromosome







decreased outer membrane permeability
RND efflux pumps (acrD) chromosome





Table 1. Resistance mechanisms and genes conferring resistance to the main antimicrobial classes in Enterobacteriaceae
*  ESBL: extended-spectrum ß-lactamases: most prevalent genes are blaTEM, blaSHV, blaCTX-M 
 AmpC: blaMOX, blaFOX, blaCMY, blaDHA, blaACC, blaMIR/ACT
**  Serine and metallo ß-lactamases: most -prevalent genes are blaKPC, blaNDM, blaVIM, blaIMP, and blaOXA-48
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Extended spectrum ß-lactamases: The most important class A enzymes are the 
ESBLs. They confer resistance to penicillins, extended-spectrum cephalosporins 
and aztreonam, and are generally inhibited by ß-lactamase inhibitors (i.e. clavulanic 
acid, tazobactam, sulbactam). TEM, SHV and CTX-M are the three main types of 
ESBLs described. The earliest ESBLs, first identified in the 1980s, were mutants 
of the plasmid-borne parent enzymes TEM-1, TEM-2 and SHV-1 ß-lactamases.7 
Over time, these enzymes have undergone amino acid substitutions, which resulted 
in over 300 currently known TEM and SHV ESBL variants. A massive shift in the 
distribution of ESBLs has occurred since 2000 with the spread of CTX-M type ESBLs 
of which five subgroups (groups 1, 2, 8, 9 and 25) are circulating worldwide, both in 
nosocomial and in community settings. 46
AmpC ß-lactamases: Several Enterobacteriaceae possesses chromosomal genes 
encoding for class C AmpCs (c-AmpC; e.g. Citrobacter freundii, Enterobacter 
spp., Serratia spp., Morganella spp.). Induction of c-ampC expression is a complex 
mechanism involving the regulatory genes ampR, ampD and ampG. These 
ß-lactamases confer resistance to cephalosporins and ß-lactam/ß-lactamase inhibitor 
combinations. Also, E. coli possess a c-AmpC but its expression is influenced by 
mutations in the promoter and attenuator regions, which may result in constitutive 
hyperproduction of c-AmpC. In addition, genes encoding AmpC ß-lactamases have 
‘escaped’ from the chromosomes of Citrobacter spp. and other genera to plasmids and 
are now circulating in various genera of the family Enterobacteriaceae. The enzymes 
they encode are called ACC, ACT, CMY, DHA, FOX, LAT, MIR and MOX, or ‘plasmid-
mediated AmpCs’.47 Like ESBLs, AmpC ß-lactamases hydrolyze 3rd generation 
cephalosporins, but unlike ESBLs, they are also active against cephamycins.
Carbapenemases: ß-lactamases that hydrolyze ß-lactam antibiotics including 
carbapenems are carbapenemases, which are either chromosomally or plasmid-
encoded. The most prevalent enzymes in Enterobacteriaceae are KPC, VIM, 
IMP, NDM-1 and OXA-48.48 Carbapenem resistance can also evolve by 
porin loss, reducing drug entry in strains already containing blaAmpC or ESBL-
activity.49 Most carbapenemase-producers are resistant to extended-spectrum 
(oxyimino) cephalosporins.50 Isolates producing such enzymes have decreased 
susceptibility to carbapenems, but with some of these enzymes (OXA-48-like 
enzymes) the organisms may appear fully susceptible to cephalosporins in vitro. 
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CA or TZBª   EDTA
Defining characteristic(s) Representative 
enzyme(s)
1 1 C Cephalosporins No  No Greater hydrolysis of cephalosporins 
than benzylpenicillin; hydrolyzes 
cephamycins




1e NIb C Cephalosporins No  No Increased hydrolysis of ceftazidime 
and often other oxyimino-ß-lactams
GC1, CMY-37
2a 2a A Penicillins Yes  No Greater hydrolysis of 
benzylpenicillin than cephalosporins
PC1
2b 2b A Penicillins,
early 
cephalosporins








Yes  No Increased hydrolysis of oxyimino-ß-





2br 2br A Penicillins No  No Resistance to clavulanic acid, 
sulbactam, and tazobactam
TEM-30, SHV-10




No  No Increased hydrolysis of oxyimino-ß-
lactams combined with resistance 
to clavulanic acid, sulbactam, and 
tazobactam
TEM-50
2c 2c A Carbenicillin Yes  No Increased hydrolysis of carbenicillin PSE-1, CARB-3
2ce NI A Carbenicillin,
cefepime
Yes  No Increased hydrolysis of carbenicillin, 
cefepime, and cefpirome
RTG-4
2d 2d D Cloxacillin Variable  No Increased hydrolysis of cloxacillin 
or oxacillin
OXA-1, OXA-10
2de NI D Extended-
spectrum
cephalosporins
Variable  No Hydrolyzes cloxacillin or oxacillin 
and oxyimino-ß-lactams
OXA-11, OXA-15
2df NI D Carbapenems Variable  No Hydrolyzes cloxacillin or oxacillin 
and carbapenems
OXA-23, OXA-48
2e 2e A Extended-
spectrum
cephalosporins
Yes  No Hydrolyzes cephalosporins.  
Inhibited by clavulanic acid but not 
aztreonam
CepA





3a 3 B (B1)
B (B3)
Carbapenems No  Yes Broad-spectrum hydrolysis including 









aCA, clavulanic acid; TZB, tazobactam.
bNI, not included
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Aminoglycosides: The major aminoglycoside resistance mechanism is based 
upon the presence of enzymes modifying the aminoglycoside molecule. 
These proteins are classified into three major classes according to the type of 
modification; AAC (N-acetyltransferases), ANT (O-nucleotidyltransferases) and APH 
(O-phosphotransferases). They are further divided into subclasses that are based on 
the site of modification and the spectrum of resistance within this class. Other known 
mechanisms of aminoglycoside resistance include decreased outer membrane 
permeability, active efflux and target alteration.51 More recently, methylation of 
the aminoglycoside binding site by 16S rRNA methylases (armA, rmtA-D, rmtF-G, 
npmA) has been found to confer high-levels of resistance to all aminoglycosides 
except streptomycin.52,53
Fluoroquinolones: Resistance to fluoroquinolones is usually mediated by 
chromosomal mutations in the quinolone resistance determining region (QRDR) 
that encodes DNA gyrase (gyrA and gyrB) and topoisomerase (parC and parE). 54 
Nevertheless, low level resistance can also arise from the expression of plasmid-
mediated quinolone resistance (PMQR) such as:
• qnrA, -B, -C, -D, qnrS that encode proteins protecting the DNA gyrase from the 
quinolone action.55
• aminoglycoside acetyltransferase encoded by the aac(6’)-Ib-cr gene that also 
acetylates quinolones.56
• plasmid-mediated quinolone efflux pumps, qepA 57 and oxqAB.58
1.9 Porins and efflux pumps in antimicrobial drug resistance
Outer membrane proteins: the outer membrane (OM) of Gram-negative bacteria 
constitutes the first permeability barrier that protects the cells against environmental 
stress. Simultaneously, it allows the selective uptake of essential nutrients and the 
secretion of metabolic waste products. The major route of entry for hydrophilic 
antibiotics through the OM is facilitated by water-filled diffusion channels formed 
by the outer membrane proteins (OMPs), called porins. Bacteria usually produce 
many porins; approximately 105 porin molecules are present in a single cell of 
E. coli. One of the bacterial strategies for drug resistance is to limit the intracellular 
access via modification of porins. It has been demonstrated that the expression 
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levels of the porins OmpC and OmpF, not only controls the permeability of the 
outer membrane to glucose and nitrogen uptake under nutrient limitation,59 but 
may also be differentially regulated by the concentration of certain antibiotics in the 
environment.60,61 One of the earliest examples is loss of the OmpF porin from E. coli 
in resistance to ß-lactams, which was found in 1981.62
OmpX is another OMP that is expressed in an inverse manner compared to the 
expression of OmpC and OmpF.63,64 The expression of OmpX is upregulated instead 
of reduced upon exposure to e.g. fluoroquinolones.51
Mutations affecting the expression and/or function of the porins have a direct impact 
on the susceptibility to antimicrobials. These mutations can have different effects, 
such as (most commonly) porin loss, a modification of the size or conductance of 
the porin channel (Figure 3).
Figure 3. Multidrug resistance mechanisms associated with porin modification. (adapted from Pagès et. al.)65 This figure shows the various 
resistance mechanisms that are associated with porin modification. The ß-lactam molecules and porin trimers are represented by blue 
circles and pink cylinders, respectively. The thickness of the straight arrows reflects the level of ß-lactam penetration through porin channels. 
The curved arrows illustrate the uptake failure that occurs with: a change (decrease) in the level of porin expression; an exchange in the type 
of porin that is expressed (restricted-channel porin); and mutation or modification that impairs the functional properties of a porin channel 
(mutated porin). The effect of pore-blocking molecules (black circles) is shown at the bottom of the figure.
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Today, porins involved in antibiotic resistance have been identified in many bacterial 
species (Table 3). For example, carbapenem resistance in K. pneumoniae and E. coli 
may be caused by the presence of carbapenemases, but can also be caused by loss 
of OMPs combined with plasmid- mediated ß-lactamase.66,67 
Another type of mutation includes those affecting regulatory proteins that control 
the expression of porin-encoding genes. For instance, the ompB operon, which 
contains the genes ompR and envZ, is known to regulate the expression of OmpC 
and OmpF in E. coli.68 In addition to the ompB locus, many other proteins, like Rob, 
SoxS and MarA are known to participate in the regulation of the transcription of 
porin genes. Overall, mutations that lead to the loss, downregulation, or alterations 
of porins have a direct impact on antimicrobial susceptibility by limiting the rate at 
which an antimicrobial agent can enter the cell. Combined with secondary resistance 
mechanisms (e.g. ß-lactamases, target alteration, efflux) a bacterium can acquire 
high-level resistance.
Efflux pumps: In addition to the influx problem, several recent reports have 
shown a significant increase in the dissemination of Enterobacteriaceae with active 
antibiotic efflux.69 This efflux occurs due to the activity of membrane transporters 
proteins, the so-called drug efflux pumps. There are essentially five families of 
chromosomally encoded bacterial efflux pumps: the resistance-nodulation-division 
(RND), major facilitator superfamily (MFS), multidrug and toxic compound extrusion 
(MATE) and small multidrug resistance (SMR) family. The RND efflux pumps, such 










Cephalosporins, carbapenems, fluoroquinolones, and chloramphenicol
Carbapenems
Klebsiella oxytoca OmpK36 Carbapenems






Imipenem, cefepime and cefpirome
Table 3. Examples of porins related to antibiotic resistance in different species
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TolC-associated efflux pumps.70 The overexpression of these efflux pump genes is 
related to antibiotic resistance in clinical E. coli isolates.71,72
In the past decade, plasmid-encoded efflux pumps have been identified. The 
plasmid-mediated quinolone resistance determinant qepA was recently detected 
in clinical isolates of E. coli from Belgium73 and Japan.57 Another plasmid-encoded 
RND efflux pump, oxqAB, has been identified in clinical isolates of E. coli and 
K. pneumoniae in Korea58 and Spain.74
1.10 Rapid detection of antimicrobial resistance mechanisms
Microbiological laboratories play a central role in the combat against antimicrobial 
resistance trends by rapid and proper recognition of resistant bacteria. Currently, 
susceptibility testing in clinical microbial diagnostic laboratories is performed 
using standardized susceptibility testing methods such as disk diffusion or by the 
use of automated systems. Routine diagnostics end at this step, as it provides 
the required information for the treatment of a patient. With the emergence and 
growing complexity of antimicrobial drug resistance, it would be advantageous to 
rapidly characterize both phenotypic and molecular traits of Enterobacteriaceae. 
To obtain a better understanding of the molecular epidemiology and characteristics 
of resistant Enterobacteriaceae more information is required, e.g. the type of 
antimicrobial resistance mechanism, presence or absence of resistance genes and 
mutations conferring resistance. Besides the detection of resistance mechanism, 
typing of isolates and detection of virulence determinants provides crucial additional 
information. To fully understand the development and dissemination of resistance, 
it is not only important to genetically characterize the overall extent and spread of 
antibiotic resistance in outbreak settings, but particularly in endemic, clinical strains. 
The clinical diagnostic microbiology field should be aiming towards surveillance 
and early detection of resistance. In addition, comprehensive assessment of the 
overall abundance in antibiotic resistance in all bacteria is likely to provide valuable 
insights. These insights may help the development of newer antibiotics or other 
specific targets to control their spread. 
Ideally, a rapid system should investigate all resistance traits in one single test 
and should provide easy to interpret results the same day the test is performed. 
Moreover, the assay should be able to identify specific variants of alleles that 
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encode for proteins with a different impact on the antibiotic resistance phenotype. 
Finally, the methodology should be easy to perform, relatively cheap, accurate and 
versatile enough to be regularly updated according to the evolution of the antibiotic 
resistance traits. 
1.11 Molecular characterization of isolates
 
During the past decade, various novel applications focusing on the detection of 
antimicrobial resistance genes/mechanisms have been developed. Next to multiplex 
PCR, the introduction of microarrays has allowed the simultaneous identification of 
a large number of genes of interest in a single assay. Biophysical technologies, 
such as matrix-assisted laser desorption/ionization time-of flight mass spectrometry 
(MALDI-TOF MS) also allows rapid identification of specific antibiotic resistance 
mechanisms. This includes the rapid detection of clinically important ß-lactamases, 
such as ESBLs and carbapenemases.52,75-78 Despite these advances in MALDI-TOF 
MS technology, the possibilities are limited to the detection of resistance involving 
enzymatic hydrolysis, which still needs complex sample preparation of bacterial 
extracts and special skills for the interpretation of the spectra. 
Advances in DNA sequencing technology have made it possible to sequence 
entire bacterial genomes. This technique has successfully been applied in genomic 
studies on typing and antimicrobial resistance in Neisseria meningitides,79 
MDR, Mycobacterium tuberculosis,80 Staphylococcus aureus,81 the German 
enterohemorrhagic E. coli O104:H4 outbreak strain,82 and Bacillus anthracis.83 
A number of studies describing whole genome sequencing of clinical isolates in 
order to characterize the genetic determinants of antibiotic resistance have been 
described.84-87
PCR-based techniques: For antimicrobial-resistant bacteria carrying specific 
resistance genes, multiplex PCR detection methods are available. Rapid identification 
of clinically relevant antimicrobial resistance genes in Enterobacteriaceae, such as 
ESBLs,88,89 plasmid-mediated AmpC,90 plasmid-mediated quinolone resistance 
genes,91,92 and carbapenemases93 can be performed once a bacterial isolate is 
cultured. Quantitative reverse transcription PCR can be utilized for quantification of 
RNA expression levels of genes.
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Microarray: The development of microarray based approaches has been another 
response to the challenge of rapid identification of multiple resistance mechanisms 
in a single isolate. Several microarrays for the genotyping of ß-lactamase genes 
have been developed. In a pilot study, we evaluated the ability of a commercially 
available microarray (Identibac AMR-veTM Array Tube) to detect clinically important 
ß-lactamases from the ESBL families (blaTEM, blaSHV, and blaCTX-M), and resistance 
genes to aminoglycosides, fluoroquinolones and cotrimoxazole in thirty-seven 
clinical K. pneumoniae isolates. The microarray reliably detected and distinguished 
the most prevalent ESBL encoding enzymes from the five groups of the CTX-M 
family. There was 72-88% correlation between the phenotypic antimicrobial 
resistance and the microarray results for aminoglycosides and cotrimoxazole. For 
susceptible isolates, the overall agreement was between 70-93%. This microarray 
is a useful tool to complement phenotypic susceptibility testing and surveillance of 
antibiotic resistance determinants in a clinical laboratory. 
Another commercially available microarray is launched by a Dutch company, 
CheckPoints B.V. This microarray is able to detect clinically relevant ESBLs, 
carbapenemases and AmpC genes. It provides definitive results within the same 
working day, allowing rapid implementation of isolation measures and appropriate 
antibiotic treatment. This company collaborates with various national and 
international research groups to evaluate and update their products.94-100
Whole genome sequencing: Direct detection of each of all resistance determinants 
in a single test requires technology with efficient multiplexing capabilities well 
beyond that of current PCR techniques and will most likely be based on whole 
genome sequencing (WGS). This technique is developing at incredible speed 
and application in clinical microbiology seems a matter of time. In theory, WGS 
technology provides complete characterization of clinical isolates with respect to 
resistance genes, their level of expression, mutations responsible for resistance, as 
well as the presence of virulence genes. Comparing isolates for epidemiological or 
evolutionary purposes is done in the same experiment. Thus, within one working 
day, all there is to know about a bacterial isolate should be available, both for 
diagnostic and research purposes. Although in its current form it may not be suited 




1.12 Scope of the thesis
The aim of the research described in this thesis is to obtain more insight into the 
mechanisms of antimicrobial resistance in multidrug resistant Enterobacteriaceae, 
recovered at the Leiden University Medical Center, the Netherlands. This 
will be investigated using different phenotypic and molecular techniques.
In addition, clonal relatedness among E. coli isolates will be characterized by 
AFLP and MLST to identify the sequence types present. Finally, a first step 
towards complete characterization of clinical isolates with respect to resistance 
genes, mutations responsible for resistance, the presence of virulence genes, 
as well as their sequence type will be made using whole genome sequencing. 
In this thesis genetic characterization of antimicrobial resistance mechanisms in 
Enterobacteriaceae will be performed using different techniques, which have been 
described in section 1.11:
• PCR and sequence analysis
• Quantitative reverse transcription PCR (qRT-PCR)
• Microarrays
• Whole genome sequencing (WGS)
In Chapter 2 resistance mechanisms are characterized in a collection of clinical 
Enterobacteriaceae resistant to ciprofloxacin and cephalosporins. Molecular 
detection of resistance genes is performed using PCR and sequence analysis of 
the specific targets for fluoroquinolone and ß-lactam resistance. Clonal relatedness 
among the E. coli isolates is characterized by the use of AFLP and multilocus 
sequence typing.
 
Chapter 3 will go into further detail with the investigation of the contribution of 
increased efflux activity and decreased influx to fluoroquinolone resistance in clinical 
E. coli isolates. Therefore a modified high-throughput phenotypic efflux assay and 





As described in Chapter 4, AmpC-mediated resistance is another clinically 
relevant and emerging resistance mechanism in Enterobacteriaceae. This study 
investigates whether increased AmpC expression is a mechanism involved 
in cefoxitin resistance in clinical cefoxitin-resistant E. coli isolates and if this 
influences 3rd generation cephalosporin activity. Therefore phenotypic AmpC 
assays, conventional and multiplex PCR and sequence analysis where appropriate, 
quantitative reverse transcription PCR and in depth analysis are all used. 
 
Chapter 5 concerns a prospective cohort study among travelers from the 
Netherlands to investigate the acquisition and duration of rectal carriage of the 
predominant resistance mechanism in Enterobacteriaceae, i.e. the presence of 
ß-lactamases: ESBLs, plasmid-mediated AmpCs and carbapenemases, after foreign 
travel. Rapid molecular characterization of all Enterobacteriaceae is performed using 
Check-MDR CT103, a commercially available microarray, and MLST is performed on 
all E. coli isolates. In addition, potential travel-associated risk factors are investigated.
In Chapter 6 the performance of the next-generation sequencing bench top, 
the Ion Torrent Personal Genome Machine® is used for the combined detection 
of antimicrobial resistance, housekeeping, and virulence genes in clinical E. coli 
isolates.
Finally in Chapter 7, implications of the findings as well as the role of innovative 
applications in the rapid detection of antimicrobial resistance mechanisms for 
clinical microbiology in the next era are discussed, with special emphasis on the 
possible role of whole genome sequencing in future clinical microbiology.
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2.1  Abstract
Objectives: To characterize the mechanisms of fluoroquinolone and cephalosporin 
resistance in Enterobacteriaceae from a Dutch teaching hospital in 2008.
 
Methods: We sequenced gyrA, gyrB, parC and parE. The presence of plasmid-
encoded genes qnrA, qnrB, qnrS, aac(6’)-Ib, qepA, blaTEM, blaSHV, blaOXA, blaCTX-M and 
blaampC was studied by PCR. Escherichia coli isolates were further characterized by 
AFLP and multilocus sequence typing (MLST). 
Results: In total, 49 Escherichia coli, 16 Klebsiella pneumoniae and three 
Enterobacter cloacae isolates were investigated. Mutations in gyrA were found in 
all E. coli isolates. Forty-five (92%) E. coli isolates carried at least one point mutation 
in parC. Most E. coli isolates (59%) also carried mutations in parE, of which I529L 
was the most prevalent. I529L was unequivocally associated with E. coli sequence 
type (ST) 131. This single nucleotide polymorphism (SNP) was later also found in 
eight out of nine ST131 strains from another collection. Twenty-nine E. coli isolates 
carried extended spectrum ß-lactamase (ESBL) genes, predominantly blaCTX-M-15. 
In E. coli, aac(6’)-Ib-cr was the predominant plasmid mediated resistance mechanism, 
whereas in K. pneumoniae qnr genes were found mostly. In K. pneumoniae isolates, 
qnr and aac(6’)-Ib-cr co-occurred with ESBL genes (n=13; blaCTX-M and blaSHV) and/or 
blaampC (n=3; blaDHA-1). 
 
Conclusion: E. coli ST131 was the predominant clone, which accumulated a high 
number of chromosomal mutations. The I529L SNP in parE was a signature of 
most, but not all ST131 strains. In contrast to E. coli, fluoroquinolone resistance 
mechanisms were predominantly plasmid-encoded in K. pneumoniae.
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2.2 Introduction
Fluoroquinolones are among the most frequently prescribed antimicrobial 
agents worldwide. Data from the European Antimicrobial Resistance Surveillance 
Network (EARS-net) show that fluoroquinolone resistance has increased 
significantly across Europe since 2001, with levels ranging from 7-53% in 2007.1 
Between 2003 and 2007, resistance rates of Escherichia coli to ciprofloxacin have 
risen from 8 % to 14% and for Klebsiella pneumoniae from < 1% to 7% in the Leiden 
University Medical Center (LUMC), a tertiary care hospital in the Netherlands. In 
2008, 5% of E. coli and 9% of K. pneumoniae isolates were extended spectrum 
ß-lactamase (ESBL) producers.
Quinolone resistance in E. coli usually occurs due to stepwise mutations in the 
quinolone resistance-determining regions (QRDRs) of gyrases (gyrA and gyrB) and/or 
topoisomerase IV (parC and parE), which are located on the bacterial chromosome. 
Since 1998, plasmid-mediated quinolone resistance (PMQR) determinants have 
emerged: qnr (qnrA-D, qnrS), aac(6’)-Ib-cr and qepA. qnr genes encode for proteins, 
which protect type II topoisomerases from quinolones. Aac(6’)-Ib-cr is a variant of 
aminoglycoside acetyltransferase and is responsible for reduced susceptibility to 
ciprofloxacin and norfloxacin by N-acetylation of a piperazinyl amine. The qepA 
gene encodes a quinolone efflux protein.2
In Europe, many authors have reported the dissemination of PMQR genes in 
Enterobacteriaceae, which are often associated with ESBLs or plasmid-mediated 
blaAmpC ß-lactamases.
3 However, data regarding the resistance mechanisms of 
fluoroquinolone resistance in cephalosporin-resistant Enterobacteriaceae in the 
Netherlands are limited. 
Therefore, we investigated the resistance mechanisms in a collection of 
Enterobacteriaceae from inpatients and outpatients recovered at the LUMC in 
2008. Clonal relatedness among the E. coli isolates was characterized by the use of 
AFLP and multilocus sequence typing (MLST).
36 Chapter 2
2.3 Materials and methods 
2.3.1 Bacterial isolates and antimicrobial susceptibility testing
Isolates were screened for reduced susceptibility to second and/or 3rd generation 
cephalosporins and ciprofloxacin as determined by the VITEK2® system (BioMérieux, 
Marcy-l’Étoile, France) in our routine laboratory from January to December 2008. 
MICs for ciprofloxacin and levofloxacin were determined using Etests (AB Biodisk, 
Solna, Sweden) according to the manufacturer’s instructions. MICs were interpreted 
using EUCAST criteria (http://www.eucast.org/clinical_breakpoints/). Nonrepetitive 
isolates with resistance to cephalosporins and ciprofloxacin (MIC of ≥ 0.125 mg/L) 
were included. 
2.3.2 Molecular detection of resistance genes
Mutations in gyrA, gyrB, parC, parE, and the presence of qnrA, qnrB, qnrS, aac(6’)-Ib, 
qepA, and the ß-lactamase genes blaTEM, blaSHV, blaOXA, blaCTX-M and blaAmpC were 
investigated by the use of polymerase chain reaction (PCR) and sequence analysis 
where appropriate.
For the primer design, an alignment of available gene sequences in GenBank® was 
made using the AlignX program (Vector NTI Advance 11, Invitrogen).
All primer sequences, PCR conditions and annealing temperatures are shown in 
Table 1. Amplification products were sequenced at the Leiden Genome Technology 
Center (LGTC®, Leiden, The Netherlands) with the same primer pairs as used for 
PCR. 
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gyrB TCTACTGCTTYACCAACAACA CGTCCGCATCGGTCATGAT 704 58
parC ATGGCAGAGCGCCTTGCG GCCGTCRAAGTTTGGCAC 437 58
parE CGGAAGATATCTGGGATCG TCTCTTCTTCCGTCAGYGC 703 58
qnrA qnrA2 GTTAAACCAGGTCTGCTGAC TTAGGTCAGCAGCTTCTCCT 480 55
qnrA qnrA5/6 GGATTTCTCACGCCAGGATT ACTCCCAAGGGTTCCAGCA 605 55
qnrB qnrB1 GGCTGYCAGTTYTATGATCG CCAAGMCGYTCCAKGAGC 502 55
qnrB qnrB3 CTTAACGCCTTGTAAATCAACG ATGGCTCTGGCACTCGTTG 584 55
qnrS qnrS ACAATCATACATATCGGCACC TTAGTCAGGATAAACAACAATAC 646 55
aac-6’-Ib ATGACTGAGCATGACCTTGC TTAGGCATCACTGCGTGTTC 518 58
qepA CGAGTATCGTGATCCGGAC AAGATGTAGACGCCGAACAT 290 60
blaTEM TCGGGGAAATGTGCG TGCTTAATCAGTGAGGACC 972 60
blaSHV GCCGGTTATTCTTATTTGTCGC ATGCCGCCGCCAGTCA 1027 60
blaCTX-M1 family TCTTCCAGAATAAGGAATCCC CCGTTTCCGCTATTACAAAC 909 60
blaCTX-M2 family ATGATGACTCAGAGCATTCGCCG TCAGAAACCGTGGGTTACGATTTTC 876 60
blaCTX-M8 family AYGATGAGACATCGCGTTAAGCGG TTAATAACCGTCGGTGACGATTTTC 876 60
blaCTX-M9 family ATGGTGACAAAGAGAGTGCAACGG GATGATTCTCGCCGCTGAAGCC 861 60
blaCTX-M26 family ATGATGAGAAAAAGCGTAAGGCGG TTAATAACCGTCGGTGACAATTCTG 876 60
blaMOX GCTGCTCAAGGAGCACAGGAT CACATTGACATAGGTGTGGTGC 520 60
blaCIT TGGCCAGAACTGACAGGCAAA TTTCTCCTGAACGTGGCTGGC 462 60
blaDHA AACTTTCACAGGTGTGCTGGGT CCGTACGCATACTGGCTTTGC 405 60
blaACC AACAGCCTCAGCAGCCGGTTA TTCGCCGCAATCATCCCTAGC 346 60
blaEBC TCGGTAAAGCCGATGTTGCGG CTT CCA CTG CGG CTG CCA GTT 302 60
blaFOX AACATGGGGTATCAGGGAGATG CAAAGCGCGTAACCGGATTGG 190 60
PCR was performed in a 50 µL PCR mixture, including 10 µL of template DNA, 0.5 µM concentration of each primer (Biolegio B.V., Nijmegen, 
the Netherlands) and 25 µL Hotstar Taq Master Mix (Qiagen Benelux B.V., Venlo, the Nederlands). The thermal cycling conditions consisted 
of an initial incubation of 15 minutes at 95°C followed by 40 cycles of 10 seconds at 95°C, 20 seconds at different annealing temperatures 
(listed in Table 1) and 2 minutes at 72°C and a final elongation step of 10 minutes at 72°C. PCR was performed using a MyCyclerTM Thermal 
Cycler (Bio-Rad, Veenendaal, The Netherlands). Products were analyzed by agarose gel electrophoresis.
Table 1. Primers used in this study
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2.3.3 Molecular typing of E. coli isolates
All E. coli isolates were typed comparatively using AFLP, as described previously.4 
Genotypic relatedness was evaluated using BioNumerics software v. 6.1 
(Applied Maths, St-Martens-Lathem, Belgium). Isolates linked at 90% or above 
were considered related and were designated by capital letters A through F. 
MLST was performed using seven housekeeping genes (adk, fumC, gyrB, icd, mdh, 
purA and recA) using the MLST Databases at the Environmental Research Institute, 
University College Cork website (http://mlst.warwick.ac.uk/mlst/). 
2.4 Results and discussion
The primary purpose of the present study was to characterize the resistance 
mechanisms to fluoroquinolones in enterobacterial isolates of our hospital, 
since these data from the Netherlands are scarce. A total of 68 nonrepetitive 
enterobacterial isolates were analyzed: 49 E. coli, 16 K. pneumoniae, and three 
Enterobacter cloacae. Table 2 shows the results for E. coli. 
In total, 44 E. coli isolates had double mutations in gyrA, at codons 83 
(S83L) and 87 (S87N, -G, or -H). While these 44 isolates had MICs of 
ciprofloxacin and levofloxacin well above the I/R breakpoint (> 1 mg/L), four 
isolates with only one mutation in gyrA had MICs below the EUCAST S/I 
breakpoint of levofloxacin (1 mg/L) but higher than those for wildtype isolates 
(≤ 0.25 mg/L). Likewise, MICs of ciprofloxacin for these four isolates were below at 
or just over the S/I breakpoint of ciprofloxacin (0.5 mg/L), but still above wildtype 
MICs (≤ 0.064 mg/L).
Forty-five (92%) E. coli isolates carried at least one point mutation in parC, mainly 
S80I, followed by E84V. No mutations were found in gyrB. These findings were in 
accordance with those of others worldwide.2
Thirty-two of the 49 (65%) E. coli isolates carried four to five mutations in the QRDR 
regions of gyrA, parC and parE combined. This number of accumulated mutations 
is high compared with those reported by others.5,6 The majority of isolates with a 
high number of QRDR mutations were E. coli ST131.








type CIPc LVXd gyrA parC parE PMQR ß-lactamase
2135 I abd. drain* 3076 u 0.25 0.5 S83L WTe WT - -
2144 O abd. drain 48 u 0.25 0.75 S83L WT WT - TEM-20
2466 I abd. drain 131 D 0.50 0.75 S83L WT S458A,
I529L
- -
2027 O urine 38 u 0.75 0.75 S83L S57T, S80I WT - CTX-M-15
2543 O urine 58 u 4 6 S83L, D87N S80I WT - -
1495 O urine 88 F 6 4 S83L, D87N E84K WT - -
1508 O urine 167 u 6 4 S83L, D87N S80I WT - CTX-M-1
2580 O blood 354 u 6 4 S83L, D87N S80I I355T - -
2480 O blood 1011 u 6 8 S83L, D87N S80I WT - CTX-M-1
2717 O urine 3077 u 8 6 S83L, D87N S80I I355T - -
2521 I sputum 167 E 12 8 S83L, D87N WT WT - -
1965 O wound 10 u 24 8 S83L, D87N S80I WT - CTX-M-1
2020 O urine 405 u >32 6 S83L, D87N S80I WT aac(6’)-
Ib-cr
CTX-M-15
2239 O urine 533 u >32 12 S83L, D87N S80I, E84G WT - SHV-12
1514 I urine 624 u >32 12 D87Y S80I WT - CTX-M-1
1632 O urine 648 B >32 12 S83L, D87N S80I S458A aac(6’)-
Ib-cr
CTX-M-15
2722 O urine 617 u >32 16 S83L, D87N S80I S458A - CTX-M-15
1604 O urine 88 F >32 24 S83L, D87N S80I S458A - -
2207 I urine 224 u >32 24 S83L, D87N E84K WT - -
2413 O urine 10 u >32 >32 S83L, D87N S80I S458A - CTX-M-1
1936 I urine 131 A >32 >32 S83L, D87N S80I, E84V I529L aac(6’)-
Ib-cr
-
2401 I thor. drain$ 131 A >32 >32 S83L, D87N S80I, E84V I529L aac(6’)-
Ib-cr
CTX-M-15
2506 I urine 131 D >32 >32 S83L, D87G S80I S458A,
I529L
- CTX-M-14
1611 O urine 131 A >32 12 S83L, D87N S80I, E84V I529L aac(6’)-
Ib-cr
CTX-M-15
1626 O urine 131 A >32 12 S83L, D87N S80I, E84V I529L aac(6’)-
Ib-cr
CTX-M-15
1629 O urine 131 A >32 >32 S83L, D87N S80I, E84V I529L aac(6’)-
Ib-cr
CTX-M-15
1945 O urine 131 A >32 12 S83L, D87N S80I, E84V I529L - CTX-M-15
2069 O urine 131 A >32 >32 S83L, D87N S80I, E84V I529L - -
2137 O blood 131 A >32 >32 S83L, D87N S80I, E84V I529L - CTX-M-27





Table 2. Distribution of fluoroquinolone resistance, amino acid substitutions and ESBL resistance among E. coli (n=49) isolates from the 
LUMC with ST and AFLP type
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An unexplained preponderance of an I529L mutation in parE, which is infrequently 
found by others, prompted us to further characterize these isolates by the use of 
AFLP and MLST in order to investigate the possible presence of a clone (Figure 1). 
Results not only showed that ST131 was the most prevalent type among our isolates, 
but also that the I529L mutation in parE was found exclusively in ST131 isolates, 
irrespective of AFLP type (A and D, Table 2). Thus, I529L was the most prevalent 
parE mutation in our collection. The closely related ST131 isolates of AFLP type A 
originated from inpatients as well as outpatients. 
aPatient status: I = inpatient; O = outpatient 
*abd. drain = abdominal drain fluid
$thor. drain = thoracic drain fluid









type CIPc LVXd gyrA parC parE PMQR ß-lactamase
2505 O urine 131 A >32 >32 S83L, D87N S80I, E84V I529L aac(6’)-
Ib-cr
CTX-M-15
2517 O urine 131 A >32 16 S83L, D87N S80I, E84V I529L aac(6’)-
Ib-cr
CTX-M-15
2574 O urine 131 A >32 >32 S83L, D87N S80I, E84V I529L aac(6’)-
Ib-cr
-
2504 O urine 156 u >32 >32 S83L, D87N S80I, E84G WT aac(6’)-
Ib-cr
-
2585 I rectal swab 156 u >32 >32 S83L, D87N S80I, E84A WT - CTX-M-15
1889 O urine 167 u >32 >32 S83L, D87N S80I S458A aac(6’)-
Ib-cr
CTX-M-15
1941 O urine 167 E >32 >32 S83L, D87N S80I WT - -
2274 O urine 167 E >32 >32 S83L, D87N S80I WT - -
2218 O blood 362 u >32 >32 S83L, D87H S80I WT aac(6’)-
Ib-cr
CTX-M-55
2418 I urine 38 u >32 >32 S83L, D87N S80I, E84G WT aac(6’)-
Ib-cr
CTX-M-15
2525 O urine 88 u >32 >32 S83L, D87N S80R S458A - -
1793 I rectal swab 453 u >32 >32 S83L, D87N S80I WT - TEM-28
1502 O urine 648 B >32 >32 S83L, D87N S80I S458A aac(6’)-
Ib-cr
-
2230 O urine 648 B >32 >32 S83L, D87N S80I S458A - -
2556 I urine 648 B >32 >32 S83L, D87N S80I S458A aac(6’)-
Ib-cr
-
2412 O urine 1193 u >32 >32 S83L, D87N S80I L416F - -
1946 I urine 393 C >32 >32 S83L, D87N S80I L416F - TEM-52
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Only two patients had been admitted to the kidney transplant ward concurrently. 
Otherwise no epidemiological links between patients could be found. Transfer of 
a single isolate between the patients with ST131, AFLP type A, therefore seems 
highly unlikely. 
Figure 1. AFLP patterns and dendrogram of 49 cephalosporin- and fluoroquinolone-resistant E. coli isolates. Numbers in the horizontal 
axis indicate percentage similarity as determined by the Pearson correlation coefficient and unweighted pair group method with arithmetic 
averages. The vertical dotted line marks the isolate delineation level (90%). The KML no. on the right indicates the isolate ID no. The letters 
indicate the different clusters (A-F) or unrelated isolates (u). The different STs are indicated by numbers. 
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To investigate whether the I529L mutation was a single nucleotide polymorphism 
(SNP) of ST131, we sequenced parE of nine additional E. coli ST131 isolates. These 
isolates had recently been isolated from residents in the Leiden area after (not 
before) returning from travel outside Europe. The MICs of ciprofloxacin for these 
isolates ranged from 0.25 to > 32 mg/L. Eight of these nine isolates showed the 
I529L SNP, one isolate had a wildtype parE. Thus, it can be concluded that the I529L 
SNP in parE can be found in most, but not all ST131 isolates. The contribution of 
this SNP to resistance to fluoro quino lones is unclear. 
The accumulation of resistance mechanisms in E. coli ST131 was also manifested 
by the presence of aac(6’)-Ib-cr in 10/15 (66%) ST131 isolates, compared to 8/34 
(23.5%) non-ST131 isolates. In addition, CTX-M ESBLs, mostly blaCTX-M-15, were found 
in 11/15 (73%) ST131 isolates, compared to 14/34 (41%) non-ST131 isolates. 
Until recently, data on the occurrence of this global ST131 clone in the Netherlands 
were absent. A study performed from January 2008 to December 2009 in the 
Rotterdam area, the Netherlands, found ST131 in patients with ESBL-producing 
E. coli isolates from bloodstream infections.7 Taken these data together with the 
present study, it may be concluded that ST131 is well established in the Netherlands, 
at least in this part of the country. 
Whereas in E. coli chromosomally encoded resistance determinants predominated, 
in K. pneumoniae resistance genes were mostly plasmid-mediated (Table 3). Qnr 
genes were found in 15/16 (94%) K. pneumoniae isolates and 5/16 (31%) showed 
aac(6’)-Ib-cr. We identified qnrA mostly (n=11; 69%); then qnrB (n=5; 31%), followed 
by qnrS (n=1; 6%) The presence of PMQR genes in K. pneumoniae isolates is 
frequently associated with combinations of several plasmid encoded ß-lactamase 
genes, both ESBL and plasmid-mediated AmpC blaDHA-1,
3
 which was confirmed by 
our data.







gyrA parC parE PMQR ß-lactamase(s)
E. cloacae 2293 I urine 0.50 0.75 S83Y WT WT - -
2155 I sputum 0.75 1 S83T
D87G
WT WT qnrA1 CTX-M-9, SHV-12
2503 I wound >32 >32 S83Y WT WT - CTX-M-1,CTX-M-9
K. pneumoniae 2288 O urine 0.38 0.5 WT WT WT - -





0.38 0.75 WT WT WT qnrA CTX-M-9, SHV-36
2261 I bronchoalveolar
fluid
0.38 0.75 WT WT WT qnrA1 CTX-M-14b
1867 I sputum 0.50 1 WT WT WT qnrA SHV-12
2166 I urine 0.75 1.5 WT WT WT qnrA SHV-12
2255 I intravenous 
catheter tip
1.5 3 WT WT WT qnrA1 CTX-M-9, SHV-12
2192 I sputum 2 3 D87Y WT WT qnrA1 -












1788 I urine 4 0.75 WT WT WT qnrA
-like
SHV-12









1888 O urine >32 6 S83F 
D87A




2195 I sputum >32 4 WT WT WT qnrA, 
qnrB4
DHA-1, SHV-12
Table 3. Distribution of fluoroquinolone resistance, amino acid substitutions and extended-spectrum ß-lactam resistance among 
E. cloacae (n=3) and K. pneumoniae (n=16) isolates from the LUMC
MIC (mg/L)
aPatient status: I = inpatient; O = outpatient
bCIP=ciprofloxacin, cLVX=levofloxacin
dWT = wildtype; - indicates the absence of a PMQR or extended-spectrum ß-lactamase
44 Chapter 2
We identified qnrA1 in one out of three E. cloacae isolates. It was found in an 
isolate with a modest reduction in susceptibility, with an MIC of ciprofloxacin of 0.75 
mg/L and of levofloxacin of 1 mg/L. This PMQR determinant was described in the 
Netherlands in E. cloacae in 2001,8 when it caused a large nosocomial outbreak. 
One of the three E. cloacae isolates was highly resistant to both fluoroquinolones 
(MICs > 32 mg/L), but no resistance mechanisms were found.
Finally, we noted the absence of the qepA gene among all isolates studied. This 
new PMQR determinant is still very rare in Europe, whereas several surveys among 
Enterobacteriaceae of human origin in China have reported a prevalence of 6%.9
In conclusion, we found E. coli ST131 to be the predominant type among our 
fluoroquinolone resistant isolates. A high number of resistance mechanisms have 
accumulated in our ST131 isolates, among which the I529L mutation in parE that 
was unequivocally associated with ST131. In contrast to E. coli, fluoroquinolone 
resistance in K. pneumoniae was associated with plasmid-encoded mechanisms 
much more than with chromosomal mutations.
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3.1 Abstract
Objectives: Resistance to ciprofloxacin in Escherichia coli is increasing parallel 
to increased use of fluoroquinolones both in the Netherlands and in other 
European countries. The objective was to investigate the contribution of active 
efflux and expression of outer membrane proteins in a collection of clinical 
E. coli isolates collected at a clinical microbiology department in a Dutch hospital. 
 
Methods: Forty-seven E. coli isolates with a wide range of ciprofloxacin minimum 
inhibitory concentrations (MICs) and known mutations in the quinolone resistance-
determining region (QRDR) were included. A fluorometric determination of 
bisbenzimide efflux was used with two different efflux pump inhibitors (EPIs). These 
results were compared to quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) for the expression levels of acrA, acrB, tolC, yhiV and mdfA efflux 
pump genes and the outer membrane proteins ompF and ompX. 
Results: Six isolates (12.7%) showed increased efflux. Although in 35 isolates (76%) 
overexpression of ≥1 efflux pump genes using qRT-PCR was present. Only the 
combined overexpression of acrAB-tolC and mdfA correlated with the phenotypic 
efflux assay using glucose/Carbonyl Cyanide m-Chloro-Phenylhydrazone (CCCP) 
with glucose.
Conclusion: Thus, efflux was involved in ciprofloxacin resistance in a limited 
number of E. coli isolates collected at a clinical microbiology department in a Dutch 
hospital complementing other resistance mechanisms. 
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3.2 Introduction
The use of fluoroquinolones has increased and correspondingly resistance to these 
drugs emerged significantly across Europe since 2001, with levels ranging from 7% 
to 53% in Escherichia coli in 2007.1 Between 2003 and 2007, resistance rates of 
E. coli to ciprofloxacin have risen from 8% to 14% in the Leiden University Medical 
Center (LUMC), a tertiary care hospital in the Netherlands. 
In E. coli fluoroquinolone resistance usually occurs due to stepwise mutations in 
the quinolone resistance determining regions (QRDRs) of the DNA gyrase genes 
(gyrA and gyrB) and/or topoisomerase IV genes (parC and parE) and the presence 
of plasmid-mediated quinolone resistance determinants (PMQRs). While mutations 
in the QRDRs are required to achieve a clinical level of resistance, decreased 
expression of the outer membrane protein (OMP) ompF or increased expression 
of ompX, as well as increased efflux pump activity have been shown to contribute 
to fluoroquinolone resistance. There are essentially five families of chromosomally 
encoded bacterial efflux pumps: the resistance-nodulation-division (RND), major 
facilitator superfamily (MFS), multidrug and toxic compound extrusion (MATE) and 
small multidrug resistance (SMR) family. The RND efflux pumps, such as AcrAB and 
YhiV, and major facilitator family (MFS) pumps such as MdfA are TolC-associated 
efflux pumps. These efflux systems are well characterized and play a major role 
in E. coli.2 The overexpression of these efflux pump genes is related to antibiotic 
resistance in clinical isolates.3,4
A variety of phenotypic methods have been used to identify active efflux systems 
in E. coli.5-13 Most of these studies have utilized ethidiumbromide as a substrate. 
The bisbenzimide dye Hoechst 33342 is also widely used to characterize efflux 
pump activity in different species, such as Lactococcus lactis and E. coli.14,15 This 
fluorescent marker has several advantages over ethidiumbromide, such as a high 
quantum yield, and it is less toxic. 
A recently described 96-wells plate fluorescence assay allows for a rapid, high 
throughput evaluation of efflux activity in clinical isolates. Bisbenzimide accumulation 
and efflux can be studied using bisbenzimide as a fluorescent dye and Carbonyl 
Cyanide m-Chloro-Phenylhydrazone (CCCP) and Phe-Arg ß-naphtylamide (PAßN) 
as efflux pump inhibitors (EPIs).16 The difference in fluorescence between the 
steady states of bisbenzimide accumulation in the absence and presence of an EPI 
reveals the contribution of active efflux in a single isolate. However, there is no 
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uniformity in the interpretation of the results, which makes it difficult to compare 
the contribution of active efflux between isolates from different studies. Another 
limitation of phenotypic efflux assays is that they do not provide information 
about the expression levels of the genes involved in efflux. Most studies that 
have investigated the contribution of active efflux in E. coli isolates use either 
phenotypic efflux assays7,8,11,17,18 or quantitative real-time polymerase chain reaction 
(qRT-PCR).3,4,19-21 A combined phenotypic and genotypic analysis of efflux pump 
activity in E. coli has been described in a limited number of studies.6,22,23,24 The 
purpose of the present study was to investigate the contribution of increased 
efflux activity and decreased influx to fluoroquinolone resistance in clinical 
E. coli isolates. A fluorometric determination of bisbenzimide efflux, with CCCP and 
PAßN as EPIs, was used and compared to qRT-PCR for the expression levels of acrA, 
acrB, tolC, yhiV and mdfA efflux pump genes and the outer membrane proteins 
ompF and ompX. 
3.3 Materials and Methods
3.3.1 Bacterial isolates
Forty-seven clinical E. coli isolates from a previous study were obtained from different 
inpatients and outpatients from the Leiden University Medical Center (LUMC), the 
Netherlands, between January and December 2008. Nonrepetitive isolates with 
resistance to ciprofloxacin MIC of ≥ 0.125 mg/L were included. All isolates showed 
≥ 1 mutation in the quinolone resistance determining regions (QRDRs) of gyrase 
A, parC and/or parE. The plasmid-mediated quinolone resistance (PMQR) gene 
aac(6’)-Ib-cr was present in 17 of the isolates. Isolate no. 2404 contained a qnrA1 
gene. E. coli ATCC 25922 and four fully susceptible E. coli isolates were included 
as negative controls. 
3.3.2 Susceptibility testing
MICs of ciprofloxacin (CIP) were determined using the agar dilution method 
according to the Clinical and Laboratory Standards Institute (CLSI) guideline. 
MICs were interpreted using EUCAST criteria (http://www.eucast.org/clinical_
breakpoints/). E. coli isolates resistant to at least three different drug classes were 
defined as multidrug resistant (MDR).
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3.3.3 Bisbenzimide accumulation and efflux assays
To determine active efflux, a semi-automated fluorometric method with 
bisbenzimide as a fluorescence marker was used as previously described. Briefly, 
cultures were grown in Mueller-Hinton broth to an OD600 of 0.6. Bacterial cells were 
collected by centrifugation at 13,000 rpm and resuspended in PBS (1 mL). The OD 
of all suspensions was adjusted to 0.3. Aliquots (0.18 mL) were pipetted in a black 
96-well microtiter plate (flat-bottomed, Greiner Bio-One, Frickenhausen, Germany). 
The bacterial cells were added in the format in duplicate: columns 1-10 isolates 
with PBS; column 11-12 heat-inactivated cells (10 min 90 °C). After adding 45µl 
bisbenzimide (25 µM), fluorescence was measured in a microtiter plate reader 
(Mithras LB 940 Berthold Technologies, Bad Wilbad, Germany). The fluorescence 
was acquired in cycles of 60 seconds at 37ºC. Fluorescence during influx was 
measured using an excitation filter of 350 nm and an emission filter of 460 nm over 
a 13-min period. The relative fluorescence at each time point was calculated in 
percentages, using the fluorescence values of the heat-inactivated cells divided by the 
fluorescence signals obtained in the test isolate. These data were plotted on a graph. 
The microtiter plate reader was stopped after 13 min to add: (a) PBS (blank), (b) PBS 
containing glucose as an energy source (final concentration of 0.4%) to measure 
efflux activity, (c) PBS containing glucose (0.4%) with 172.4 µM PAßN or (d) 38.8 µM 
CCCP to inhibit efflux. All tests were performed in duplicate. Fluorescence during 
efflux was measured using an excitation filter of 350 nm and an emission filter of 
460 nm. Intrinsic efflux activity was determined using the reference strain E. coli 
ATCC 25922 and four fully susceptible E. coli isolates. Efflux activity was expressed 
as the area between curves (ABC) which was calculated by subtracting the relative 
fluorescence in the wells containing CCCP/PAßN from that in the wells with glucose 
at each time point. For these five isolates, the mean and standard deviation (SD) of 
intrinsic efflux activity was calculated. Efflux was considered to be increased at 1.5x 
the SD above the mean of intrinsic efflux activity in the susceptible isolates.
3.3.4 RNA extraction and quantitative realtime-PCR (qRT-PCR)
Several colonies from overnight cultures were resuspended in PBS to make 
suspension of 0.5 McFarland. The suspension was diluted 1:1000 in trypticase soy 
broth (Beckton Dickinson B.V., Breda, The Netherlands) and incubated at 37ºC 
with shaking (150 rpm). The cultures were grown to a mid-log growth phase, which 
corresponded to an OD600 of 0.3.
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Total RNA was extracted using RNeasy kit (Qiagen Benelux B.V, Venlo, the 
Nederlands) according to the manufacturer’s instructions. Genomic DNA was 
removed by DNase I kit (Invitrogen, Breda, the Netherlands). The concentrations 
and purity of the resulting RNA samples were measured at 260nm using a Nanodrop 
ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, USA).
Relative quantification of gene expression was performed by using the OneStep 
RT-PCR Kit (Qiagen Benelux B.V, Venlo, the Nederlands) with SYBR green (stock 
10.000x Sigma-Alderich, Zwijndrecht, the Netherlands) in a CFX96TM Real-Time PCR 
Detection System (Bio-Rad, Veenendaal, The Netherlands). The genes included in 
the analysis were acrA, acrB, tolC, mdfA, yhiV, ompF and ompX; glyceraldehyde 
3-phosphate dehydrogenase (gapA) was used as a reference marker. 
For primer design, an alignment of gene sequences in GenBank® was made using 
the AlignX program (Vector NTI Advance 11, Invitrogen). All primer sequences and 
annealing temperatures are shown in Table 1. 









































Table 1. Primer sequences used in this studya
aAll primers were designed in this study
bF, forward; R, reverse
Efflux in Escherichia coli 53
All primers were synthesized by Biolegio B.V., Nijmegen, the Netherlands. The RT-PCR 
mixture (50 μl) contained 1.2 μl of both forward and reverse gene-specific primers, 
2 μl of dNTPs (10mM), 10 μl of 5xQiagen OS RT-PCR buffer, 1.5 μl of 2.5x SYBR green, 
1 μg of template RNA, 2 μl of Qiagen OS RT-PCR enzyme mix.
Each sample was placed on a 96-well plate (Bio-Rad Laboratories B.V., Veenendaal, 
the Netherlands) and subjected to one-step reverse transcription at 50°C for 30 min 
for cDNA synthesis, 35 cycles of denaturation at 95°C for 15 s, annealing at 60°C 
for 30s and extension at 72°C for 30s. PCR cycling was followed by melting curve 
analysis of 55-95°C (temperature transition rate of 0.5°C s-1).
In order to assess relative gene expression levels, cycle threshold (CT) 
values normalized against the housekeeping gene (gapA) were calculated 
and compared with those for E. coli ATCC 25922 using the 2-∆∆CT 
formula. Overexpression was defined as ≥ 1.5 fold increase in the expression of 
the gene.
3.3.5 Statistical analysis
Data analysis was performed using SPSS (version 20.0, IBM Corp, New York, USA). 
Student’s t-test was performed at a 5% level of significance (one-tailed, unpaired). 
The strength of a correlation between two variables (effect size) was calculated using 
the Kendall’s tau b. This is a statistic method to measure the association between 
measured quantities.
3.4 Results
3.4.1 Antimicrobial susceptibility testing
The MICs of ciprofloxacin of the 47 clinical E. coli isolates varied from 0.5 to 1024 
mg/L. Forty-two isolates (89%) were classified as multidrug resistant (Table 2). 
The MICs of bisbenzimide and the efflux pump inhibitors (EPI): PAßN and CCCP 
(Sigma-Aldrich, Zwijndrecht, the Netherlands) were determined for all isolates and 
the quality control strain E. coli ATCC 25922 using the agar dilution method in 
accordance with CLSI guidelines. Based on these results a concentration of 25 µM 
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0.008 - NDj ND 2.02 1.60 - - - - -
Q84 0.016 - ND ND 2.33 1.49 - - - - +
Q82 0.016 - ND ND 2.34 1.66 - - - - +
Q80 0.016 - ND ND 2.43 1.31 - - - - +
Q83 0.016 - ND ND 2.51 0.72 - - - - +
2027 0.5 - 3 - 1.14 0.96 - + + + +
2144 0.5 + 1 - 2.43 0.71 + + + + +
2466 1 + 3 - 2.54 1.12 - - + - +
1508 4 + 3 - 0.16 1.47 - - - + -
2521 8 + 3 - 1.32 0.59 - - - - +
2717 8 + 4 - 1.80 1.56 + + + - +
2543 8 + 3 - 1.83 1.29 - - - - +
2580 8 + 4 - 1.87 1.23 - - + - +
2480 8 + 3 - 1.91 0.97 - - + - +
1495 8 - 3 - 2.31 1.21 - - + + -
2239 8 + 4 - 2.45 1.73 - + + + -
1936 16 - 5 + 1.32 1.01 - - + + +
2020 16 + 3 + 1.69 0.72 - - + + +
1604 16 + 3 - 1.84 0.72 + - + + -
1946 16 + 4 - 1.87 0.58 - - - + +
1965 16 + 3 - 1.95 1.63 - - - - -
2506 16 + 5 - 2.45 1.13 - - - + +
1514 16 + 2 - 2.68 1.29 - + - + +
1945 32 + 5 - 1.18 1.07 + + + - -
2207 32 + 4 - 1.71 0.63 + + + + +
2574 32 + 5 + 1.84 0.65 - - + - +
2722 32 + 4 - 1.99 0.64 + - + + -
2525 32 + 4 - 2.07 2.80 - - + - +
2230 32 - 4 - 2.13 0.23 - + + - +
2585 32 + 4 - 2.16 0.99 - - - - +
2069 32 + 5 - 2.24 0.97 + + + + -
2274 64 + 3 - 0.85 0.64 - + + + -
1941 64 + 3 - 1.58 1.01 + - - - -
Table 2. Overview of antimicrobial susceptibility, mutations, area between the curves and gene expression of efflux pump genes and outer 
membrane proteins
Continued
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aCIP mg/L; MIC of ciprofloxacin as determined with agar dilution
bMDR = multidrug resistant: +, if the isolate was resistant to ≥3 different drug classes; -, if the isolate was resistant to 
<3 different drug classes 
cQRDR = quinolone resistance determining region. The numbers indicate the number of mutations in the quinolone resistance determining 
regions of gyrA. parC and parE as determined in a previous study (Paltansing et al., 2012)28
dPMQR = plasmid-mediated quinolone resistance determinant; +. present; -. absent.
eand f= area between the curves in phenotypic efflux activity in the presence of glucose subtracted from glucose with the addition of the 
EPIs CCCP or PAßN. The numbers in bold indicate that the ABC was 1.5x SD above the mean for increased phenotypic efflux activity.
gas determined by qRT-PCR; +, upregulated gene; -, no upregulation.
has determined by qRT-PCR; +, upregulated gene; -, no upregulation.
ias determined by qRT-PCR; +,downregulated gene; -, no downregulation.
jND = not determined
2504 64 + 4 + 1.86 0.15 - - - - -
2412 64 + 4 - 1.93 0.75 + + + + +
2413 64 + 4 - 2.19 0.79 + + + - -
1611 64 + 5 + 2.20 1.22 + - + + +
2404 64 + 5 + 2.34 0.88 + - + - -
1632 64 + 4 + 2.52 0.94 + - + - +
2556 64 + 4 + 2.55 0.93 + + + - +
2500 128 + 5 + 1.31 0.43 - - + - +
2505 128 + 5 + 1.41 0.44 - + + - +
2517 128 + 5 + 1.45 0.59 - - - - +
1626 128 + 5 + 2.20 0.30 + - + + +
2532 128 + 5 - 2.54 0.93 - - - - +
1629 128 + 5 + 3.07 1.97 - - + + +
2401 128 + 5 + 3.11 0.48 + + + - +
1502 128 + 4 + 3.11 0.76 + - + + +
1793 1024 + 3 - 1.56 0.66 - - - + +
2218 1024 + 3 + 1.65 0.49 - + - - -
1889 1024 + 4 + 2.14 1.12 + - + + +
2418 1024 - 4 + 3.08 0.73 - + + - +
Area between 
the curves
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3.4.2 Efflux activity evaluation; accumulation and efflux of bisbenzimide
Table 2 shows the efflux activity, expressed as ABC, for all isolates tested, including 
the fluoroquinolone-susceptible isolates. The reference strain E. coli ATCC 25922 
showed inhibition of efflux activity, which was affected by CCCP and less so by PAßN 
(Figure 1). This was considered as the intrinsic efflux activity of E. coli ATCC 25922. 
The four fully susceptible E. coli isolates showed similar results. For the E. coli ATCC 
25922 and the four susceptible E. coli isolates, the ABC between glucose/CCCP 
with glucose ranged from 2.02-2.51, with a mean of 2.33 (SD: 0.18). For PAßN, the 
ABC between glucose/PAßN with glucose with ranged from 0.72-1.66, with a mean 
proportion of 1.36 (SD: 0.38). Efflux was considered to be increased, if the ABC 
between glucose/CCCP with glucose was ≥ 2.60 or glucose/ PAßN with glucose 
was ≥ 1.93. 
Figure 1. Accumulation (0-13 min) and efflux activity (13-30 min) of bisbenzimide by E. coli ATCC 25922 in the presence of glucose and in 
the presence of the optimum concentration of the EPIs CCCP and PAßN at 37°C.
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One of the fluoroquinolone resistant isolates (no 1629) showed inhibition of 
active efflux in the presence of CCCP as with PAßN (Figure 2). Active efflux in the 
presence of CCCP only was found in four isolates (9%). In the remaining 33 isolates 
no increased efflux was found with CCCP. One additional isolate (2525) showed 
increased efflux with PAßN only.
One isolate showed an ABC of 1.63 (no.1965), which was higher than the intrinsic 
efflux activity of the reference strain ATCC 25922, but below the level of active efflux. 
The remaining isolates showed an absence of an inhibitory effect in the experiments 
with PAßN. There was no association between the increasing MICs values, target 
alterations or an MDR phenotype and the presence of increased efflux activity. 
Figure 2. Accumulation (0-13 min) and efflux activity (13-30 min) of bisbenzimide by E. coli isolate 1629 in the presence of glucose and in 
the presence of the optimum concentration of the EPIs CCCP and PABN at 37 °C.
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3.4.3 Analysis of quantification of RNA expression by qRT-PCR
Table 2 also shows the expression level of the efflux pump genes for all isolates 
tested, including the fluoroquinolone-susceptible isolates. Overexpression of 
≥1 efflux pump genes was present in 35 isolates (76%). Eighteen isolates showed 
overexpression of acrAB-tolC, 33 isolates showed overexpression of mdfA 
and 17 isolates of yhiV. Nine isolates showed expression of three efflux pumps, 
acrAB-TolC, mdfA and yhiV. Eleven isolates showed no overexpression of any of 
the efflux pump genes tested. No clear correlation was found between efflux and 
MICs of ciprofloxacin. Combining (a) the number of QRDR mutations and (b) the 
presence of plasmid-mediated quinolone resistance determinants with genotypic 
efflux results did not reveal any correlation. Decreased expression of ompF was 
found in 33 isolates, respectively. Twenty-two isolates showed an upregulation of 
ompX.
3.4.4 Correlation between phenotypic efflux activity and overexpression of 
efflux pump genes 
Nine isolates showed overexpression of all three efflux pump genes investigated 
(group 1), eight isolates showed acrAB-tolC and mdfA overexpression (group 2), 
fifteen isolates showed either yhiV or mdfA overexpression (group 3) and eleven 
isolates showed no genotypic overexpression (group 4). A significant correlation 
between the ABC of glucose/CCCP with glucose and the overexpression of 
acrAB-tolC with the mdfA efflux pump gene only (group 2 isolates; p=0.018, 
Kendall’s tau b=0.343). The ABC between glucose and PAßN with glucose showed 
no significant correlations with overexpression with any of the groups tested 
(p=0.198).
3.5 Discussion
In the present study, the contribution of active efflux and expression of OMPs to 
fluoroquinolone resistance in a collection of clinical E. coli isolates was investigated 
using a combined phenotypic and genotypic approach. 
Efflux pumps are expressed at a basal level in susceptible isolates and can be up-or 
downregulated in resistant isolates. The current study compared efflux in clinical 
fluoroquinolone resistant isolates to that in the reference wildtype E. coli ATCC 
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25922 strain with functional efflux genes. In other studies on phenotypic efflux 
laboratory generated mutant E. coli strains have been used to describe active efflux 
in clinical isolates.7,22,25 Based on phenotypic tests, six of 47 (12.7%) resistant isolates 
showed increased efflux activity.
The occurrence of increased efflux seems to be variable in clinical E. coli 
isolates.6,22,26 Christiansen et. al.6 found an indication of efflux in 76.7% of 60 clinical 
E. coli isolates with an MIC for ciprofloxacin ranging from 0.06-512 mg/L using a 
modified broth microdilution assay with the use of PAßN and 1-(1-naphtylmethyl) 
piperazine (NMP) as EPIs. Karczmaraczyk et. al.22 used ethidiumbromide accumulation 
experiments to determine the activity of the AcrAB-TolC efflux pump. They found 
increased phenotypic efflux in 8/11 ciprofloxacin resistant E. coli isolates from food-
producing animals using PAßN. Amabile-Cuevas et al.27 on the other hand using a 
broth microdilution assay with PAßN found increased efflux in 12% of their clinical 
isolates, a percentage similar to ours. However, comparison of efflux results in clinical 
isolates from different studies remains difficult as different phenotypic methods 
and/or selection criteria have been used to detect phenotypic efflux activity. In the 
absence of established criteria to define active efflux in clinical isolates, we used the 
calculation of the ABC. 
The fact that most isolates in this collection already showed a high number of 
accumulated QRDR mutations could also account for the lack of active efflux.28 
A recent publication of Singh et al.29 investigated the contributions and interplay 
of fluoroquinolone resistance mechanisms at various time points during resistance 
development in a E. coli laboratory standard strain (MG1655) and two isogenic 
derivatives (ΔacrAB and ΔacrR). Interestingly, they found that in the initial stages 
of emerging resistance, efflux pump overexpression occurred before gyrase 
mutations and that once mutations were found, the pump activity had returned 
to normal levels. The isolates in our collection had accumulated high numbers of 
QRDR mutations already and may have had their efflux activity already tuned down. 
However, the six isolates with active efflux were amongst those with a high number 
of QRDR mutations and high MICs.
Of more than 40 putative transporters in E. coli, efflux pumps of the RND family, 
which are inhibited by PAßN, affect fluoroquinolone MICs when expressed with 
their own promotors under laboratory growth conditions.21,30 In both canine/
feline and human E. coli isolates PAßN has been shown to reverse or reduce the 
fluoroquinolone MICs.8,23,31 
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In contrast, our results show that PAßN did not have much effect on the extrusion of 
bisbenzimide, suggesting that active efflux by RND efflux pumps did not contribute 
to ciprofloxacin resistance in the majority of our clinical isolates.
Using the genotypic approach, relative quantification of efflux gene expression levels 
was normalized against a fully susceptible reference strain, E. coli ATCC 25922, as 
is customary.3,4,23 In the present collection, various combinations of gene expression 
levels were found. This included: (a) alterations in the OMPs and overexpression of 
efflux pump genes; (b) no OMP alterations but only overexpression of efflux genes (c) 
only OMPs alterations without overexpression of efflux genes (d) no OMP alterations 
or overexpression of efflux genes. The results of the OMP alterations showed that 
outer membrane influx resistance is also involved. Although a significant decrease 
of bisbenzimide influx was not found. The lack of correlation may be explained by 
the fact that bisbenzimide uses other routes to enter the bacterial cell.
Convergence between the phenotypic and genotypic method was observed in 
isolates with overexpression of acrAB-tolC and mdfA and the ABC of glucose/CCCP 
with glucose in the phenotypic efflux assay. In E. coli, the tripartite acrAB-tolC system 
is considered to be the most important efflux pump.32 Swick et al. investigated 
fluoroquinolone susceptible and MDR E. coli isolates and found that overexpression 
of acrAB correlated with an MDR phenotype.4 In laboratory-generated mutants, 
overexpression of the efflux pumps acrAB or mdfA have been shown to cause three 
to six-fold increase in fluoroquinolone resistance.21 Previous studies also reported 
that the simultaneous overexpression of acrAB and mdfA results in synergistic 
increases in resistance to fluoroquinolones.21,33 Our results show that simultaneous 
overexpression of these efflux pumps can be detected using the phenotypic assay 
with glucose and CCCP as inhibitor, which can be used as a screening tool to 
detect active efflux. In the remaining isolates, no correlation was found between 
phenotypic detection of active efflux or MICs with mRNA gene expression levels 
of the efflux genes investigated. Quantification of gene expression levels does not 
necessarily provide information on the final expression of the gene product and its 
functionality. Although mRNA expression of multidrug efflux pumps correlated well 
with protein expression levels using laboratory strains of Pseudomonas aeruginosa,34 
clinical isolates also showed discrepancies between mRNA expression and the 
corresponding protein. Molecular mechanisms causing these discrepancies include 
the half-lives of specific mRNAs or specific protein35 and the post-transcriptional 
control of the protein translation rate.36 
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In conclusion, active efflux was not the predominant resistance mechanism in 
clinical resistant E. coli isolates from our hospital. Living organisms have the capacity 
to adapt to changing environments. Increased efflux is not the only mechanism 
involved in the physiological adaptation process. There is a well regulated and 
coordinated interplay of multiple mechanisms of resistance. The determination 
of active efflux under defined experimental conditions may contribute to a better 
understanding of the contribution of active efflux in clinical MDR E. coli isolates. 
Acknowledgements
We thank Yi Lee and Jouraima Ras for their excellent technical assistance and 
dr. Wil Goessens and dr. Miguel Viveiros for their helpful discussions.
Disclosure statement




EARS-Net (2008). Antimicrobial resistance surveillance 
in Europe 2007. Annual Report of the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net). Stockholm: ECDC; 2007. 1-156.
Piddock LJ. Multidrug-resistance efflux pumps - not 
just for resistance. Nat Rev Microbiol 2006; 4: 629-36.
Yasufuku T, Shigemura K, Shirakawa T, et al. Correlation 
of overexpression of efflux pump genes with antibiotic 
resistance in Escherichia coli strains clinically isolated 
from urinary tract infection patients. J Clin Microbiol 
2011; 49: 189-94.
Swick MC, Morgan-Linnell SK, Carlson KM, et al. 
Expression of multidrug efflux pump genes acrAB-tolC, 
mdfA, and norE in Escherichia coli clinical isolates as a 
function of fluoroquinolone and multidrug resistance. 
Antimicrob Agents Chemother 2011; 55: 921-4.
Bohnert JA, Karamian B, Nikaido H. Optimized Nile 
Red efflux assay of AcrAB-TolC multidrug efflux system 
shows competition between substrates. Antimicrob 
Agents Chemother 2010; 54: 3770-5.
Christiansen N, Nielsen L, Jakobsen L, et al. 
Fluoroquinolone resistance mechanisms in urinary tract 
pathogenic Escherichia coli isolated during rapidly 
increasing fluoroquinolone consumption in a low-use 
country. Microb Drug Resist 2011; 17: 395-406.
Coldham NG, Webber M, Woodward MJ, et al. A 
96-well plate fluorescence assay for assessment of 
cellular permeability and active efflux in Salmonella 
enterica serovar Typhimurium and Escherichia coli. 
J Antimicrob Chemother 2010; 65: 1655-63.
Kern WV, Steinke P, Schumacher A, et al. Effect of 
1-(1-naphthylmethyl)-piperazine, a novel putative 
efflux pump inhibitor, on antimicrobial drug 
susceptibility in clinical isolates of Escherichia coli. 
J Antimicrob Chemother 2006; 57: 339-43.
Martins M, Santos B, Martins A, et al. An instrument-
free method for the demonstration of efflux pump 
activity of bacteria. In Vivo 2006; 20: 657-64.
Martins M, Couto I, Viveiros M, et al. Identification 
of efflux-mediated multidrug resistance in bacterial 
clinical isolates by two simple methods. Methods Mol 
Biol 2010; 642: 143-57.
Paixao L, Rodrigues L, Couto I, et al. Fluorometric 
determination of ethidium bromide efflux kinetics in 
Escherichia coli. J Biol Eng 2009; 3: 18.
Viveiros M, Martins A, Paixao L, et al. Demonstration of 
intrinsic efflux activity of Escherichia coli K-12 AG100 
by an automated ethidium bromide method. Int J 
Antimicrob Agents 2008; 31: 458-62.
Viveiros M, Rodrigues L, Martins M, et al. Evaluation 
of efflux activity of bacteria by a semi-automated 




























van den Berg van Saparoea HB, Lubelski J, van MR, 
et al. Proton motive force-dependent Hoechst 33342 
transport by the ABC transporter LmrA of Lactococcus 
lactis. Biochemistry 2005; 44: 16931-8.
Lewinson O, Adler J, Poelarends GJ, et al. The 
Escherichia coli multidrug transporter MdfA catalyzes 
both electrogenic and electroneutral transport 
reactions. Proc Natl Acad Sci USA 2003; 100: 1667-72.
Webber MA, Coldham NG. Measuring the activity of 
active efflux in gram-negative bacteria. Methods Mol 
Biol 2010; 642: 173-80.
Chenia HY, Pillay B, Pillay D. Analysis of the 
mechanisms of fluoroquinolone resistance in urinary 
tract pathogens. J Antimicrob Chemother 2006; 58: 
1274-8.
Marchetti ML, Errecalde J, Mestorino N. Effect of 
1-(1-naphthylmethyl)-piperazine on antimicrobial 
agent susceptibility in multidrug resistant isogenic 
and veterinary Escherichia coli field strains. J Med 
Microbiol 2012; 61: 786-92.
Mazzariol A, Tokue Y, Kanegawa TM, et al. High-
level fluoroquinolone-resistant clinical isolates of 
Escherichia coli overproduce multidrug efflux protein 
AcrA. Antimicrob Agents Chemother 2000; 44: 3441-3. 
Viveiros M, Dupont M, Rodrigues L, et al. Antibiotic 
stress, genetic response and altered permeability of 
E. coli. PLoS One 2007; 2: e365.
Yang S, Clayton SR, Zechiedrich EL. Relative 
contributions of the AcrAB, MdfA and NorE efflux 
pumps to quinolone resistance in Escherichia coli. 
J Antimicrob Chemother 2003; 51: 545-56.
Karczmarczyk M, Martins M, Quinn T, et al. Mechanisms 
of fluoroquinolone resistance in Escherichia coli 
isolates from food-producing animals. Appl Environ 
Microbiol 2011; 77: 7113-20.
Liu X, Boothe DM, Thungrat K, et al. Mechanisms 
accounting for fluoroquinolone multidrug resistance 
Escherichia coli isolated from companion animals. Vet 
Microbiol 2012; 28: 159-68
Mesaros N, Glupczynski Y, Avrain L, et al. A combined 
phenotypic and genotypic method for the detection 
of Mex efflux pumps in Pseudomonas aeruginosa. 
J Antimicrob Chemother 2007; 59: 378-86.
Martins A, Spengler G, Rodrigues L, et al. pH 
Modulation of efflux pump activity of multidrug 
resistant Escherichia coli: protection during its passage 
and eventual colonization of the colon. PLoS One 
2009; 4: e6656.
Lautenbach E, Metlay JP, Mao X, et al. The prevalence 
of fluoroquinolone resistance mechanisms in colonizing 
Escherichia coli isolates recovered from hospitalized 
patients. Clin Infect Dis 2010; 51: 280-5.
Efflux in Escherichia coli 63
Amabile-Cuevas CF, Arredondo-Garcia JL, Cruz 
A, et al. Fluoroquinolone resistance in clinical and 
environmental isolates of Escherichia coli in Mexico 
City. J Appl Microbiol 2010; 108: 158-62.
Paltansing S, Kraakman ME, Ras JM, et al. 
Characterization of fluoroquinolone and cephalosporin 
resistance mechanisms in Enterobacteriaceae isolated 
in a Dutch teaching hospital reveals the presence of an 
Escherichia coli ST131 clone with a specific mutation in 
parE. J Antimicrob Chemother 2013; 68: 40-5.
Singh R, Swick MC, Ledesma KR, et al. Temporal 
interplay between efflux pumps and target mutations 
in development of antibiotic resistance in Escherichia 
coli. Antimicrob Agents Chemother 2012; 56: 1680-5.
Sulavik MC, Houseweart C, Cramer C, et al. Antibiotic 
susceptibility profiles of Escherichia coli strains lacking 
multidrug efflux pump genes. Antimicrob Agents 
Chemother 2001; 45: 1126-36.
Saenz Y, Ruiz J, Zarazaga M, et al. Effect of the 
efflux pump inhibitor Phe-Arg-ß-naphthylamide 
on the MIC values of the quinolones, tetracycline 
and chloramphenicol, in Escherichia coli isolates of 
different origin. J Antimicrob Chemother 2004; 53: 
544-5.
Zgurskaya HI, Nikaido H. Bypassing the periplasm: 
reconstitution of the AcrAB multidrug efflux pump 
of Escherichia coli. Proc Natl Acad Sci USA 1999; 96: 
7190-5.
Lee A, Mao W, Warren MS, et al. Interplay between 
efflux pumps may provide either additive or 
multiplicative effects on drug resistance. J Bacteriol 
2000; 182: 3142-50.
Yoneda K, Chikumi H, Murata T, et al. Measurement 
of Pseudomonas aeruginosa multidrug efflux pumps 
by quantitative real-time polymerase chain reaction. 
FEMS Microbiol Lett 2005; 243: 125-31.
Varshavsky A. The N-end rule: functions, mysteries, 
uses. Proc Natl Acad Sci U S A 1996; 93: 12142-9.
Nogueira T, Springer M. Post-transcriptional control by 
global regulators of gene expression in bacteria. Curr 













Increased expression levels of chromosomal AmpC 
ß-lactamase in clinical Escherichia coli isolates and 
their effect on susceptibility to extended-spectrum 
cephalosporins
S. Paltansing,1 M.E.M. Kraakman,1 H.A.M van Boxtel,2 I. Kors,1 E. Wessels,1 
W.H.F. Goessens,3 J.P.M. Tommassen,2 A.T. Bernards1
 
1 Department of Medical Microbiology. Leiden University Medical Center, 
The Netherlands
2  Department of Molecular Microbiology, Institute of Biomembranes, 
Utrecht University, Utrecht, The Netherlands
3  Department of Medical Microbiology and Infectious Diseases, 
Erasmus University Medical Center, Rotterdam, The Netherlands
Microbial Drug Resistance 2014 Sep 4 (epub ahead of print) 
66 Chapter 4
4.1 Abstract 
Objectives: Forty-nine clinical Escherichia coli isolates, both extended-spectrum 
ß-lactamase (ESBL)-negative and ESBL-positive, were studied to investigate whether 
increased AmpC expression is a mechanism involved in cefoxitin resistance and if 
this influences 3rd generation cephalosporin activity.
Methods: Nine of 33 (27.2%) cefoxitin-resistant (minimum inhibitory concentration 
(MIC) > 8 mg/L) isolates showed hyperproduction of chromosomal AmpC (c-AmpC) 
based on (i) at least two positive tests using AmpC-inhibitors, (ii) mutations in 
the promoter/attenuator regions, and (iii) a 6.1 to 163-fold increase in c-ampC 
expression by qRT-PCR. 
Results: In ESBL-negative isolates, MICs of ceftazidime and cefotaxime were mostly 
above wildtype level, but below the S/I breakpoint (EUCAST guideline), except 
for one isolate with MICs of 4 mg/L. No plasmid-mediated AmpCs were found. 
Periplasmic extracts of nine c-AmpC hyperproducers were pre-incubated with or 
without cefuroxime or ceftazidime and analyzed by SDS-PAGE. Cefuroxime and 
ceftazidime were stable to hydrolysis but acted as inhibitors of the enzyme. None of 
these isolates showed loss of porins. 
Conclusion: Thus, cefoxitin-resistance has low specificity for detecting upregulated 
c-AmpC production. c-AmpC hyperproducing E. coli is mostly still susceptible 
to 3rd generation cephalosporins but less than wildtype E. coli. Surveillance of 
cefoxitin-resistant E. coli to monitor developments in the activity of 3rd generation 
cephalosporins against c-AmpC hyperproducers is warranted.
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4.2 Introduction
Although extended-spectrum ß-lactamases (ESBLs) are a major cause of resistance to 
cephalosporins in Escherichia coli, the involvement of AmpC enzymes is increasingly 
reported.1 All isolates of E. coli carry a chromosomal ampC gene (c-ampC). In 
Enterobacter, Citrobacter, Morganella, and Serratia, c-ampC expression is usually 
inducible by ß-lactam antibiotics. Induction of c-ampC expression is a complex 
mechanism involving the regulatory genes ampR, ampD and ampG.2 Unlike in 
the other members of the Enterobacteriaceae, c-ampC is not inducible in E. coli 
because the ampR regulatory gene is lacking. However, expression of c-ampC is 
influenced by mutations in the promoter and attenuator regions, which may result 
in constitutive hyperproduction of c-AmpC.3,4 Hyperexpression of c-ampC in clinical 
E. coli isolates has been described with varying susceptibility to 3rd-generation 
cephalosporins.4-6 Besides c-AmpC hyperproduction, E. coli can acquire transferable 
plasmid-encoded AmpC (p-AmpC) enzymes.7,8
In our laboratory, the resistance rate of E. coli isolates to ceftazidime corresponds to 
the ESBL rate (approximately 8% in 2011), but cefuroxime resistance is approximately 
twice as high. Cefuroxime resistance in ESBL-negative E. coli isolates is usually 
accompanied by cefoxitin resistance, which is suggestive for AmpC production. 
Instead of cefuroxime, which is our first-line antibiotic, ceftazidime is then the 
cephalosporin of choice in our hospital.
To investigate whether increased AmpC expression is involved in cefuroxime and 
cefoxitin resistance in these ESBL-negative isolates and if this influences ceftazidime 
activity, we investigated a collection of E. coli isolates with various combinations 
of cephalosporin resistance. In addition, all isolates were phenotypically and 
genotypically characterized for AmpC production. As other mechanisms, such as 
increased efflux and decreased expression of outer membrane proteins (OMPs), 
also contribute to cefuroxime resistance in ESBL-negative E. coli isolates,9 the OMPs 
of different isolates were analyzed.
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4.3 Material and methods
4.3.1 Bacterial isolates and antimicrobial susceptibility testing
Between July 2008 and January 2010, nonreplicate clinical isolates of E. coli that were 
either ESBL-producers or showed resistance to at least three different categories of 
antimicrobial agents (fluoroquinolones, aminoglycosides, ß-lactams, cotrimoxazole) 
were collected at the Department of Medical Microbiology of the Leiden University 
Medical Center (LUMC), Netherlands.
From this collection, we selected 22 nonreplicate ESBL-negative E. coli isolates that 
showed resistance to cefoxitin (MIC > 8 mg/L) and cefuroxime. We added a panel 
of cefoxitin resistant, ESBL-positive isolates (n=4); cefoxitin resistant, cephalosporin 
susceptible isolates (n=7) and cefoxitin susceptible, ESBL-positive isolates (n=11) 
to investigate the role of AmpC-production in these subsets of isolates. Five 
cephalosporin-susceptible isolates were included as controls. Minimum inhibitory 
concentration (MICs) of cefoxitin, cefuroxime, ceftazidime and cefotaxime were 
determined using Etests (BioMérieux, France) according to the manufacturer’s 
instructions. MICs were interpreted using EUCAST criteria (http://www.eucast.org/
clinical_breakpoints/). Tests for synergy between cephalosporins and clavulanic acid 
were performed using combination disk diffusion test for ESBL detection (Rosco 
Diagnostica A/S, Denmark) according to the Clinical Laboratory Standards Institute’s 
guidelines.10
4.3.2 Phenotypic AmpC testing
The AmpC Etest with cefotetan and cefotetan-cloxacillin (BioMérieux, France) 
was performed according to the manufacturer’s instructions. Ratios of the MICs 
of cefotetan and cefotetan-cloxacillin of ≥ 8 are considered positive for AmpC 
production. The cefoxitin-boronic acid and cefoxitin-cloxacillin disk tests were 
performed using paper disks. In brief, 30-µg cefoxitin disks (Becton Dickinson, 
Germany) were supplemented with 20 µL of phenylboronic acid (stock solution 
20 mg/mL) (Sigma-Aldrich, Netherlands) or with 20 µL of cloxacillin (stock 37.5 
mg/mL) (Sigma-Aldrich). A test was considered positive for AmpC ß-lactamase 
production if the inhibition zone around the disk containing cefoxitin with an 
inhibitor was ≥ 4 mm larger than without the inhibitor.11
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4.3.3 Real-time quantitative reverse-transcription PCR (qRT-PCR)
Total RNA was isolated from cultures grown to mid-log growth phase using the 
RNeasy kit (Qiagen Benelux B.V, Venlo, Netherlands) according to the manufacturer’s 
instructions. Genomic DNA was removed with the DNase I kit (Invitrogen, Breda, 
Netherlands). The expression level of the ampC gene and the reference gene gapA 
encoding glyceraldehyde 3-phosphate dehydrogenase was assessed by real-time 
qRT-PCR using the OneStep RT-PCR Kit (Qiagen) with SYBR green (10 000 x stock 
solution; Sigma-Aldrich). Primer sequences are listed in Table 1. 
The ampC mRNA mean normalized expression was calibrated as fold differences 
using the mean normalized expression level of the reference E. coli strain ATCC 
25922 as 1.0 using the delta-delta cycle threshold method as described by Livak 
et al.12
4.3.4 Chromosomal ampC gene and promoter/attenuator sequencing
For mutation analysis, the c-ampC gene and ampC promoter/attenuator region 
were amplified using primers as described in Table 1. Sequencing was performed 
at the Leiden Genome Technology Center (LGTC®, Leiden, Netherlands). 
Sequence analysis was performed using BioNumerics version 6.6 (Applied-Maths, 
Sint-Martens-Latem, Belgium).
Table 1. Primer sequences used in this study
Target Primer 
directiona






gapA F GGCCAGGACATCGTTTCCAA 60 100  This study
R TCGATGATGCCGAAGTTATCGTT
ampC F CCTCTTGCTCCACATTTGC 60 1134 This study
R CCCAGGTAAAGTAATAAGGTTTAC
ampC promoter/attenuator region F GATCGTTCTGCCGCTGTG 60 271 Corvèc et al.b
R GGGCAGCAAATGTGGAGCAA
aF, forward; R, reverse
For primer design, an alignment of gene sequences in GenBank was made using the AlignX program (Vector NTI Advance 11, Invitrogen).
The qRT-PCR mixture (50 μl) contained 1.2 μl (0.5 µM) of both forward and reverse primers (Biolegio B.V., Nijmegen, Netherlands), 2 μl of 
dNTPs (10 mM), 10 μl of 5 x OS RT-PCR buffer (Qiagen), 1.5 μl of 2.5 x SYBR green, 10 μl of template RNA (1:10 diluted), 2 μl of OS RT-PCR 
enzyme mix (Qiagen). Each sample was placed on a 96-well plate (Bio-Rad Laboratories B.V., Veenendaal, Netherlands) and subjected to 
one-step reverse transcription at 50°C for 30 min for cDNA synthesis, followed by 35 cycles of denaturation at 95°C for 15 s, annealing at 
60°C for 30 s and extension at 72°C for 30 s. PCR cycling was followed by melting curve analysis of 70-99°C (temperature transition rate 
of 0.5°C/s).
bAs described by Corvèc S, Prodhomme A, Giraudeau C, Dauvergne S, Reynaud A, Caroff N. Most Escherichia coli strains overproducing 
chromosomal AmpC ß-lactamase belong to phylogenetic group A. J Antimicrob Chemother 2007;60: 872-876.
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4.3.5 Molecular detection of p-ampC ß-lactamase genes 
A multiplex PCR was used for the detection of the six p-ampC gene families as 
described by Perez-Perez and Hanson.8
4.3.6 Isolation of cell fractions
Cell envelopes were isolated from bacteria grown overnight at 37°C in L-broth, 
which is composed of 1% tryptone, 0.5% yeast extract, 0.5% NaCl, 0.002% thymine, 
pH 7.0.13 Cells were disrupted by ultrasonication (Branson B-12 Heinemann, 
Schwäbisch Gmünd, Germany), and sarkosyl (2% end concentration) was added 
to the lysates to dissolve the inner membrane proteins. After 30 min incubation at 
room temperature, the insoluble OMPs were collected by centrifugation for 30 min 
at 16.000 × g. 
For isolation of whole cell lysates, bacteria exponentially growing in L-broth were 
converted to spheroplasts as described.14 Briefly, the cells were pelleted, washed 
in physiological salt solution and resuspended to 1010 cells/mL in 1 mL of 10 mM 
Tris-HCl (pH 8), 25% sucrose. Subsequently, 10 µL of lysozyme (20 mg/mL) and 
2 mL of 1.5 mM EDTA (pH 7.5) were added, and the mixture was incubated on ice 
for 30 min. Whole cell lysates were then obtained by sonication of the spheroplasts 
after a freeze-thaw cycle. 
To isolate the periplasmic fraction, 5 mM MgCl2 (end concentration) was added 
to spheroplasts prepared as above. The spheroplasts were then removed by 
centrifugation for 1 min at 16 000 × g and the supernatant was used as periplasmic 
extract.
4.3.7 SDS-PAGE and Western blotting
Cell fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) as described by Laemmli et. al.15 with 11% acrylamide, 
0.2% SDS and 5 M urea in the running gel unless otherwise indicated. Proteins were 
either stained in the gels with Coomassie Brilliant Blue or transferred to nitrocellulose 
membranes by electroblotting. 
The blots were incubated with either a polyclonal antiserum raised against the 
E. coli porin PhoE, which cross-reacts with the related porins OmpF and OmpC, 16 or 
an anti-AmpC antiserum (Aviva Systems Biology, San Diego, USA) and subsequently 
with alkaline phosphatase-conjugated goat anti-rabbit-IgG antiserum (BioSource 
International Inc, Camarillo, CA, USA). 
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The blots were then stained with 0.5 mg/mL 5-bromo-4-chloro-3-indolyl phosphate 
and 0.1 mg/mL nitroblue tetrazolium (Sigma-Aldrich) in 100 mM NaHCO3, 1 mM 
MgCl2 (pH 9.8) until colour developed.
4.3.8 ß-Lactamase assays
ß-Lactamase activity was determined in whole cell lysates of triplicate cultures 
using nitrocefin (Calbiochem, Merck KGaA, Darmstadt, Germany) as a chromogenic 
substrate.17 Appropriate dilutions of the extracts in 1 mL of 10 mM HEPES, 
5 mM MgCl2 (pH 7.2) were incubated at room temperature with 0.05 mM nitrocefin 
and the initial rate of nitrocefin cleavage was measured by the change in optical 
density at 486 nm (OD486). A change in OD486 corresponds to the degradation of 
51 nmol nitrocefin and the measured activity was calculated back to the ß-lactamase 
activity of 108 or 109 cells. 
To study the degradation of cefuroxime (Hikma Pharmaceuticals, London, United 
Kingdom) and ceftazidime (Fresenius Kabi, Bad Homburg, Germany), periplasmic 
extracts were incubated in 1 mL of 10 mM HEPES, 5 mM MgCl2 (pH 7.2) with 
50 nmol/mL of the antibiotics, and opening of the ß-lactam ring was measured 
during 5 min at 275 or 260 nm, respectively, using a Unicam UV1 spectrometer. The 
degradation of cefazolin (Hikma Pharmaceuticals) measured at 270 nm was used as 
a control.
Inhibition of ß-lactamase activity by cephalosporins was tested by incubating 
periplasmic extracts for 1 min with 0.005, 0.05, 0.5, 5 and 50 μM cefuroxime or 
ceftazidime, prior to the addition of 50 μM nitrocefin and subsequent measurement 
of nitrocefin hydrolysis. 
Preincubation of periplasmic extracts with cefazolin at 5 and 50 μM was used as a 
control in this assay. 
4.3.9 Zymography 
For zymography, samples of periplasmic fractions were analyzed by semi-native 
SDS-PAGE without SDS in the gel18 and ß-lactamase activity was detected in situ 
using nitrocefin as the substrate as described.16 The result was photographed 
immediately.
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MIC mg/La Phenotypic AmpC test resultsb 
Isolate
 













2483* >256 64 4.0 4.0 - + + + -73/-32/-10/+58 89.3
2942* 24 12 1.5 0.75 - + + + -73/-32/-28 20.8
2529* 16 12 1.0 0.5 - indet + + -73/-32/-28 20.5
2958* 16 8 0.38 0.38 - + + + -32 56.1
4478* 16 16 0.75 0.75 - + + + -73/1bp insertion (-18) 25.6
3430* 16 12 1.0 0.5 - + + - -73/-28/1bp insertion(-18) 17.3
2527 48 16 0.5 0.38 - - - - -76/+22/+26/+27/+32   1.3
3245 32 16 0.38 0.25 - - - + -88/-82/-18/-1/+58   1.1
3069 32 16 0.5 0.38 - - - - WTc   1.2
3365* 32 12 1.5 0.19 - indet - - -73/-28   2.6
3831 24 24 0.75 0.25 - - - - WT   0.5
4408 24 24 0.5 0.25 - - - - WT   0.4
4112 24 16 0.5 0.25 - - - - -73/-28   1.2
3559* 24 12 0.5 0.25 - - - + -88/-82/-18/-1/+58   1.3
2123 24 12 0.5 0.25 - - - - -73/-28   0.4
4174* 24 8 0.38 0.19 - - - + WT   1.1
1941 16 12 0.50 0.25 - - - - -76/+22/+26/+27/+32   0.9
2491 16 12 0.38 0.25 - - - - -88/-82/-18/-1   2.2
2069 16 12 0.38 0.25 - - - - -73/-28   2.0
4095 16 8 0.25 0.19 - - - - WT   0.7
3664 16 8 1 0.19 - - - + -73/-28   0.9
4479 16 6 1 0.125 - - - + -88/-82/-18/-1/+58   1.9
4484 12 16 0.50 0.38 - - - - -88/-82/-18/-1   2.2
4472 12 12 0.75 0.125 - - - - WT   0.3
4354 12 12 0.50 0.25 - - - - WT   2.4
3609 12 12 0.38 0.25 - - - - -73/-28   0.6
3834 12 12 0.38 0.25 - - - - WT   0.9
2764 12 8 0.50 0.19 - - - - WT   0.8
3602 12 8 0.25 0.125 - - - - -88/-82/-18/-1   1.3
3671 8 6 0.38 0.094 - - - - -73/-28/+17   0.8
3275 6 4 0.25 0.094 - - - - -73/-28   0.5
3816* 4 3 0.19 0.064 - - - - -73/-28 0.3
2717 3 4 0.125 0.094 - - - - -73/-28/+58 2.5
5154* 2 4 0.19 0.094 - - - - -88/-82/-18/-1/+58 0.6
Table 2. MIC values, phenotypic AmpC test results, mutations detected in the ampC promoter/attenuator region and the fold c-ampC 
expression by qRT-PCR for the 49 clinical E. coli isolates included in this study
Continued
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4.4 Results 
4.4.1 AmpC production and susceptibility to cephalosporins
The results of phenotypic tests for AmpC, promoter/attenuator sequencing, 
qRT-PCRs and susceptibility assays of the 49 E. coli isolates are presented in Table 
2 on the left page and above. For 7/49 E. coli isolates, all three phenotypic AmpC 
tests were positive. For 2/49 E. coli isolates, two phenotypic tests were positive. 
Five isolates showed a positive result only in the AmpC cefoxitin-cloxacillin disk 
test. The remaining isolates did not show AmpC hyperproduction in any of the 
phenotypic assays used. Isolates with at least two positive phenotypic tests showed 
a 6.1 to 163.1-fold increase of expression of the chromosomal ampC gene by real-
time qRT-PCR (Table 2). 
1495* 64 32 6 2 + + + + -88/-82/-42/-18/-1/+58 163.1
3633* 24 64 12 16 + + + + -88/-82/-42-/-18/-1/+58 69.6
4197* 12 >256 32 >256 + + + + -73/-28/+34/+58 6.1
3531* 16 >256 4 16 + - - - WT 0.9
2026 8 >256 16 >256 + - - - WT 0.9
3869 4 >256 64 >256 + - - - WT 2.7
4019 4 >256 12 >256 + - - - -73/-28 2.3
4433 3 >256 8 >256 + - - - WT 2.8
3796 3 >256 0.5 >256 + - - - WT 1.0
1952 3 >256 8 >256 + - - - -73/-28 1.0
4092 3 6 >256 0.75 + - - - -76/+22/+26/+27/+32 1.7
4097 2 >256 2 >256 + - - - -88/-82/-18/-1/+58 1.1
4246 2 >256 2 >256 + - - - -88/-82/-18/-1/+58 1.0
3847 1.5 >256 4 >256 + - - - -73/-28 0.9
4196 1.5 >256 0.5 32 + - - - -88/-82/-18/-1 0.2
Table 2. Continued
aMIC in mg/L as determined by Etest, bPhenotypic AmpC test results: + , positive; -, negative; indet, indeterminate, cWT, wildtype
FOX, cefoxitin; CXM, cefuroxime; CAZ, ceftazidime; CTX,cefotaxime; BA, boronic acid; CLX, cloxacillin
*Isolates that were included for further analysis. 
E. coli isolates positive for AmpC activity in ≥ two phenotypic tests + an increased RNA expression level + the presence of mutations in 
the ampC promoter/attenuator mutations associated with c-ampC overexpression were considered as c-AmpC hyperproducers and are 
indicated in bold.
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Genetic analysis revealed seven different promoter sequence variants, previously 
found to be associated with c-AmpC hyperproduction, in the nine isolates with at 
least two positive phenotypic tests and increased c-ampC expression (Table 2). Four 
isolates (2483, 2942, 2529, and 2958) contained a T to A transversion in the promoter 
region at position -32, which leads to the optimization of the -35 box from TTGTCA 
to TTGACA. The additional substitution at position -10 in isolate 2483 creates an 
optimization of the Pribnow box from TACAAT to TATAAT, which explains the even 
higher expression level of ampC in this isolate. An insertion of a single base pair (bp) 
at position -18 was found in two isolates (4478 and 3430). This insertion increases 
the spacer region between the wildtype -35 and -10 boxes from 16 to 17 bp, which 
is the optimal distance between these promoter elements. Two isolates (1495 and 
3633) showed substitutions in the promoter region amongst others at positions -42 
and -18, which creates an alternate displaced promoter that is identical to the ampC 
promoter sequence of Shigella. Only isolate 4197 did not contain a substitution in 
the promoter region that could explain the increased abundance of the c-ampC 
transcript. In this case, a substitution in the attenuator region at position +34, which 
is expected to destabilize the stem-loop structure of this element, could account for 
the increased c-ampC expression level. 
Twenty-six of the isolates also had several mutations compared with E. coli ATCC 
25922 (Table 2), but none of these were identified as potentially of influence on 
the promoter or attenuator function. The promoter/attenuator region in the 
remaining isolates (n=14) did not show mutations relative to the reference strain. 
Sequence analysis of the ampC coding region did not show any amino-acid changes 
previously described to lead to extended-spectrum cephalosporinase activity (data 
not shown). p-AmpC were not detected in any of the 49 isolates.
Thus, nine of the 49 isolates were categorized as c-AmpC hyperproducers on the 
basis of (i) positive results in at least two phenotypic AmpC tests, (ii) increased 
c-ampC expression in the qRT-PCR experiments, and (iii) mutations in the ampC 
promoter/attenuator regions associated with c-AmpC hyperproduction.
The MICs of cefoxitin, cefuroxime, ceftazidime and cefotaxime are shown in Table 2. 
Five of six ESBL-negative, c-AmpC hyperproducing isolates showed elevated MICs 
of ceftazidime, i.e. above the epidemiological cut-off of wildtype (WT) strains of ≤ 
0.5 mg/L, whereas only five of the 23 ESBL-negative, cefoxitin-resistant, c-AmpC 
non-hyperproducers had ceftazidime MICs above the WT cut-off. 
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MICs of cefotaxime were above WT cut-off of ≤ 0.25 mg/L in all six hyperproducers 
and in only three of the 23 non-hyperproducers. One ESBL-negative, c-AmpC 
hyperproducing isolate (2483) had MICs of ceftazidime and cefotaxime of 4 mg/L 
and thus was intermediately susceptible to ceftazidime and cefotaxime-resistant. 
MICs of cefuroxime (median: MIC >256 mg/L), ceftazidime (median: MIC 8 mg/L) 
and cefotaxime (median: MIC >256 mg/L) in the ESBL-positive isolates were higher 
than MICs of cefuroxime (median: MIC 12 mg/L), ceftazidime (median: MIC 1 mg/L) 
and cefotaxime (median: MIC 0.25 mg/L) in the ESBL-negative isolates irrespective 
of c-AmpC production. Four of the 15 ESBL-positive isolates were cefoxitin resistant, 
three of which were c-AmpC hyperproducers. 
4.4.2 Detection of c-AmpC production levels
To verify the hyperproduction of the AmpC enzyme at the protein level, cell 
extracts of the nine c-AmpC producing isolates were analyzed by zymography. 
E. coli ATCC 25922 (ATCC) and isolates 3816, 5154, 3365, 4174, 3559, and 3531, 
which did not show increased expression of ampC in the qRT-PCR 
experiments (Table 2), were included as negative controls The zymogram 
of periplasmic extracts revealed, besides a 28-kDa band present in six of the 15 
isolates examined, a very prominent band with the expected apparent molecular 
weight of ~35 kDa present in all nine isolates with increased c-ampC levels (Fig. 1). 
Figure 1. Zymogram analysis of periplasmic extracts revealing expression of the ß-lactamases in clinical E. coli isolates 
with nitrocefin as a ß-lactamase substrate. A predominant band of 35 kDa with ß-lactamase activity was detected in 
nine isolates with increased c-ampC expression levels. A 28-kDa band was found in six isolates. The lane marked MW 
contains the molecular marker proteins, the molecular mass of which is indicated (in kDa). c-AmpC hyperproducing 
isolates are indicated in bold, whilst strain ATCC25922 (ATCC) and isolates 3816, 5154, 3365, 4174, 3559, and 3531, 
which did not show increased expression of c-ampC in the qRT-PCR experiments (Table 2) were included as negative 
controls.
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The hypothesis that this protein represents AmpC was further confirmed in Western 
blotting experiments (Fig. 2), which revealed a reaction of AmpC-specific antibodies 
with a 35-kDa band in the periplasmic fractions of all but one of these nine isolates; 
in the deviating isolate (4197), the c-AmpC production levels were apparently too 
low for detection with the antiserum.
4.4.3 Analysis of ß-lactamase activity 
To determine whether the increased c-ampC expression in the various isolates 
correlated with increased ß-lactamase activity, the rate of nitrocefin hydrolysis 
in whole cell lysates of c-AmpC hyperproducing isolates was determined. 
In comparison to the ß-lactamase activity of E. coli ATCC 25922, isolates 2483, 2958, 
4478, 2942, 2529 and 3430 demonstrated a 100- to 500-fold higher ß-lactamase 
activity. In a positive control isolate, i.e. strain EC-8 which produces CTX-M-1, OXA-1 
and CMY-2,16 the rate of nitrocefin hydrolysis was even approximately 10.000 
times higher than in E. coli ATCC 25922. Nitrocefin hydrolysis rates in lysates of 
the c-AmpC hyperproducing isolates that also produced ESBL (isolates 1495, 3633 
and 4197) was 500- to 1.200-fold higher than in the reference strain. There was 
no clear correlation between nitrocefin hydrolysis rate and the c-ampC expression 
levels, which is largely due to the contribution of ESBLs and other ß-lactamases in 
nitrocefin degradation.
Next, we evaluated whether hyperproduced c-AmpC enzyme could hydrolyze the 
cephalosporins cefuroxime and ceftazidime. For these experiments, periplasmic 
extracts of isolates 2483 and 4478 were used, because of their high c-ampC 
expression level and the absence of ESBL activity or other ß-lactamases detected 
by zymography. No hydrolysis of cefuroxime or ceftazidime could be detected 
(<1 nmol/min/109 cells). In control experiments with cefazolin as the substrate, 
hydrolysis rates of 10.9 and 4.1 nmol/min/108 cells were observed in the cell lysates of 
isolates 2483 and 4478, respectively. In another control experiment using cell lysates 
of isolate EC-8, hydrolysis rates of 38 and 4.5 nmol/min/109 cells for cefuroxime and 
Figure 2. Western blot detection of ß-lactamases. Periplasmic extracts of clinical E. coli isolates and reference E. coli strain ATCC 25922 
(ATCC) were electrophoresed on denaturing SDS-PAGE gels, and the gels were incubated with antisera directed against AmpC. The 
lane marked MW contains the molecular marker proteins, the molecular mass of which is indicated (in thousands) at the left. c-AmpC 
hyperproducing isolates are indicated in bold, whilst strain ATCC25922 (ATCC) and isolates 3816, 5154, 3365, 4174, 3559, and 3531, which 
did not show increased expression of ampC in the qRT-PCR experiments (Table 2), were included as negative controls.
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ceftazidime, respectively, were detected. Thus, the cephalosporins cefuroxime and 
ceftazidime are poor substrates for c-AmpC and/or the hyperproduction levels in 
isolates 2483 and 4478 are not high enough to measure their hydrolysis in whole-
cell lysates of these isolates with the assay used.
As c-AmpC-mediated hydrolysis of cefuroxime and ceftazidime was undetectable, 
we next considered the possibility that these cephalosporins are irreversibly bound 
by the enzyme thereby acting as enzyme inhibitors. Inhibition of ß-lactamase activity 
was assessed by preincubating periplasmic extracts of the isolates 2483 and 4478 
for 1 min with cefuroxime or ceftazidime at various concentrations and subsequently 
determining the remaining ß-lactamase activity by measuring the hydrolysis of 
nitrocefin (Fig. 3; results isolate 4478 not shown). Nitrocefin hydrolysis was inhibited 
by ~50% after preincubation with cefuroxime at a concentration 10,000-fold lower 
than that of nitrocefin and was completely inhibited with cefuroxime when used at 
a 100-fold lower concentration. Ceftazidime appeared a weaker enzyme inhibitor; 
a 14% reduction in enzyme activity was detected at a concentration 1000-fold lower 
than that of nitrocefin and 95% reduction was observed at equimolar concentrations. 
In control experiments, high amounts of the hydrolysable cefazoline only marginally 
inhibited the hydrolysis of nitrocefin (data not shown).
Figure 3. Inhibition of ß-lactamase activity by ceftazidime and cefuroxime. Periplasmic extracts of isolate 2483 were 
incubated during 1 min with various concentrations of ceftazidime or cefuroxime as indicated on the X-axis. Subsequently, 
the remaining ß-lactamase activity was determined using nitrocefin as ß-lactamase substrate. ß-Lactamase activity 
after preincubation without an antibiotic agent is set at 100%. The bars and error bars indicate means and standard 
deviations of three independent experiments.
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The observation that cefuroxime and, to a lesser extent, ceftazidime act as inhibitors of 
c-AmpC suggests that these antibiotics bind the enzyme to form poorly hydrolysable 
acyl-enzyme adducts. The formation of such acyl-enzyme complex can be assessed 
in SDS-PAGE by a reduction in the electrophoretic mobility of the enzyme after 
binding the substrate.16 To test this possibility, periplasmic extracts of the isolates 
2483 and 4478 were either incubated or not with cefuroxime or ceftazidime and 
subsequently analyzed by SDS-PAGE and Western blotting with AmpC-specific 
antiserum. The results showed a slight decrease in the electrophoretic mobility of 
the ~35 kDa c-AmpC band after preincubation with meropenem, cefuroxime and 
ceftazidime (Fig.4; results isolate 4478 not shown), consistent with the postulated 
covalent binding of the substrates to the AmpC protein. This shift was not found in 
the control experiments using cefazolin (data not shown).
4.4.4 OMP analysis
It is known that reduced permeability of the outer membrane can also contribute 
to resistance to cephalosporins. The permeability of the outer membrane to 
ß-lactam antibiotics is largely determined by the presence of a class of abundant, 
channel-forming OMPs, designated porins. E. coli K-12 strains generally produce 
two porins, OmpF and OmpC, when grown under routine laboratory conditions.
To study if the c-AmpC hyperproducing isolates also produced porins, OMPs from 
various isolates were subjected to SDS-PAGE. The OMP profiles showed abundant 
bands with similar apparent molecular weights as the porins and OmpA in all 
isolates examined, except for isolate 3559, which showed only minor bands in this 
molecular weight range (Fig. 5A and B). Western blot analysis with a porin-specific 
antiserum confirmed the presence of one to three porins in all isolates and again 
showed relatively low levels of a porin in isolate 3559 (Fig. 5C).
Figure 4. Covalent modification of AmpC with meropenem, cefuroxime and ceftazidime revealed by SDS-PAGE. Periplasmic extract of 
isolate 2483 was either incubated (+) or not (-) for 20 min at room temperature with 1 mM of the antibiotics and analyzed by SDS-PAGE 
after boiling of the samples. The gel used for this experiment contained 8% acrylamide and 8 M urea. After blotting, the blot was incubated 
with anti-AmpC antiserum. 
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4.5 Discussion
The purpose of the present study was to investigate the contribution of ampC 
expression in cefoxitin-resistant, ESBL-negative isolates and its impact on 
3rd generation cephalosporin activity, in a collection of clinical E. coli isolates. The 
phenotypic AmpC tests in nine isolates correlated with the expression level of RNA 
from the c-ampC gene and with mutations in the promoter/attenuator region of the 
c-ampC gene found by others to be associated with c-AmpC hyperproduction.19-22 
Since no plasmid-encoded AmpC was found in any of the isolates, all AmpC activity 
in our isolates was of chromosomal origin. Thus, c-AmpC hyperproduction was 
found in nine out of 33 (27.2%) cefoxitin-resistant isolates, i.e. in six of the 29 (20.6%) 
ESBL-negative isolates and in three of four ESBL-positive isolates. 
Since average MICs were higher in c-AmpC hyperproducers than in non-
hyperproducers it is concluded that the c-AmpC hyperproduction affects the 
susceptibility to 3rd generation cephalosporins. In the clinical laboratory, this 
decrease in inhibitory activity may go largely undetected, because the MICs were 
in the range between wildtype and the S/I breakpoint of susceptibility, except for 
one c-AmpC hyperproducing, ESBL-negative isolate which clearly showed loss 
of susceptibility to the 3rd generation cephalosporins with MICs of 4 mg/L. In the 
ESBL-positive isolates, the ESBL enzyme probably overrules the effect of c-AmpC 
hyperproduction on cephalosporins, since the MICs of all three cephalosporins 
Figure 5. Analysis of the OMP profiles of E. coli isolates. OMPs were extracted and separated by SDS-PAGE. 
The proteins were either stained in the gel (panel A) or blotted and probed with an OmpA-specific 
monoclonal antibody (panel B) or a porin-specific antiserum (panel C). The lanes marked ATCC and K-12 
show the OMP profiles of E. coli strain ATCC 25922 and E. coli K-12 strain MG1655, respectively, which 
were which were included for reference. The positions of OmpA,and of the porins OmpC and OmpF in the 
K-12 reference strain are indicated. Only the relevant part of the gel, containing the major OMPs, is shown. 
The lane marked MW contains molecular-mass marker proteins and their molecular weights are indicated 
(in thousands) at the left.
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were significantly higher than in the ESBL-negative isolates and were similar in 
c-AmpC hyperproducers and non-hyperproducers. 
The loss of the expression of porins, which facilitate the transport of ß-lactams into 
the bacterial cell, are also known to contribute to resistance.23 Nonetheless, the 
study of porin expression in clinical isolates is highly complex due to the variety 
of porins that can be expressed in different strains and the number of regulatory 
genes and external factors involved. All of the c-AmpC hyperproducing and control 
isolates studied here in detail still produced at least one porin, and five out of the 
six AmpC-overproducing, ESBL-negative isolates (no. 2483, 2529, 2958, 4478, 
and 3430) produced two or even three porins. Therefore, reduced access to the 
periplasm probably does not play a role in the decreased susceptibility of these 
strains to cephalosporins. 
Compared to other ß-lactamases, c-AmpC ß-lactamases have been reported to show 
poor hydrolysis rates for ceftazidime and compared to other ß-lactamases,24 and 
this was confirmed in the present study. It has been suggested that cephalosporins 
may be rendered inactive by mere ‘trapping’ to periplasmic inducible ß-lactamases 
as speculated in Enterobacter cloacae and Pseudomonas aeruginosa.25 In this 
study, we were able to demonstrate that preincubation of periplasmic extracts from 
c-AmpC hyperproducing isolates with small amounts of cefuroxime or ceftazidime 
was sufficient to at least partially inhibit the hydrolysis of nitrocefin in suggesting the 
formation of a stable cephalosporin-enzyme complex. Additional evidence for the 
formation of a stable acyl-enzyme complex was obtained by SDS-PAGE and Western 
blotting, which revealed a decreased electrophoretic mobility of the ß-lactamase 
after preincubation with cefuroxime or ceftazidime. Antunes et al.26 recently also 
described covalent trapping as the mechanism of resistance to ceftazidime caused 
by a deacylation-deficient mutant derivative of the class A TEM-1 ß-lactamase. 
Similarly, evidence for the mechanism of antibiotic trapping by plasmid-encoded 
CMY-2 in carbapenem resistance was found in a porin-deficient, carbapenem resistant 
E. coli isolated from a liver transplant patient.16 Based on our results and supported 
by data described in literature, the reduced susceptibility to cephalosporins can 
partially be explained by c-AmpC hyperproduction in the E. coli isolates studied. 
This enzyme, if present in high amounts, is able to ‘trap’ cephalosporins entering the 
periplasm into a biologically inactive complex. It is expected that mutant derivatives 
of such isolates with limited entry of cephalosporins into the periplasm due to the 
loss of porins will show dramatically decreased susceptibility to cephalosporins. 
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Such mutants might be selected under continuous selection pressure of 
cephalosporin treatment.
In the present study, c-AmpC hyperproduction was not predominant among 
cefoxitin-resistant isolates. As porins were found in the four cefoxitin-resistant non-
AmpC producers examined, it is suggestive that efflux may be responsible for 
the resistance phenotype in these isolates. The contribution of efflux in ß-lactam 
resistance has been proven in a set of isogenic E. coli K-12 strains, in which 
inactivation of the AcrAB efflux pump often resulted in a significant decrease in 
MICs of cefoxitin and cefuroxime.27
For clinical microbiologists, proper recognition of AmpC-producing E. coli is 
important for clinical management. Administration of 3rd generation cephalosporins 
has resulted in treatment failure in two patients with c-AmpC hyperproducing 
isolates.28 MICs of ceftazidime of 4 mg/L and cefotaxime of 2 mg/L were described 
in these patients, comparable to the MICs of one c-AmpC hyperproducing isolate 
(no. 2483) reported in the present study. Recognition of AmpC-production is difficult 
and no accepted guidelines are available. Resistance to cefoxitin can suggest AmpC-
mediated resistance, but because we found it in 27.2% of the cefoxitin-resistant 
isolates only, it is not a specific marker. Although a comparison of phenotypic tests 
was not the purpose of this study, AmpC production was most reliably detected 
using the cefoxitin-boronic acid disk test, which appeared completely consistent 
with the qRT-PCR results. This test is inexpensive and can be used in all clinical 
laboratories. 
It has been suggested to report E. coli with c-AmpC hyperproduction as resistant 
to 3rd generation cephalosporins irrespective of in vitro susceptibility.29 However, 
although no longer wild-type strains, the MICs are often still within the susceptibility 
range and the treatment failures described so far were recognizable by MICs 
above the S/I breakpoints. In our opinion, the interpretation of 3rd generation 
cephalosporins should not be changed to ‘resistant’ on susceptibility reports in order 
to avoid inappropriate use of other classes of antibiotic agents and the emergence 
of resistance. We do recommend surveillance to monitor any developments in 
the resistance to 3rd generation cephalosporins by testing for increased AmpC 
production in cefoxitin-resistant E. coli isolates and by establishing MICs of 
3rd generation cephalosporins in c-AmpC hyperproducers.
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5.1 Abstract 
Objectives: A prospective cohort study was performed among travelers from 
the Netherlands to investigate the acquisition of carbapenemase-producing 
Enterobacteriaceae (CP-E) and extended-spectrum ß-lactamase producing 
Enterobacteriaceae (ESBL-E) and associated risk factors. 
Methods: Questionnaires were administered and rectal swabs were collected 
and tested before and after return. ESBLs were characterized using a microarray 
(Checkpoints). Multilocus sequence typing (MLST) was performed on Escherichia 
coli isolates. 
Results: Of 370 travelers, 32 (8.6%) were colonized with ESBL-E before travel, 113 
(30,5%) acquired an ESBL-E during travel and 26 were still colonized six months 
after return. No CPE were found. Independent risk factors for ESBL-E acquisition 
were travel to South and East Asia. MLST showed extensive genetic diversity among 
E. coli. Predominant ESBLs were CTX-M enzymes. 
Conclusion: The acquisition rate of ESBL-E in travelers from the Netherlands 
was high (30.5%). Active surveillance for ESBL-E and CP-E and contact isolation 
precautions may be recommended at admission to medical facilities for patients, 
who traveled to Asia during the previous six months.
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5.2 Introduction 
The effect of international travel on the spread of multidrug resistant 
Enterobacteriaceae (MDR-E) has become more evident in the past few years. Data 
obtained in prospective studies among returning travelers from Australia, Canada, 
Sweden and New York during 2007-2010 revealed high carriage rates of extended-
spectrum ß-lactamase producing Enterobacteriaceae (ESBL-E) varying from 18-
25% after foreign travel.1-4 Two of these studies also reported a pre-travel ESBL-E 
carriage rate of 7.8%. 
The identification of carbapenemase-producing Enterobacteriaceae (CP-E) 
produced another set of challenges. Carbapenemases, such as Klebsiella pneumoniae 
carbapenemases (KPC), New Delhi metallo-ß-lactamase (NDM), OXA-48, 
VIM and IMP, are plasmid-encoded enzymes, which have emerged worldwide. The 
rate of acquisition of CP-E after foreign travel is unknown and only reported in case 
reports, as recently reviewed by Van der Bij and Pitout.5 In The Netherlands, CP-E 
were found for the first time in 2010.6 No data were available on the pre-and post-
travel carriage rates among travelers from the Netherlands.
Our objective was to investigate whether Dutch travelers are at risk of acquiring 
MDR-E (ESBL-E and/or CP-E) by use of a prospective cohort study design. Because 
detailed microbiological data of the isolates and epidemiological data are crucial 
for assessing the real public health impacts of these organisms, we also investigated 
the persistence of intestinal colonization and possible spread to household contacts 
six months after the travelers returned. 
5.3 Materials and Methods
5.3.1 Study design
A prospective cohort study was conducted at the travel clinic at the Leiden University 
Medical Center (LUMC) and at the Hollands Midden Municipal Health Services (MHS) 
in Leiden, The Netherlands. During March-September 2011, all adults who made 
an appointment for travel advice and had the intention to travel to areas outside 
Europe, North America and Australia were invited to participate in the study. 
Travelers < 18 years of age and those who traveled > 3 months were excluded.Only 
one person of a couple or travel group was included. Participants were asked to 
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complete an electronic questionnaire and to deliver a rectal swab immediately before 
and immediately after travel. Questionnaires were used to collect demographic 
data, previous medical history and travel information. Travelers who acquired a 
MDR-E after foreign travel were asked to fill out a third questionnaire and deliver a 
third rectal swab six months after return. 
If travelers were positive for MDR-E six months after return, their household contacts 
were also requested to submit a rectal swab and questionnaire. Household contacts 
were defined as persons who shared the same household with a participant on a 
regular basis. MDR-E positive participants were asked to deliver a fourth rectal swab 
at the same time. The study was approved by the Leiden University Medical Center 
medical ethics committee.
5.3.2 Bacterial isolates 
Rectal swabs were collected with the Stuart Agar Gel Medium Transport Swabs 
(Copan Diagnostics, Corona, CA). The swabs were inoculated in trypticase soy 
broth (TSB) supplemented with cefotaxime 0.25 mg/L and vancomycine 8 mg/L 
(MP products, Groningen, The Netherlands) and incubated for 24 hours at 37°C. 
After overnight incubation the TSB broths were subcultured on chromogenic ESBL 
screening agar (ESBL-ID, BioMérieux) and sheep blood agar as a growth control. 
All Gram-negative rods growing on the ESBL-ID were identified by MaldiTof-MS 
with BioTyper software (version 3.0; Bruker Daltonics, Germany) and antimicrobial 
susceptibility testing was perform using the VITEK2® system (BioMérieux, Marcy-
l’Étoile, France). All isolates underwent ESBL confirmatory disk testing by disk 
diffusion for ceftazidime and cefotaxime or cefepime (in cefoxitin resistant isolates) 
with and without clavulanic acid as recommended by the Clinical Laboratory 
Standards Institute’s guidelines. 
MICs for meropenem and ertapenem were determined using Etests (AB Biodisk, 
Solna, Sweden) according to the manufacturer’s instructions. MICs were interpreted 
using EUCAST criteria (http://www.eucast.org/clinical_breakpoints/).
5.3.4 Molecular characterization of ß-lactamases
Molecular characterization of the ß-lactamase genes in ESBL-E was performed by 
using Check-MDR CT103 microarray, version 1.1 (Checkpoints B.V., Wageningen, 
The Netherlands). The principals of the microarray system and interpretation 
software have been described previously.7 Concisely, the system combines ligation-
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mediated amplification with the detection of amplified products on a microarray to 
detect the various carbapenemase genes: (OXA-48, NDM-1, IMP, VIM and KPC), 
CTX-M groups (CTX-M group 1, 2, 9 or combined 8/25) and the most prevalent 
ESBL-associated single nucleotide polymorphisms (SNPs) in TEM and SHV-variants. 
Furthermore, the six plasmid-mediated AmpC ß-lactamases can be identified 
(www.lahey.org/studies).
5.3.5 Molecular typing of Escherichia coli isolates
Multilocus sequence typing (MLST) was performed on all E. coli isolates using seven 
housekeeping genes (adk, fumC, gyrB, icd, mdh, purA and recA) to determine the 
corresponding sequence type (ST) and to designate the sequence type complex 
(STC) by using the MLST Databases at the Environmental Research Institute, 
University College Cork website (http://mlst.warwick.ac.uk/mlst/). 
5.3.6 Data analysis
A logistic regression model was used to determine risk factors for the acquisition of 
ESBL-E/CP-E after foreign travel for a total of 338 participants. Associations between 
acquiring an ESBL-E/CP-E post-travel and different variables are calculated as odds 
ratios and p-values. Participants who were positive for ESBL-E/CP-E before travel 
were analyzed separately. Database processing and statistical analyses (univariate 
and multivariate analysis) were performed by using the SPSS software version 20.0 
(SPSS Inc., Chicago, IL, USA). MLST analysis was performed using BioNumerics 
software v.6.6 (Applied Maths, St-Martens-Lathem, Belgium).
5.4 Results
5.4.1 Study population and travel characteristics
In total, 521 participants were invited to participate in the study. 370 travelers 
completed two questionnaires and sent in two rectal swabs and were included 
in the analysis (Figure 1). The median age of the study population was 33 years 
(range 19-82) and 234 (63.2%) were women. The median length of stay abroad 
was 21 days (range 6-90 days). The most common reason for travel was vacation 
(n=277). Of the 370 participants, 113 (30.5%), whose pretravel swabs were negative, 
acquired MDR-E during foreign travel. Of these 113 participants, 19 (16.8%) still 
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carried MDR-E six months after return. In 32 of the 370 participants (8.6%), MDR-E 
was identified before travel. Twenty (62.5%) of these 32 participants returned with 
MDR-E, 7 of whom were still colonized after six months (35%). No MDR-E was found 
before or after travel in 225 participants (60.8%).
5.4.2 Travel-associated risk factors for ESBL-acquisition in returning travelers
For the analysis of travel-associated risk factors, data of 338 returning travelers with 
negative pretravel swabs were used (Table 1). In total, 65 countries were visited; 
these are subdivided in 10 subcontinents. The most common destinations were 
Indonesia (n=62), Thailand (n=30), Malaysia (n=27), Cambodia (n=21), China (n=39), 
Kenya (n=30), Tanzania (n=24), Surinam (n=20) and South Africa (n=19). 
The highest ESBL-E acquisition rates were identified among travelers who visited 
countries in Asia: 73% in South Asia and 67% in East Asia. Univariate and multivariate 
analysis showed that the travel destinations South and East Asia were significant risk 
factors for the acquisition of ESBL-E in returning travelers (p<0.001). Participants 
traveling to Asia (all subcontinents) were more likely to return with an ESBL-E after 
a self-arranged trip (odds ratio 1.7; p=0.07) and stay in hostels/lodges (odds ratio 
1.9; p= 0.08), although this was not statistically significant. There were no other risk 
factors for the acquisition of ESBL-E after foreign travel. 
Figure 1. Flowchart of participants in the study
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Table 1. Person and travel characteristics and risk factors for ESBL-E acquisition in a cohort of 338 travelers from the Netherlands*
Variable No.(%)  
negative pre- 














Gender, female 144 (64) 69 (61.1) 0.88 (0.55-1.41) 0.60
Age
18-25 years 54 (24.0) 28 (24.8) 1.0
26-33 years 66 (29.3) 24 (21.2) 0.39 (0.17-0.92) 0.03
34-51 years 56 (24.9) 28 (24.8) 0.67 (0.28-1.61) 0.37
≥ 52 years 43 (21.8) 33 (29.2) 1.46 (0.60-3.54) 0.41
Vegetarian 13 (5.8)   6 (5.3) 0.91 (0.34-2.47) 0.86
Health care worker 59 (26.2) 27 (23.9) 0.88 (0.52-1.49) 0.64
Daily contact with farm 
animals 
 8 (3.6)   4 (3.5) 1.0 (0.29-3.38) 0.99
Visit to identified risk areas
during previous 12 months 
1.01 (0.64-1.61) 0.96
None 138 (61.3) 69 (61.1)
Africa 26   (11.6) 15 (13.3)
Asia 21   (9.3) 12 (10.6)
India 5     (2.2) 4    (3.5)
Middle East 26   (11.6) 13 (11.5)
Central America and
Carribean Region
17   (7.6) 7   (6.2)
South America 6     (2.7) 5    (4.4)
Medical problem ‡
None 161 (71.6) 84 (74.3)
Inflammatory bowel disease 2 (0.9) 1 (0.9)
Chronic diarrhea 3 (1.3) 0
Chronic constipation 3 (1.3) 1 (0.9)
Irritable bowel syndrome 17 (3.1) 7 (6.2)
Diabetes mellitus 3 (1.3) 1 (0.9)
Gastroesophageal reflux 12 (5.3) 4 (3.5)
Recurrent UTIs 4 (1.8) 1 (0.9)
Autoimmune disease 7 (3.1) 2 (1.8)
Abdominal pain with 
unknown origin
5 (2.2) 2 (1.8)
Gallbladder problems 4 (1.7) 1 (0.9)
Transplantation 1 (0.4) 0
Coeliac disease 0 2 (1.8)
Other 30 (13.3) 18 (15.9)
Antibiotic use during 12 
months before travel
47 (20.9) 17 (15.1) 0.85 (0.56-1.29) 0.45
Hospitalization during 12 months
before travel
<3 months prior 5 (2.2) 3 (2.7)
3-6 months prior 2 (0.9) 1 (0.9)
6-9 months prior 1 (0.4) 1 (0.9)
9-12 months prior 2 (0.9) 2 (1.8)
Travel destination, by 
subcontinents¶
Southeast Asia 73 (32.4) 37 (32.7) 1.01 (0.63-1.64) 0.96
East Asia 11 (4.9) 22 (19.5) 4.70 (2.19-10.1) <0.001 3.95 (1.78-8.73) 0.001
South Asia 7 (3.1) 18 (15.9) 5.90 (2.39-14.60) <0.001 5.09 (2-12.92) 0.001
Central Asia 2 (0.9) 1 (0.9) 1.0 (0.089-1.11) 0.99
Middle East 13 (5.8) 2 (1.8) 0.29 (0.07-1.33) 0.11 0.28 (0.06-1.30) 0.103
North Africa 6 (2.7) 4 (3.5)
Central Africa 39 (17.3) 17 (15)
Southern Africa 23 (10.2) 3 (2.7) 0.24 (0.07-0.82) 0.02 0.24 (0.07-0.85) 0.027
Central America and the 
Caribbean
21 (9.3) 7 (6.2) 0.64 (0.26-1.56) 0.33
South America 30 (13.3) 2 (1.8) 0.12 (0.027-0.50) 0.004 0.14 (0.03-0.59) 0.008
Continued
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Median duration of stay in 
days (range)
21 (6-90) 22 (6-89) 0.99 (0.976-1.004) 0.17 1.0 (0.97-1.0) 0.22
Type of travel 
Self-arranged travel 95 (42.2) 52 (46) 1.17 (0.74-1.84) 0.51
Backpacking 51 (22.7) 25 (22.1) 0.97 (0.56-1.67) 0.91
Organized group travel 62 (27.6) 27 (23.9) 0.83 (0.49-1.39) 0.47
Cruise 1 (0.4) 0
Other 16 (7.1) 9 (8)
Own (holiday) home 16 (7.1) 3 (2.7)
Other 3 (1.3) 3 (2.7)
Reason for travel 
Vacation 166 (73.8) 83 (73.5)
Visit family/friends 8 (3.6) 8 (7.1)
Business 15 (6.7) 9 (8.0)    
Study 18 (8) 7 (6.2)    
Volunteer work 10 (4.4) 5 (4.4)
Travel group composition
Alone 25 (11.1) 14 (12.4) 1.13 (0.56-2.27) 0.73
With 1 partner 102 (45.3) 44 (38.9) 0.77 (0.49-1.22) 0.26
More partners 44 (19.6) 30 (26.5)
Group travel 54 (24.0) 25 (22.1) 1.23 (0.78-1.93) 0.37
Accomodation during travel
Luxury hotels 78 (34.7) 34 (30.1) 0.81 (0.50-1.32) 0.40
Hostels 50 (22.2) 30 (26.5) 1.27 (0.75-2.13) 0.38
Budget hotels 49 (21.8) 27 (23.9) 1.13 (0.66-1.93) 0.66
Own holiday home 16 (7.1) 3 (2.7)
Camping 10 (4.4) 6 (5.3)
With family/friends 8 (3.6) 5 (4.4)
Locals 7 (3.1) 3 (2.7)
Boat 4 (1.8) 2 (1.8)
Other 3 (1.3) 3 (2.7)
Diarrhea during travel 83 (36.9) 45 (39.8) 1.13 (0.71-1.80) 0.60
Companion travelers with 
diarrhea
115 (51.1) 61 (54) 1.1 (0.71-1.77) 0.62
Antibiotic use during travel 10 (4.4) 9 (8.0) 1.86 (0.73-4.72) 0.19 1.98 (0.72-5.47) 0.16
Table 1. Continued
*Data are presented as no. (%), unless stated otherwise. Blank cells indicate no data available for value. OR, odds ratio; UTI, urinary tract 
infection.
†Variables with p < 0.2 in the univariate analysis were included in the multivariate logistic regression model.
‡Participants could report >1 medical problem.
§ Travel destinations visited by the travelers who completed the study were divided in 10 subcontinents (n = no. of travelers per destination. 
One participant could have visited >1 country): Southeast Asia: Cambodia (n = 21), Philippines (n = 1), Indonesia (n = 62), Laos (n = 9), 
Malaysia, (n = 27), Singapore (n = 9), Thailand (n = 30) and Vietnam (n = 17); East Asia: People’s Republic of China (n = 39), Japan (n = 1), 
Mongolia (n = 4) and Taiwan (n = 1); South Asia: Bangladesh (n = 1), India, (n = 20) Maldives (n = 2), Nepal (n = 8) and Sri Lanka (n = 5); 
Central Asia: Kazakhstan,(n = 2), Kyrgyzstan (n = 2) Uzbekistan (n = 2) and Turkmenistan (n = 1); Middle East: Iran (n = 1), Jordan (n = 1), 
 Turkey (n = 14) Emirates(n = 3); North Africa: Egypt (n = 10) and Morocco (n = 5); Central Africa: Benin (n = 1), Cameroon (n = 1), 
Congo (n = 7), Gambia (n = 2), Ghana (n = 1), Kenya (n = 30), Liberia (n = 1), Rwanda (n = 1), Sierra Leone (n = 1), Tanzania (n = 24) and 
Uganda (n = 9); Southern Africa: Angola (n = 1), Botswana (n = 5), Lesotho (n = 2), Madagascar (n = 3), Malawi (n = 5), Mauritius (n = 1), 
Mozambique (n = 2), Namibia (n = 7) South Africa (n = 19), Swaziland (n = 6), Zambia (n = 6)and Zimbabwe. (n = 1); Central America and 
the Caribbean: Belize (n = 2), Bonaire (n = 1), Costa Rica (n = 9), Cuba (n = 5), Curacao (n = 1), Dominican Republic (n = 4), Grenada (n = 1), 
Guatemala (n = 4), Honduras (n = 2), Mexico (n = 9), Nicaragua (n = 5) and Panama (n = 3); South-America: Argentina (n = 3), Bolivia (n = 2), 
Brazil (n = 5), Chile (n = 2), Ecuador (n = 3), Guyana (n = 3, Peru (n = 3), Surinam (n = 20), Trinidad and Tobago (n = 2) and Venezuela (n = 1).
Variable No.(%)  
negative pre- 
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The incidence proportions of ESBL-E after foreign travel are listed in Table 2. 
5.4.3 Microbiological results and molecular characterization 
A total of 133 participants were colonized with an MDR-E after travel. This group 
consisted of 113 travelers, who had initially negative pretravel swabs. In addition, 
20 participants who had positive pretravel swabs also returned colonized with 
MDR-E. The ESBL-E of these 133 post-travel swabs consisted of 146 E. coli, 
10 K. pneumoniae and 2 Enterobacter cloacae isolates.
No CP-E were found among the pre-and post-travel isolates. Molecular 
characterization of the post-travel isolates demonstrated that CTX-M group 1 
ESBL (n=110) predominated (CTX-M-1 like, n=4; CTX-M-3 like, n=1; CTX-M-15 
like, n=85; CTX-M-32 like, n=20), followed by CTX-M group 9 ESBL (n=42), CTX-M 
group 2 (n=2) and CTX-M group8/25 (n=1). One E. coli isolate carried an SHV-
ESBL (238S+240K). In addition some isolates coproduced plasmid-mediated AmpC 
ß-lactamase, ACT/MIR (n=1) or CMY-2 (n=2).
Thirty-four ESBL-E were isolated from pretravel rectal swabs from 32 participants. 
Twenty-nine (85.3%) of them were positive for E. coli, 4 Klebsiella pneumoniae (11.8%) 
and 1 for Citrobacter freundii (2.9%). The CTX-M group 1 ESBL (n=22) predominated 
(CTX-M-1 like, n=4; CTX-M-15 like, n=16; CTX-M-32 like, n=2); the remaining 
ESBL isolates belonged to CTX-M group 9 ESBL (n=8) and CTX-M group 2 (n=1). 
Table 2. Incidence proportions and incidence rates for ESBL-E in 338 Dutch travelers
* Pdt: person days of travel; 
† SE standard error.
‡ The ESBL incidence rate per 100 person days of travel is represented by 4 ESBL-E carrying returning travelers from North Africa. Three 
of them had traveled for 7 days and one traveler had a 25-day stay abroad, which explains the high standard error.
Destination No of 
travelers






Mean duration of 
travel (all travelers)
ESBL incidence rate 
per 100 pdt* (SE†)
Southeast Asia 110 37 (34) 34 (4.5) 2980 27 1.24 (0.20)
East Asia 33 22 (67) 67 (8.3) 776 24 2.83 (0.60)
South Asia 25 18 (72) 72 (9.2) 599 24 3.01 (0.70)
Central Asia 3 1 (30)  33 (33.3) 94 31 1.06 (1.06)
North Africa 10 4 (40)  40 (16.3) 112 11.2  3.57 (1.76) ‡
Middle Africa 56 17 (30) 30 (6.2) 1637 29 1.04 (0.25)
Southern Africa 25 3 (12) 12 (6.6) 631 25 0.48 (0.27)
Middle East 15 2 (13) 13 (9.1) 222 14.8 0.90 (0.64)
Central America 
and the Caribbean
28 7 (25) 25 (8.3) 544 19 1.29 (0.48)
South America 32 2 (6) 6 (4.4) 922 29 0.22 (0.15)
All travelers 338 113 (33) 33 (2.6) 8536 25 1.32 (0.12)
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Two E. coli isolates carried an SHV-ESBL (238S+240K). 
Co-resistance to other classes of antimicrobial drugs was common in pre- and post-
travel isolates; 67% displayed resistance to cotrimoxazole, 36% to ciprofloxacin, 
37% to tobramycin, 35% to gentamicin and 29% to nitrofurantoin. All isolates were 
susceptible to colistin and carbapenems.
5.4.4 MLST of ESBL-producing E. coli isolates
MLST of 146 E. coli isolates from the post-travel swabs identified 86 different 
sequence types (ST); 31 new STs were found. The most prevalent STs were: ST38 
(12%; n=17), ST10 (7%; n=10) and ST131 (4%; n=9). The distribution of the CTX-M 
groups and types and STs is displayed in Figure 2. There was no association 
between ST and ESBL-type, nor were STs associated with specific travel destinations. 
Pretravel isolates showed a similar diversity of STs, of which three were ST131. 
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Figure 2. Multilocus sequence typing of Escherichia coli (n=146) from the post-travel isolates of 133 travelers from the Netherlands. The 
numbers indicate the most prevalent sequence types (STs). Gray shadow indicates that >1 ST belongs to the same complex. The following 
sequences belong to STC10: ST4,10, 34, 43, 44, 48, 167, 193, 215, 218, 227, and 617. Thick connecting lines indicate single-locus variants; 
thin connecting lines indicate variants with 2–3 loci differences; dashed connecting lines indicate variants with 4 loci differences; dotted 
connecting lines indicate 5–7 loci differences.
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5.4.5 Prolonged carriage and household contacts
Of the 133 participants whose samples were positive for ESBL-E after return, 127 
(95.4%) completed the follow-up survey and provided samples after six months. 
ESBL-E was isolated from 26 samples (20.4%) (Table 3). None of these participants 
reported the use of antibiotics, or were hospitalised during the previous six months; 
none were healthcare workers and none reported contact with farm animals. Seven 
participants reported diarrhea.
Of 113 participants, who had initially negative pretravel swabs and positive swabs 
immediately after return, 19 (16.8%) were still colonized after six months. Of these, 
7 participants had samples that were positive for E. coli with the same ST six months 
after return. Nine participants carried an E. coli with a different ST six months 
after return. Three were positive for a different species six months after return. 
Eleven household contacts of 4 MDR-E positive participants agreed to cooperate 
and submitted a rectal swab. ESBL-producing E. coli was isolated from 2 (18.1%) 
household contacts, each from different households. The first household contact 
carried a different ESBL-producing E. coli than the associated traveler before and 
after travel. Both isolates carried a CTX-M group 9 enzyme. The second household 
contact was positive for SHV-ESBL producing E. coli ST2599. The associated 
traveler's sample were positive for E. coli ST617 and ST38 immediately after travel, 
K. pneumoniae six months after return and a CTX-M-15 like E. coli ST3363 in the 
fourth rectal swab.
Of 20 participants whose samples were positive before and after return, 7 participants 
(35.0%) were still colonized six months after return. Of these 7 participants, 5 carried 
a similar strain: 2 carried a CTX-M- group 9-producing E. coli with an identical ST 
as before travel, 2 carried a similar ST but with a different CTX-M group enzyme as 
before travel and one participant carried a CTX-M group 1 producing K. pneumoniae 
during the study period. Two participants returned with an E. coli with a different ST. 
No household contacts participated in this subgroup of travelers.
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Table 3. Microbiological and molecular characteristics of rectal swabs samples collected from travelers from the Netherlands immediately 
pre-and post-travel and 6 months after return*
*ID, participant identification number; CTX-M, extended-spectrum ß-lactamase enzyme; ST, sequence type; Neg, no species were isolated 
from sample; E., Escherichia; K.p., Klebsiella pneumoniae; NA, not applicable; ND, no sequence type data available.
†None of the participants with a positive rectal swab sample after 6 months reported antimicrobial drug use during the 6 months after 
return.
Immediate post-travel samples  
Post-travel sample 6 
























25 Neg NA NA E. coli 9 131 Neg NA NA E. coli 9 131
45 Neg NA NA E. coli 1 405 E. coli 9 38 E. coli 1 405
56 Neg NA NA E. coli 1 3036 E. coli 1 517 E. coli 1 3267
60 Neg NA NA E.  coli 1 648 K. p. 1 ND E.  coli 1 648
61 Neg NA NA E. coli 1 648 E. coli 9 227 E. coli 1 131
62 Neg NA NA E. coli 9 3037 Neg NA NA E. coli 9 501
80 Neg NA NA E. coli 1 131 Neg NA NA E. coli 9 1177
86 Neg NA NA E. coli 1 93 E. coli 1 2090 E. cloacae 9 ND
137 Neg NA NA E. coli 1 155 E. coli 1 617 E. coli 9 131
204 Neg NA NA E. coli 1 38 Neg NA NA K. p. 1 ND
211 Neg NA NA E. coli 1 3044 Neg NA NA K. p. 1 ND
222 Neg NA NA E. coli 9 2003 Neg NA NA E. coli 9 2003
238 Neg NA NA E. coli 9 414 Neg NA NA E. coli 9 10
251 Neg NA NA E. coli 1 34 Neg NA NA E. coli 1 450
309 Neg NA NA E. coli 1 3045 Neg NA NA E. coli 1 3045
373 Neg NA NA E. coli 1 38 Neg NA NA E. coli 1 3266
387 Neg NA NA E. coli 1 131 Neg NA NA E. coli 1 131
454 Neg NA NA E. coli 9 10 Neg NA NA E. coli 9 10
474 Neg NA NA E. coli 1 154 Neg NA NA E. coli 1 131
12 E. coli 9 38 E. coli 1 3074 Neg NA NA E. coli 1 38
105 E. coli 1 191 E. coli 1 120 E. coli 1 38 E. coli 1 120
255 E. coli 9 131 E. coli 1 617 Neg NA NA E. coli 9 131
269 K. p. 1 ND K. p. 1 ND Neg NA NA K. p. 1 ND
283 E. coli 9 131 E. coli 1 46 Neg NA NA E. coli 9 131
505 E. coli 1 1163 E. coli 1 69 Neg NA NA E. coli 9 3268
512 E. coli 9 657 E. coli 9 657 Neg NA NA E. coli 1 657
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5.5 Discussion
The results of this study show a high ESBL-E carriage rate of 30.5% among healthy 
participating travelers from the Netherlands after return. This finding is worrisome, 
because this ESBL-E carriage rate is higher compared with those in recent studies that 
identified international travel as an independent risk factor for ESBL-E colonization.1-4 
It is striking that none of the potential travel-associated risk factors investigated in 
this study, other than traveling to South and East Asia, were found to contribute to 
this high ESBL-E carriage rate. Additional risk factors were not revealed by including 
the univariate analysis the 13 participants who had a positive pretravel swab, and 
acquired an ESBL-producing E. coli during travel with a different ST than before 
travel. Gastroenteritis during travel was found to be associated with the risk of ESBL-E 
acquisition in Swedish travelers.3 That association was not found in this study, which 
may reflect less fecal-oral contamination while traveling. Baaten et. al. reported that 
diseases transmitted by the fecal-oral route among travelers to non-industrialized 
countries have declined because of improved hygiene standards at the destination 
as measured by the human developmental index, sanitation index and the water 
source index.8 The sanitation index (SI) levels, which represent the proportion of 
the population that has access to sanitation, were the lowest for Sub-Saharan Africa 
and the Indian subcontinent. On the basis of these indices, we would expect the 
incidence of ESBL-E acquisition to be similar among travelers in countries in Asia 
and Africa. Nonetheless, participating travelers to Asia had the highest post-travel 
colonization rates. Travelers to Asia most likely differ in their eating habits compared 
to travelers to African countries, since the former are more likely to eat in individual 
establishments outside of hotels or from street vendors. Thus, the high incidence 
rate found in returning travelers from Asia in this study may result from the increased 
risk for foodborne exposure.
No CP-E were found despite the fact that countries were visited where CP-E are 
prevalent in hospitals and in the environment.5 Other known risk areas besides 
India, for the acquisition of CP-E, such as the USA, Greece, Italy and the Balkan 
region were not included in this study, because these travelers do not visit the Travel 
Clinic of the LUMC. Many citizens from the Netherlands have relatives in North-
African countries or Turkey whom they visit frequently. OXA-48 producing bacteria 
are endemic to these countries.9 These travelers do not consult travel clinics and 
may well return carrying OXA-48 producing isolates unnoticed.
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Peirano et. al.2 reported that the prevalence of ST131, an uropathogenic E. coli, 
notorious for its worldwide expansion and spread of CTX-M-15, was similar among 
travelers and non-travelers from the Calgary region. The most prevalent ESBL among 
the travelers participating in this study was the CTX-M-15 like enzyme. However, this 
enzyme was found in a plethora of different sequences types of E. coli. Participants 
in the Leiden area not only showed a great heterogeneity of sequence types, but 
also harboured different CTX-M-types after travel and six months after return. 
The majority of the E. coli strains identified in the participants in this study were 
of sequence types that clustered around ST10 and belonged to sequence type 
complex 10 (STC10). STC10 strains essentially belong to the non-virulent, commensal 
phylogenetic group A.10 In a recent study based in France, isolates belonging to 
STC10 were found to be the most prevalent among fecal samples of healthy carriers 
of nalidixic acid resistant (but ESBL-negative) E. coli.11 It is also the most prevalent 
STC in the MLST database. Data from this study show that transmissible genetic 
elements containing resistance genes are exchanged with naïve E. coli strains of 
the human intestinal microbiota during foreign travel combined with foodborne 
exposure. 
Although 26 participants had positive results for ESBL-E six months after travel, 
they were not all positive for the same enterobacterial strain that was identified 
immediately after travel. In 8 travelers colonized with E. coli, an ESBL of the same 
CTX-M group was found in the immediate post-travel sample as after six months, 
but E. coli with a different ST was detected. In 11 travelers, the strain persisted 
during the study period. It is possible that more strain types were present in the 
rectal samples where colony morphology of different strains was not discriminative. 
However, it is also possible that the transfer of ESBL genes between strains within 
a host is a frequent occurrence. Or, the acquisition of a new ESBL-E occurs at the 
expense of the resident strain.
Interhousehold transmission of ESBL-E has been demonstrated in the community 
setting.12,13 Clonally related strains could be found for 66% of the isolates from 
infected community patients and their corresponding household contacts.13 Because 
of the limited data on household contacts in the present study, the transmission 
dynamics of ESBL-E in households after foreign travel remain to be discovered. 
The high pretravel ESBL-E carriage rate among our study participants (8.6%) was 
an unexpected finding. Two recent studies on the ESBL-E carriage rate in the 
community have been conducted in the Amsterdam area. In the first study, 10.1% of 
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the fecal samples from outpatients with gastrointestinal discomfort being assessed 
by their general practitioners yielded ESBL-E, predominantly CTX-M-15 producing 
E. coli.14 In a second study, investigating the prevalence of ESBL-E carriage in the 
general community, a carriage rate of 8.5% was found (E.A. Reuland, unpublished 
data). Although no data on travel history were given, the investigators pointed out 
that foreign travel might be responsible for at least part of ESBL-E carriage rates 
among outpatients from the Netherlands. This finding is supported by data from 
our study: 50% of participants who had a positive pretravel swab had traveled 
during the previous 12 months. This high percentage of carriers identified in this 
study before travel points towards ongoing importation of ESBL-E. Other potential 
reservoirs for ESBL-E are poultry and other retail meat, which have been found to be 
contaminated with ESBL-producing E. coli strains harboring the genes on identical 
plasmids as found in human isolates.15, 16
International travel is growing and the number of intercontinental flights has 
increased during the past decade. The findings in this study support the role of 
international travel on the ESBL-E acquisition and carriage rates among travelers 
from the Netherlands, especially to South and East Asia. The high pre- and post-
travel carriage rates among persons traveling from the Netherlands indicate that 
the consequences of increased foreign travel are already manifest in this country. 
The lack of apparent travel-associated risk factors, the spread of CTX-M enzymes 
through a highly diverse population of E. coli, the association of ESBL-production 
with multidrug resistance, and the possible role of other sources make containing 
the spread difficult. These factors also complicate the implementation of other 
strategies, such as pretravel advice, and imply that all travelers to Asia should be 
considered for carriage of ESBL-E. Although CP-E were not found in this study, 
CP-E have been introduced into the Netherlands by returning travelers,6,17-19 and 
introduction by asymptomatic travelers to the Netherlands from countries where 
CP-E are endemic, may largely go unnoticed. There is no reason to assume that, 
after CP-E are introduced, their spread will be less dynamic than of ESBL-E. This 
inference has serious implications for implementation of screening methods and 
effective infection control strategies. On the basis of the results of this study, we 
recommend active surveillance of CP-E and ESBL-E and at least temporary contact 
isolation precautions for patients being admitted to hospitals after travel to Asia 
during the previous six months.
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Objectives: Whole genome sequencing (WGS) technology is a high throughput 
method to rapidly identify all genes of interest in clinical multidrug resistant 
Escherichia coli.
 
Methods: Ten well characterized clinical isolates of E. coli were selected for WGS 
by the use of Ion Torrent to determine the presence of antimicrobial resistance 
mechanisms for ß-lactam antibiotics, fluoroquinolones, aminoglycosides and 
cotrimoxazole. In addition, Ion Torrent sequencing was used to assess the multilocus 
sequence type (MLST) and the presence of 13 virulence genes. Results were 
compared with conventional PCR and sequence data for 18 antimicrobial resistance 
genes. 
Results: For 17 antimicrobial resistance genes WGS results were consistent 
with conventional PCR and sequencing data. Only blaSHV genes were difficult to 
recognize, due to a low coverage rate. In addition, this technique identified 
13 virulence genes and determined the ST type correctly in all isolates. 
 
Conclusion: It is concluded that Ion Torrent sequencing of clinical isolates is an 
excellent approach to rapidly identify antimicrobial resistance genes, to detect 
virulence genes and to determine the sequence type in one single run.
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6.2 Introduction 
Multidrug resistant Escherichia coli increases in incidence across Europe.1 As such, 
accurate and rapid antimicrobial susceptibility testing in multidrug resistant isolates 
delivers direct clinical benefit. Besides determining species and antimicrobial 
susceptibility testing, other characteristics, such as virulence genes provide 
valuable information on the emergence of virulent and epidemic strains. For that, 
a single test which provides all characteristics is indispensable. Whole genome 
sequencing (WGS) technology provides rapid complete genome sequencing and 
thereby potentially full characterization of the genetic profile of a bacterial strain. 
During recent years there has been a dramatic reduction in cost and an increase 
in the quality of WGS, making this technology economically feasible as a routine 
tool, not only for scientific research2,3 but also for clinical diagnostics4-11 and 
surveillance. The introduction of affordable and fast bench-top next-generation 
sequencer machines like the Ion Torrent Personal Genome Machine® (PGM) makes 
this technology feasible as a routine tool for clinical diagnostics. The Ion Torrent 
PGM® has successfully been applied in niche areas, such as the detection of drug 
resistance in Mycobacterium tuberculosis strains,12 genomic typing of Neisseria 
meningitidis13 and in a retrospective outbreak investigation of extended spectrum 
ß-lactamase (ESBL)-producing E. coli.14 WGS for detection and characterization of 
microorganisms directly from clinical samples has been published recently.6
However, there is little knowledge regarding the concordance between Ion Torrent 
sequencing data and conventional PCR and/or phenotypic testing in clinical 
multidrug resistant E. coli isolates, typing results, and the presence of virulence 
genes in an endemic setting. The purpose of the present study was to assess the 
performance of the Ion Torrent PGM® for the combined detection of antimicrobial 
resistance in clinical E. coli isolates, i.e. the resistance genes for ß-lactam antibiotics, 
including carbapenems, fluoroquinolones, aminoglycosides and cotrimoxazole, 
housekeeping and virulence genes.
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6.3 Materials and Methods 
6.3.1 Bacterial strains and antimicrobial susceptibility testing
Ten clinical E. coli isolates with various sequence types were selected as representative 
of multidrug resistant phenotypes. Of these isolates, phenotypic antimicrobial 
susceptibility (AST) results, as well as conventional PCR and sequencing data on 
selected antimicrobial resistance genes and multilocus sequence typing (MSLT) data 
from a previous study were available15 to assess the concordance with Ion Torrent 
sequencing data. No conventional PCR data were available for genes encoding 
resistance to cotrimoxazole and aminoglycosides, nor for the presence of virulence 
genes.
All isolates were identified by MaldiTof-MS with BioTyper software (version 3.0; 
BrukerDaltonics, Germany) and antimicrobial susceptibility testing was performed 
using the VITEK2® system (BioMérieux, Marcy-l’Étoile, France). ESBL production 
was investigated by the combination disk test with ceftazidime and cefotaxime 
or cefepime (in cefoxitin resistant isolates) with and without clavulanic acid as 
recommended by the Clinical Laboratory Standards Institute’s guidelines. MICs 
for meropenem were determined using Etests (BioMérieux, Marcy-l’Étoile, France) 
according to the manufacturer’s instructions. MICs were interpreted using EUCAST 
criteria (http://www.eucast.org/clinical_breakpoints/).
Screening for gyrA, gyrB, parC, parE, qnrA, qnrB, qnrS, aac(6’)-Ib, qepA, the 
ß-lactamase genes blaTEM, blaSHV, blaOXA, and blaCTX-M was performed as described 
previously.15 Phenotypic screening and confirmation of carbapenemases was 
performed using the Modified Hodge test and multiplex PCR of the carbapenemase 
genes blaKPC, blaNDM, blaOXA-48, blaVIM and blaIMP.
16
6.3.2 DNA isolation
E. coli isolates were incubated on sheep blood agar (BioMérieux, Marcy-l’Étoile, 
France) overnight at 37°C. DNA isolation was performed using the DNAeasy Tissue 
Kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. The purity 
of the DNA was measured with a NanoDrop 1000 apparatus (NanoDrop products), 
and the quantity was estimated by a fluorescence-based method using a Qubit 
double-stranded DNA BR assay kit and a Qubit fluorometer (Life Technologies, 
Germany) according to the manufacturer’s instructions.
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6.3.3 Emulsion PCR and sequencing on the Ion Torrent
The genomic DNA samples were processed into Ion Torrent sequencing 
libraries using the Ion Xpress™ Plus gDNA Fragment Library Preparation 
method (Life Technologies; 4471269, Germany) using the guidelines provided 
by the manufacturer. Libraries were generated using 1 µg of the genomic DNA. 
Each sample was assigned a unique sequence barcode during this step. The final 
library fragment size was set to 300bp using a standard agarose gel size selection. 
Template preparation by ePCR and Ion sphere enrichment procedures were 
performed using the OneTouch system and Enrichment system, respectively using 
standard protocols (Ion OneTouch™ 200 Template Kit v2; 4478316). Samples were 
sequenced on Ion 318-chips (Life Technologies; 4469496), using the standard single 
end 200 bp read lengths [Ion PGM™ Sequencing 200 Kit v2; 4482006]. On each Ion 
Torrent 318- chip, two barcoded samples were sequenced. Primary analysis of the 
sequencing data to generate FASTQ files was done using Torrent Suite version 2.2. 
6.3.4 Data analysis
The analysis of the sequenced reads has two major components: one is focused on 
the identification of genes by means of coverage and variant calling; the other one 
is focused on the typing of variants to determine the sequence type. First, all reads 
are mapped to the reference genome (AC 000091.1) using the TMAP aligner with 
default settings. Then the unaligned reads are extracted from the resulting BAM file 
using SAMTools, which are subsequently converted back to FASTQ files using an 
in-house script (Figure 1 on the next page). 
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For more information about the used tools and their versions, see Table 1. All in-
house scripts and the pipeline are available online.17 All calculations were done on 
a cluster with
 
360Us running the Open Grid Scheduler.
Name Version  Description
TMAP 0.0.19 Ion Torrent Aligner
SAMTools 0.1.19 Alignment manipulation tools
Piletools 0.21.dev Mpileup manipulation tools.a
Wiggelen 0.2.0 Wiggle track manipulation tools.b
Unmap None Convert BAM to FASTQ.c





Table 1. Tools and version number used for the analysis
Figure 1. The short reads are mapped to the genomic reference sequence using TMAP. Unmapped reads are mapped in parallel to 
candidate plasmid reference sequences. For reference sequences on genome and plasmids variants are called and a consensus sequence 
is generated.
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6.3.5 Gene identification
The reads from all sequenced genomes were aligned with the sequences of all 
674 genes of interest (https://git.lumc.nl/j.f.j.laros/paltansing-ecoli/blob/master/
analysis/genes.csv for the list of genes). Two metrics were used in order to identify 
these genes. First, the fraction of non-N content was assessed in order to calculate 
the horizontal coverage of the gene. Then, the number of variants compared to 
the reference sequence was used to distinguish between different gene variants. 
A coverage rate of 100% without variants was chosen to define the presence of a 
gene. 
6.3.6 MLST
Consensus sequence construction of the Ion Torrent sequencing data of the seven 
housekeeping genes (adk, fumC, gyrB, icd, mdh, purA and recA) was performed 
and converted to FASTA with Fastools. The FASTA sequences were entered into the 
MLST database of the Environmental Research Institute, University College Cork 
website (http://mlst.warwick.ac.uk/mlst/) to determine the sequence type.
6.3.7 Virulence genes
The presence/absence of thirteen virulence genes coding for fimbriae: fimA, fimI, 
fimC and fimD; iron-hydroxamate transporter units: fhuB and fhuD; flagellin: fliC; 
lipopolysaccharide rfaY, rfaK, fepE and fepC; genes coding for invasion: aslA, csgA 
and csgB was investigated.
6.4 Results
6.4.1 Performance data
The turnaround time from DNA isolation to sequence reads was about 24 hours. 
Sequencing yielded 2.29× 106 reads on average per strain with a mean read length 
of 235 nucleotides. Of these reads, 80% mapped to the reference genome, giving 
an average coverage of 92x.
6.4.2 Sequencing of cultured isolates
WGS led to the same species identification of the 10 isolates conventionally 
identified as E. coli (16S rRNA gene).
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ß-lactams Fluoroquinolones Aminoglycosides
AMP CAZ CTX ESBLa MER CIP GEN/TOB CTR
Isolate P P Pa Pa bla gene(s) P Gb P G P G P G
1508 R R R + TEM-1
CTX-M-1
S - R gyrA:S83L, D87N
parC:S80I
R aadA5 R sul2
dfrA17
1632 R R R + TEM-1
OXA-1
CTX-M-15









1941 R - S S - - S - R gyrA:S83L, D87N
parC:S80I
R aadA1 R sul2
dfrA1
2218 R R R + OXA-1
CTX-M-55







2404 R - R R + CTX-M-9a
SHV-12*








2480 R R R + TEM-1
CTX-M-1






2500 R R R + TEM-1
OXA-1
CTX-M-15









2506 R R R + TEM-1
CTX-M14




R aadA5 R sul2
dfrA17
4300 R R R Indet OXA-1
SHV-12*
I - R gyrA:S83L, D87N
parC:S80I
parE:S458A
R aadA1 R sul1













Table 2. Phenotypical susceptibility and resistance genes detected in clinical E. coli isolates using Ion Torrent sequencing
AMP, ampicillin; CAZ, ceftazidime; CTX, cefotaxime; ESBL,extended-spectrum-ß-lactamase; MER, meropenem; CIP, ciprofloxacin; GEN, 
gentamicin; TOB, tobramycin; CTR, cotrimoxazole; P, phenotype;G, genotype;S, sensitive; I, intermediate, R, resistant  
aESBL confirmatory disk testing+, positive; -, negative; b-, no genotype found; indet, indeterminate. bla, ß-lactamase 
Bold face indicates that conventional PCR and sequencing as well as Ion Torrent sequencing data were concordant in these isolates. 
*indicates that conventional PCR and sequencing as well as Ion Torrent sequencing data were not concordant in these isolates.
Italicized text indicates genes identified with Ion Torrent sequencing.
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An overview of the phenotypic AST and the resistance genes of individual isolates 
as detected by the Ion Torrent is shown in Table 2 on the left page.
Ion Torrent sequencing data of these isolates showed 100% concordance with 
conventional PCR and sequencing data for the ß-lactamases: blaTEM, blaOXA and 
blaCTX-M types. For the blaCTX-M type of ESBLs, conventional and Ion Torrent sequencing 
results were concordant in all ESBL positive isolates (n=8). WGS data correlated with 
previously identified single nucleotide polymorphisms in the quinolone resistance 
determining regions of gyrA, parC and parE, associated with resistance to 
ciprofloxacin in all cases. In addition, the presence of plasmid-mediated quinolone 
resistance genes qnr and aac(6’)-Ib-cr were consistent with the results as found with 
conventional PCR and sequencing, as previously described.15 No qepA or oxqAB 
loci were found by either method. 
Three isolates contained blaSHV-12 by conventional PCR and amplicon sequencing. In 
one isolate (2404), the blaSHV gene was found with Ion Torrent sequencing. However, 
it was not able to discriminate between the exact blaSHV-type. In the remaining two 
isolates, 4300 and 6059, the presence of blaSHV-12 could not be detected with a 100% 
coverage rate. The coverage rate for blaSHV-12 in these two isolates was only 97.2% 
and 97.7%, respectively. 
The MICs of meropenem for the isolates 4300 and 6059 were 1.5 mg/L and 4 mg/L, 
respectively. No carbapenemase production was detected among these two isolates 
with the Modified Hodge test. Two multiplex real-time PCR for detection of KPC, 
NDM, OXA-48, VIM and IMP- type carbapenemases were negative in both isolates. 
This is in agreement with Ion Torrent sequencing data, in which carbapenemase 
genes were not detected in either genome.
No conventional PCR was performed for genes encoding resistance to cotrimoxazole 
and aminoglycosides. We sought whether representative genes were present, as 
described in the literature. Aminoglycoside resistance was typically associated with 
the presence of aac-like and aadA-like genes. Other aminoglycoside resistance loci 
included ant-3 in two isolates. No aph-like enzymes were detected. 
Cotrimoxazole resistance was associated with the presence of sul and dfrA genes 




Table 3 summarizes the MLST results. For all ten isolates, conventional typing results 
were concordant with the Ion Torrent sequence data generated.
6.4.4 Virulence genes
Thirteen virulence genes coding for fimbriae: fimA, fimI, fimC and fimD; iron-
hydroxamate transporter units: fhuB and fhuD; flagellin: fliC; lipopolysaccharide 
rfaY, rfaK, fepE and fepC; genes coding for invasion: aslA, csgA and csgB were 
identified (Table 4). Compared to the other sequence types, ST131 strains isolated 
from urine samples, both harbored most of the virulence characteristics investigated, 
i.e. 12 out of 13. In two E. coli ST167, also from urine samples, only 8 out of 13 
virulence genes were found. None of the genes coding for fimbriae (fimA, fimI, 
fimC, fimD) and no rfaK encoding a lipopolysaccharide were found in these strains.
Although phenotypic AST results for E. coli ST648 (isolate 1632 from urine) 
were similar to the E. coli ST 131 strains, only six virulence genes were found. 
The remaining sequence types did not show any relation to the number of virulence 
genes.
Isolate adk fumC gyrB icd mdh purA recA ST
1508 10 11 4 8 8 13 2 167
1632 92 4 87 96 70 58 2 648
1941 10 11 4 8 8 13 2 167
2218 62 100 17 31 5 5 4 362
2404 18 106 17 6 5 5 4 393
2480 6 4 159 44 112 1 17 1011
2500 53 40 47 13 36 28 29 131
2506 53 40 47 13 36 28 29 131
4300 6 4 324 1 20 12 7 3583
6059 35 37 29 25 4 5 73 405
ST, sequence type
Table 3. Results from the 10 E. coli isolates showing alleles and ST-type
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6.5 Discussion 
In the present study, we conducted a pilot project to determine if WGS technology 
allows for an efficient extended characterization of routine isolates, beyond what 
is customary in a routine diagnostic setting. Using WGS on multidrug resistant 
E. coli isolates, we were able to obtain species on the basis of the 16S rRNA gene, 
multilocus sequence type, as well as the identification of antimicrobial resistance 
and virulence genes. In a recent study, prediction of antimicrobial susceptibility was 
performed using a study database of >100 known resistant loci, including plasmid-
mediated and chromosomal resistance genes on 74 E. coli and 69 Klebsiella 
pneumoniae isolates, that were sequenced using the Illumina HiSeq 2000 platform.18 
High sensitivity and specificity was obtained compared with phenotypic methods 
in routine use. 
One disadvantage of the Illumina HiSeq is that it has a long run time of 12 days at high 
costs. The Ion Torrent PGM® has a turnaround time of 24 hours from DNA isolation 
to sequence reads. It is clear that for most uses in routine clinical microbiology a 
fast, cheap and compact bench-top machines, is preferable to the large, expensive, 
high-capacity machines like the Illumina HiSeq. 
This report describes the application of the 318-chip for the Ion PGM platform, 
which supports for up to 200 bp read lengths. Long reads add to a higher coverage 
rate of the genome, which is important to detect single nucleotide polymorphisms 
Table 4. Virulence genes present in 10 E. coli isolates as found with Ion Torrent sequencing
+, gene present;-, gene absent
ST, sequence type
Virulence genes
Isolate ST specimen fimA fimI fimC fimD fhuB fhuD fliC rfaY rfaK fepE aslA csgA csgB
2500 131 urine + + + + + + - + + + + + +
2506 131 urine + + + + + + - + + + + + +
6059 405 blood + + + + + + + - - + + + +
2218 362 blood + + + + + + + - - + + + +
2404 393 sputum + + + + + + + - - + + + +
2480 1011 blood + + + + + + - - - + + + +
4300 3583 blood + + + + + + + - - + - + +
1508 167 urine - - - - + + + + - + + + +
1941 167 urine - - - - + + + + - + + + +
1632 648 urine - - - - + + + - - + + + -
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(SNPs) at crucial sites. In this study, all SNPs in the seven housekeeping genes were 
accurately detected. With regard to SHV-type detection, no reliable discrimination 
of the blaSHV-type could be made. Accurate SNP calling is important to distinguish 
the exact blaSHV-type, because this family of ß-lactamases comprises both non-ESBL 
and ESBL variants. In this study, isolates with blaSHV-12 showed a low coverage rate, 
most likely due to poor mapping to the reference. This problem may be overcome 
in future with the generation of longer reads (>200 bp) or alternative methods for 
mapping based assembly as performed in this study.
Although clinical decision making based on WGS data was not the purpose of 
the present study, missing the blaSHV genes would not have affected treatment or 
infection control measures in two cases, since blaCTX-M already accounted for ESBL-
activity. The remaining case (no. 4300) would be of concern if no phenotypic AST 
was conducted, as the presence of blaSHV with extended-spectrum activity could not 
be detected and no plasmid-mediated blaAmpC or carbapenemases were identified. 
As no carbapenemases were found in our isolates, it is likely that porin loss combined 
with ESBL-production is responsible for reduced susceptibility to meropenem,19, 20 
which needs further investigation. The WGS approach to investigate the resistance 
mechanisms porin expression and efflux pump activity have to be systematically 
investigated in association with phenotypic results. In addition, alternative sequence-
based methods in the field of bacterial transcriptomics such as RNA-Seq needs to 
be explored.21
The WGS approach has created the additional opportunity to identify virulence 
genes, which provides information on the virulence potential of a specific isolate. 
Routine typing, surveillance and outbreak detection of verotoxigenic E. coli 
is already applicable and may also be used for typing and surveillance of other 
pathogens.22 Several research studies using WGS have revealed that E. coli ST131 
possess a variable complement of genes encoding established virulence factors in 
urinary tract infections.23-25 
Broadly disseminated international clones such as ST131, ST405 and ST648 have 
emerged among E. coli that produce CTX-M ß-lactamases as important causes of 
community-onset urinary tract and bloodstream infections. These STs were found 
to have more virulence factors present compared to other ST38 and non-STs.26 We 
were able to show that most of the virulence factors investigated were present in 
ST131 (12 out of 13) and ST405 (11 out of 13) compared to ST648 (6 out of 13). 
The precise role of these virulence factors remains to be elucidated; however 
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the combination of antimicrobial resistance and the presence of certain virulence 
factors might be important for their spread. Identifying virulence genes with the 
WGS approach is still at an early stage, but with the increase usage of this method 
providing new understanding of virulence factors in different STs. In addition to 
resistance prediction, the identification of virulence genes combined with patient 
characteristics may potentially predict the virulence potential of an isolate in 
the human host, i.e. the probability of recurrent infection and progression of an 
uncomplicated infection to bacteraemia.
Sequence based diagnostics will become a part of the clinical microbiology in the 
next era. The huge potential of WGS lies in its completeness: once sequenced 
the genetic information results in full characterization of clinical isolates. Therefore, 
WGS is a promising alternative to current diagnostic and reference tests. The data of 
this retrospective, proof-of-principle experiment is promising for the future. Further 
work is required to assess the performance and cost-effectiveness of antimicrobial 
resistance prediction from WGS data in a routine diagnostic setting. The advances 
provided by WGS, combined with clinical outcome data, should greatly enhance 
our understanding of the genetic basis of antimicrobial resistance, molecular 
epidemiology and virulence traits.
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7.1 The continuing problem of antimicrobial resistance
Antimicrobial resistance among Enterobacteriaceae has progressively increased 
and has accelerated within the past 15 years. The spread of resistance is unlikely 
to stop and may compromise the value of established antimicrobial agents. 
The increase in resistance is mainly due to the spread of clones carrying genes 
encoding for extended-spectrum ß-lactamases or carbapenemases.1-3 A report 
from the European Center for Disease Prevention and Control published in 2009 
estimated that approximately 400,000 infections in Europe were associated with 
resistant strains, resulting in 25,000 extra deaths and 2.5 million extra hospital days.4 
The Dutch surveillance report NETHMAP 2013 indicates that 6% of the clinical 
Klebsiella pneumoniae and 8% of the Escherichia coli isolates recovered from 
unselected hospital departments are highly resistant microorganisms.5 Increasing 
resistance rates to 3rd generation cephalosporins are reported from 3.5% in 2008 
to 5.7% in 2012 for E. coli and from 4.0% to 7.5% for K. pneumoniae respectively. 
At present, cefuroxime and gentamicin are still used as empirical therapy in case of 
sepsis in the Leiden University Medical Center (LUMC). Given the rise of multidrug 
resistance and the mechanisms involved in Enterobacteriaceae in our hospital 
setting, it remains to be seen whether this will continue to be the appropriate choice.
Despite the recognized need for new antimicrobials for clinical use, the reality is that 
only two new classes of antibiotics, oxazolidinone and lipopeptide, active against 
Gram-positive bacteria have been brought to market in the past 14 years.6 The Pew 
Charitable Trusts is a large independent non-profit, non-governmental organization 
founded in 1948, that has assessed antibiotics currently in clinical development, 
which is available online and updated regularly (http://www.pewhealth.org/other-
resource/antibiotics-currently-in-clinical-development-85899541594).However, 
given the inevitability that some in development will fail to obtain final approval, it 
is clear that there are too few drugs in development to meet current and anticipated 
patient needs.
The aim of the research described in this thesis was to obtain more insight into 
the four principal mechanisms of antimicrobial resistance in multidrug resistant 
Enterobacteriaceae, recovered at the LUMC, the Netherlands. This discussion will 
try to define some useful future strategies, based upon the results of this thesis and 
the other recent insights that will first be briefly summarized.
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7.2 Necessity of rapid molecular detection 
Antibiotic resistance genes were present among clinical isolates at very low levels 
prior to the introduction of antibiotics, and it is largely the selective pressure of 
antibiotic use, not only in humans but also in pets and livestock, which has caused 
the rise. The increasing mobility of people across the globe has further contributed 
to the spread of antimicrobial resistance. The rise in antimicrobial resistance relates 
not only to the number of individuals infected or colonized with antimicrobial 
resistant Enterobacteriaceae, but also to the diversity of underlying resistance 
mechanisms, which will continue to increase in the years ahead. In multidrug 
resistant strains of today, it is common that all four of principal mechanisms play a 
role in resistance, with strains having multiple determinants affecting susceptibility 
to each antimicrobial agent.
As shown in all chapters of this thesis, molecular characterization of antimicrobial 
resistance mechanisms illustrates the heterogeneity of antimicrobial resistance 
mechanisms involved in multidrug resistant Enterobacteriaceae. Besides important 
transferable extended-spectrum ß-lactamases, CTX-M, SHV, TEM, OXA, plasmid 
mediated AmpC ß-lactamases, carbapenemases, other enzymes such as the 
plasmid-mediated quinolone resistance Qnr and AAC-6’-Ib-cr should be tested for 
Enterobacteriaceae. As described in chapter 2, 3, and 4 molecular characterization 
revealed that chromosomally-encoded resistance traits such as mutations in the 
GyrA, ParC, ParE, chromosomal efflux activity, c-AmpC with its promoter/attenuator 
region are of importance as well. Although multiplex PCR and sequence analysis, 
qRT-PCR and microarrays are well established methods, as used in various chapters 
of this thesis, their use is insufficient to investigate the numerous genes involved. 
In the current era of multidrug resistance, molecular tests need to be rapid and 
highly multiplexed and multifaceted in a single assay. Therefore, improved 
diagnostic approaches for the rapid and adequate detection of antimicrobial 
resistance, epidemiological markers and virulence characteristics are essential. 
Besides early and sensitive detection of resistance mechanisms by non-phenotypic 
tests, preventive measures and active surveillance will become more important in 
the near future.
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7.3 Implications for future strategies
7.3.1 Potential for whole genome sequencing
Microbiological laboratories play a central role in the combat against antimicrobial 
resistance trends by rapid and proper recognition of multidrug resistant 
Enterobacteriaceae. The use of phenotypic tests, PCR-based techniques and 
microarrays has all demonstrated their utility to detect resistance. To obtain a 
better understanding of the current molecular epidemiology and characteristics of 
multidrug resistant Enterobacteriaceae more information is required, e.g. the type 
of antimicrobial resistance mechanism, presence or absence of resistance genes 
and specific mutations conferring resistance. 
With the emergence of the new tools of whole genome sequencing (WGS), it allows 
to sequence full bacterial genomes in an efficient way. WGS enables an integrated 
approach to study the complete genome of a bacterial isolate, which can be 
determined within hours, providing identification to the species, its susceptibility to 
antibiotics, its virulence characteristics and epidemiological markers, as described 
in chapter 6. This technique has become fast, making WGS compatible with the 
routine microbiology workflow.7,8 A sample preparation method for rapid single 
colony WGS of different bacterial species has been validated for clinical use.9 It is 
therefore to be considered likely that applications of WGS will play an important 
role in the approach to antimicrobial resistance and the following paragraphs will 
discuss some relevant topics for future research, related to this development.
7.3.2 Understanding and predicting antimicrobial resistance 
First attempts to predict antimicrobial susceptibilities using WGS data in different 
species, such as Staphylococcus aureus,10 Mycobacterium tuberculosis 11 as well as 
for E. coli and K. pneumoniae 12 have been reported recently with promising results. 
Despite rapid advances in this field and major advantages of this technique, 
WGS for the detection of antimicrobial resistance is still not yet widely adopted 
by clinical microbiology laboratories. The WGS approach in the absence of any 
phenotypic support for the functionality of a resistance gene or mutation could lead 
to major errors (reported as resistant and actually susceptible) and preclude the 
use of potentially useful therapies. Conversely, the absence of an identifiable gene 
or mutation sequence does not guarantee susceptibility. To be used confidentially 
in clinical practice, reliable genotypic prediction of the antimicrobial resistance 
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phenotype has to be demonstrated to the same standards as any new phenotypic 
method, using large diverse sets of unrelated isolates. Comprehensively validated 
genotypic prediction of antimicrobial resistance, ready for implementation in clinical 
practice will require multiple large studies.
In fact, it is likely that phenotypic methods will continue to be used, at least for the 
near future, to screen microbial isolates for unrecognized resistance patterns, and, 
thus, their mechanisms of resistance, before gene-level inquiry is pursued. However, 
the need for routine phenotyping will diminish as laboratories increasingly use WGS 
data, combined with phenotypic data, to elucidate the contribution of all underlying 
genetics in resistance. Further investigation is required to determine to what extent 
it will be possible to rely on genotype alone. The need for phenotypic verification 
of the genotype might be partly circumvented by WGS transcriptomics using 
RNA-Seq, thus, providing direct evidence of functional resistance rather than using 
gene identification.13 
Although WGS is not suitable for resistance prediction in clinical practice yet, 
sequencing the whole genome provides full characterization of a bacterial strain, 
providing all genetic information on species identification, sequence type and 
virulence determination in a single test. WGS as a single platform for extracting all 
the information required is an attractive alternative in the routine diagnostic setting.
7.3.3 Routine typing and virulence determination 
In addition to resistance prediction, completely sequenced genomes can provide 
for epidemiological typing and detection of virulence genes. Analysis of sequence 
typing and virulence factors in clinically relevant isolates has already been found 
useful in outbreak investigations.14,15 Several studies using WGS have revealed 
that E. coli ST131 possess a variable complement of genes encoding established 
virulence factors in urinary tract infections.16,17 
For useful application in clinical microbiology, it is necessary to conduct the relevant 
WGS analysis in realtime. Routine typing, surveillance and outbreak detection of 
verotoxigenic E. coli is already applicable and may also be used for typing and 
surveillance of other pathogens.18 The expanded use of WGS in clinical microbiology 
has the potential to produce the equivalent of a HapMap for microbes 
(http://hapmap.ncbi.nlm.nih.gov/). When combined with data generated by 
the human HapMap, the risk of infection by specific strains or clones carrying 
characterized virulence factors in individuals of a particular haplotype could begin 
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to be assessed. Even more promising would be simultaneous genotyping of host 
and bacterial isolate, to define critical host factors in response to infection and 
progression of disease and treatment tailored to the patient’s host characteristics. 
7.3.4 Data management and reporting
Although WGS provides detailed information that will, in theory, enable routine 
diagnostic microbiology solely on the basis of the bacterial genomes, it is a 
formidable challenge to define and extract the appropriate information from the 
large amount of sequence data that is generated.19,20 Thus, to facilitate the use 
of WGS data for routine diagnostics, typing and surveillance, it is important that 
the sequence data can be automatically and quickly converted to clinically relevant 
information that can be easily interpreted without bioinformatics skills. At present, 
there are several databases for the investigation of antimicrobial resistance genes, 
including the Antibiotic Resistance Genes Database,21 Resfinder for acquired 
antimicrobial resistance genes22 and Antibiotic Resistance Cassette Database (RAC).23 
For bacterial typing, different comprehensible web-tools for WGS analysis are 
available, such as the Bacterial Isolate Genome Sequence Database (BIGSDB),24-26 
MLST predictor,27 and snp-Tree.28 VirulenceFinder, for detection of E. coli virulence 
genes has been added recently.29 While most of these databases are new and 
well updated, they have diverse sources. Reference data should be stored and 
maintained in one centralized, expandable and up-to-date database, e.g. to include 
novel resistance determinants. 
Predictions about the resistance and susceptibility need to be accurate for proper 
patient management. One solution is the creation of an international, online 
database, divided into two parts. The first part is a depository into which accredited 
diagnostic laboratories routinely deposit WGS data, combined with clinical and 
epidemiological data, from across the world. These data could provide for an 
expert panel to discuss and propose new markers for antimicrobial drug resistance 
or to link genotype directly to disease outcome. Harmonization of these genotypic 
markers could be modelled in an international up-to-date diagnostic WGS database 
for routine clinical microbiology laboratories with approved markers for automated 
WGS data interpretation.
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7.3.5 Screening for gastrointestinal colonization
Early detection of multidrug resistant Enterobacteriaceae (MDR-E) carriage could 
allow timely implementation of infection control measures and the appropriate 
selection of antimicrobials. On-admission surveillance for ESBL-E has been 
associated with a reduced incidence of MDR-E infections during hospitalization.30 
In 2013, a guideline for the detection of highly resistant microorganisms (HRMO) 
has been implemented nationally.31 Patients are placed in contact isolation and 
screened for HRMO-carriage, if patients are transferred from a foreign hospital, or if 
they come from any ward with an ongoing outbreak.31
Travel to geographic areas with high prevalence of antimicrobial resistant bacteria 
has been shown to be a risk factor for the acquisition of MDR-E.32 Prospective 
cohort studies among travelers returning from Australia, Canada, Sweden and New 
York revealed high carriage rates of varying from 18-25% after foreign travel 33-36 
and showed that travel to India or the Indian subcontinent was the highest risk 
factor. The study presented in chapter 5 also highlighted international travel as a 
significant risk factor for the acquisition of MDR-E. The high pre- and post-travel 
carriage rate of 8.6% and 30.5% of MDR-E respectively as found in chapter 5 has 
recently been confirmed in another group of 122 returning healthy travelers from 
the Netherlands.37 The high rates of ESBL fecal colonization as found in chapter 5 
highlights the importance of a targeted screening strategy for Dutch hospitals. The 
present results implicate that it is necessary to perform active surveillance of MDR-E 
in patients on admission, who returned from Asia during the previous 6 months, 
which are not considered to be high risk carriers yet. 
Colonization of healthy subjects with antimicrobial resistant Enterobacteriaceae 
could contribute to the amplification of resistance both in the community and 
nosocomial settings.38-40 Metagenomic analysis of the fecal microbiome of 162 
individuals from Denmark, Spain and China were compared to environmental 
and agricultural metagenomic data sets. The presence of resistance genes was 
significantly higher in the gut microbiome, reaching an average of 0.266% of the 
total number of gut genes. Individuals from China showed the highest diversity of 
resistance genes, whereas individuals from Denmark showed the lowest levels of 
diversity and abundance.41 Another study on the gut microbiome also found a higher 
abundance of resistance determinants in the microbiota of individuals from Spain, 
Italy and France compared with individuals from Denmark, the United States and 
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Japan42 WGS directly on rectal swabs may allow realtime generation of locally and 
nationally relevant epidemiological data, allowing strains to be tracked, their relative 
importance evaluated and control efforts to be meaningfully targeted. Furthermore, 
the higher level of discrimination will permit the detection and monitoring of newly 
emerging strains. Linked with clinical surveillance data, this could provide as early 
warning system. 
7.4 Culture-free sequencing 
WGS technology is developing at incredible speed and has already transformed 
the research landscape in microbiology. In the next five years, future developments 
of workflow and pipelines will facilitate research on antimicrobial resistance 
mechanisms, genes, virulence markers and epidemiological profiling in a diagnostic 
setting.43-45 Full bacterial genomes can already be obtained from a single DNA 
molecule using the PacBio long-read, single cell molecule, real-time sequencing 
technology.46-48 This technique has recently been used to investigate the resistome 
of cow manure, in which novel and diverse antimicrobial resistance determinants 
conferring resistance to chloramphenicol, kanamycin, tetracycline, or ß-lactam 
antibiotics were found.49 
If we assume that WGS will become increasingly affordable, rapid, and simple to 
use and that technologies and databases will evolve to the extent that WGS will 
be highly reproducible and reliable, application in clinical microbiology directly on 
clinical samples seems a matter of time. Current and realistic future applications of 
WGS in routine clinical microbiological laboratories are illustrated in Figure 1.
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Figure 1. A comparison of the current and future methods in routine clinical microbiology
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The eventual adaptation of WGS in every clinical laboratory will provide all 
information: identification to the species, its susceptibility to antibiotics, its virulence 
characteristics and epidemiological markers. Because results are obtained rapidly, 
WGS may ultimately replace most if not all current phenotypical microbiological 
methods. If WGS would fulfill such expectations, this will revolutionize diagnostics 
and clinical practice. Empirical antibiotic treatment will be reduced in time to a 
minimum or tailored therapy may even be started immediately. Furthermore, 
monitoring and surveillance of antimicrobial resistance could be performed in real-
time. 
Another promising approach is sequence-based metagenomics, which involves 
extracting and random sequencing of DNA directly from a variety of environment 
(e.g. soil, agriculture, livestock, river/sea/lake, aquaculture and the human gut) 
including DNA from uncultured bacteria.50-53 The application of metagenomics 
will not only facilitate future identification of novel resistance mechanisms, but will 
be used for the prediction of antibiotic resistance and distinct host features, for 
example in the human microbiome.54
To be fully useful, WGS data will have to be shared on local, national and international 
level; integrated post-genomic approaches to store epidemiological and genomic 
data are under development.55, 56 In this respect we could and should learn from 
micro-organisms who survive thanks to their ability and practice to exchange 
resistance information rapidly. Enterobacteriaceae readily exchange information at 
a high speed and so should we.
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In de gezondheidszorg wordt de behandeling van bacteriële infecties met 
antibiotica in toenemende mate bemoeilijkt door het voorkomen van bacteriën, 
die resistent zijn tegen meerdere soorten antibiotica. De zogenaamde eerste-, 
tweede- en soms ook derdelijns antibiotica zijn steeds vaker onbruikbaar als gevolg 
hiervan. Het in de afgelopen jaren sterk toegenomen gebruik van antimicrobiële 
middelen, zowel binnen als buiten het ziekenhuis, ligt zonder twijfel ten grondslag 
aan deze ontwikkelingen. Antibioticagebruik, en dan vooral suboptimaal, langdurig 
of herhaald, is de belangrijkste factor die leidt tot selectie en verspreiding van 
resistente bacteriestammen. Maar ook het gebruik ervan in de veeteelt kan via 
vleesconsumptie, direct contact met dieren of besmetting van het milieu leiden 
tot ongewenste verspreiding van resistente bacteriën. Tot slot kan reizen naar het 
buitenland leiden tot import van resistente bacteriën.
Het is duidelijk dat de ziektelast van resistentie in Europa toeneemt. 
Een schatting is dat dit neerkomt op zo’n 25.000 extra sterfgevallen per jaar 
en 2,5 miljoen extra ziekenhuisligdagen. Wanneer multiresistente bacteriën infecties 
veroorzaken, is de gebruikelijke behandeling met antibiotica soms onwerkzaam en 
treedt dus een vertraging op in de behandeling. Daarnaast vergt het geïsoleerd 
verplegen van deze patiënten extra inspanningen en is belastend voor zowel 
het ziekenhuispersoneel als voor de patiënt. Verder nemen ook de kosten voor 
verpleging en verzorging toe. Ook bij patiënten, die buiten het ziekenhuis een 
infectie oplopen en niet een medische voorgeschiedenis hebben waarin van 
antibioticumgebruik sprake is, wordt een multiresistente bacterie steeds vaker 
gevonden als oorzakelijk agens. 
Bij een ernstige infectie wordt microbiologische diagnostiek ingezet om de 
oorzakelijke bacterie te determineren en tevens de gevoeligheid voor antibiotica 
te bepalen. Er zijn verschillende methoden om deze gevoeligheid te meten. Veelal 
wordt antibioticaresistentie bepaald door middel van geautomatiseerde apparatuur. 
Dit gebeurt op basis van optische meting van bacteriële groei in reeksen met 
verschillende antibioticaconcentraties. Zowel de kweek- als de geautomatiseerde 
methode levert een uitslag die verdeeld kan worden in gevoelig (S), intermediair 
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gevoelig (I) of resistent (R). Dit geeft echter geen informatie over de achterliggende 
resistentiemechanismen, die hieraan ten grondslag liggen. Ook duurt dit proces 
enkele dagen totdat de definitieve uitslag bekend is.
 
Resistentiemechanismen
Resistentie tegen antibiotica bij bacteriën kan een gevolg zijn van verschillende 
resistentiemechanismen. De bacteriële resistentiemechanismen zijn:
1. Productie van een enzym dat het antibioticum inactiveert.
2. Veranderingen in het aangrijpingspunt, waarop het antibioticum werkzaam is.
3. Een verhoogde activiteit van efflux pompen, waardoor het antibioticum naar 
buiten wordt gepompt.
4. Barrières om de bacterie binnen te dringen door een verandering in permeabiliteit 
van de celmembraan, bijvoorbeeld door verlies van buitenmembraaneiwitten 
op de bacteriële celwand, zodat een antibioticum niet meer wordt opgenomen.
Een bacterie kan zowel een intrinsieke als een verworven resistentie hebben tegen 
een antibioticum. Intrinsieke resistentie is een stabiele genetische eigenschap 
die gecodeerd is in het bacteriële chromosomale DNA. Intrinsieke antibiotica-
resistentiegenen kunnen permanent actief zijn of geïnduceerd worden door de 
blootstelling aan een specifiek antibioticum. Een bacterie kan ook resistent zijn 
door een intrinsieke eigenschap zoals het ontbreken van een bindingsplaats 
voor een specifieke antibioticum. Bacteriën kunnen ook resistentie verwerven 
door een mutatie in het bacteriële chromosomale DNA. In de meeste gevallen 
van verworven resistentie hebben bacteriën verschillende stappen nodig, waarbij 
elke stap op zich slechts een lichte verandering in gevoeligheid geeft. Bestaande 
resistentiemechanismen kunnen ook actiever worden door bijkomende mutaties. 
Behalve door mutaties kunnen bacteriën resistentie ontwikkelen door het verwerven 
van nieuw genetisch materiaal. Sommige bacteriën wisselen chromosomaal 
DNA uit in een proces dat transformatie heet. Het nieuw ingebrachte DNA 
kan recombineren met vergelijkbare sequenties in het chromosomale DNA 
van de ontvangende bacterie. Transformatie zorgt voor genetische variatie 
die zich vooral verspreid van de ’moeder-’ naar de ’dochtercel’ (verticaal). 
Daarnaast kunnen bacteriën mobiele genetische elementen bevatten: plasmiden, 
(conjugatieve) transposonen en integronen. Genetische informatie die aanwezig is 
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in deze elementen kan worden overgedragen tussen verschillende stammen van 
één bacteriesoort en tussen verschillende bacteriesoorten. Dit wordt horizontale 
genoverdracht genoemd. De mobiele genetische elementen vergroten de 
mogelijkheid tot overdracht van resistentiegenen en resistentieontwikkeling. 
Voor een effectief antibioticumbeleid is meer inzicht nodig in de epidemiologie van 
de onderliggende antimicrobiële resistentiegenen van multiresistente bacteriën, de 
verspreiding van deze resistentiegenen en de factoren die bijdragen aan de selectie 
en de transmissie van multiresistente bacteriën. Het identificeren en karakteriseren 
van resistentiegenen van een groot aantal isolaten is echter zeer arbeidsintensief. 
De nieuwe generatie sequencing-technologieën, de zogenaamde ‘next-generation 
sequencing’ (NGS) technieken, zijn in staat grotere stukken DNA tegelijkertijd te 
sequencen en dus geschikter voor het ontrafelen van hele genomen. Hierdoor kan 
binnen korte tijd een enorme hoeveelheid DNA-sequentie worden geproduceerd. 
In dit proefschrift zijn de resistentiemechanismen bij Enterobacteriaceae 
bestudeerd. Enterobacteriaceae zijn normale darmbewoners, die op andere 
plaatsen in het lichaam milde tot levensbedreigende infecties kunnen veroorzaken. 
Enterobacteriaceae zijn Gram-negatieve staven en de meest voorkomende zijn: 
Escherichia coli, Klebsiella en Enterobacter. Minder vaak worden Proteus, Serratia, 
Citrobacter en Morganella gevonden. Voor alle genoemde species geldt, dat ze over 
diverse resistentiemechanismen tegelijk kunnen beschikken en zich in toenemende 
mate manifesteren als multiresistente bacteriën. 
De snel toenemende resistentie tegen antibiotica in deze groep van bacteriën is 
voor een belangrijk deel toe te schrijven aan de productie van extended-spectrum-
ß-lactamases (ESBLs) en AmpC ß-lactamases. Deze enzymen zijn in staat de meest 
voorgeschreven antibiotica, cefalosporines, tegen infecties met Enterobacteriaceae 
onwerkzaam te maken. Een ander veelgebruikt antibioticum is ciprofloxacine, 
welke behoort tot de klasse van de fluoroquinolonen. Ciprofloxacine is een 
breedspectrum antibioticum dat zowel tegen Gram-positieve als Gram-negatieve 
bacteriën werkzaam is. Het blokkeert de DNA replicatie door te binden aan DNA 
gyrase, waardoor tweezijdige breuken in het DNA ontstaan. Selectie voor bacteriën 
met puntmutaties in de genen die coderen voor DNA gyrase en topoisomerase IV 
(gyrA, gyrB, parC and parE) zijn lang veronderstelt als belangrijkste oorzaak voor 
resistentie tegen ciprofloxacine. Naast puntmutaties op het bacteriële chromosoom 
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zijn ook plasmid-geassocieerde mechanismen, zoals de genen qnr en aac-(6’)-Ib-cr. 
Ook kan een verhoogde activiteit van effluxpompen en/of verlies van porines op de 
bacteriële celwand bijdragen aan resistentie tegen fluoroquinolonen.
Hoofdstuk 2
In hoofdstuk 2 is de moleculaire karakterisering van antimicrobiële resistentie 
genen in 68 multiresistente Enterobacteriaceae, afkomstig van verschillende LUMC-
patiënten in het jaar 2008 beschreven. Met behulp van moleculaire technieken (PCR) 
zijn de chromosomale genen gyrase A, gyrase B, parC en parE in kaart gebracht. 
Daarnaast is onderzocht of deze bacteriën de plasmidaal-gecodeerde genen qnrA, 
qnrB, qnrS, aac(6’)-Ib-cr en qepA bevatten. Ook werd de aanwezigheid van ESBLs 
onderzocht. Tenslotte is clonale verwantschap van de Escherichia coli isolaten 
onderzocht.
In totaal werden 49 E. coli, 16 Klebsiella pneumoniae and 3 Enterobacter cloacae 
isolaten onderzocht. In alle E. coli isolaten werd een mutatie in het gyrase A gen 
gevonden. In 45 (92%) van de E. coli isolaten werd tenminste 1 mutatie in het parC 
gen gevonden. In 59% van de E. coli isolaten waren ook mutaties in het parE gen 
aanwezig. De meest voorkomende mutatie in het parE gen was I529L, welke was 
geassocieerd met E. coli met sequentie type 131 (ST131). 
Bovendien werd in 29 E. coli isolaten een ESBL gen gevonden; de meest 
voorkomende was blaCTX-M-15. In de onderzochte Klebsiella isolaten werden 
voornamelijk de plasmidaal gecodeerde qnr, en aac(6’)-Ib-cr genen samen met 
ESBL genen (n=13; blaCTX-M and blaSHV) en/of blaampC (n=3; blaDHA-1) aangetoond. 
E. coli isolaten hebben voornamelijk chromosomale mutaties, die leiden tot 
resistentie tegen fluoroquinolonen. De I529L mutatie in het parE gen komt in de 
meeste, maar niet in alle ST131 isolaten voor. In tegenstelling tot de E. coli isolaten 




Het onderzoek in hoofdstuk 3 beschrijft een studie naar de verhoogde activiteit 
van effluxpompen in 47 E. coli stammen, met een verminderde gevoeligheid voor 
ciprofloxacine en cefalosporines, afkomstig van verschillende LUMC-patiënten 
in het jaar 2008. Het doel van deze studie was te onderzoeken of verhoogde 
efflux pompactiviteit bijdraagt aan resistentie tegen fluoroquinolonen in E. coli 
isolaten. De activiteit van effluxpompen is bestudeerd met een geoptimaliseerde 
fluorometrische methode met behulp van bisbenzimide als fluorescentiemarker. 
De expressie van effluxpomp genen zoals acrA, acrB, tolC, yhiV en mdfA zijn 
onderzocht met behulp van kwantitatieve real-time reverse transcriptie-PCR (qRT-
PCR). Ook zijn de expressieniveau‘s van de buitenmembraan-eiwitten ompF en 
ompX bepaald.
Met behulp van de RT-PCR methode kon in 35 isolaten overexpressie van messenger 
RNA van ≥1 efflux pomp aangetoond worden. Met behulp van de fluorometrische 
methode werd in 6 isolaten een verhoogde efflux pomp activiteit aangetoond. 
Alleen de gecombineerde overexpressie van acrAB-TolC en mdfA correleerde met 
de resultaten van de fenotypische fluorometrische methode. De bijdrage van actieve 
effluxpomp activiteit aan de resistentie tegen fluoroquinolonen was beperkt.
Hoofdstuk 4
In een tweede onderzoek naar cefalosporine resistentie, beschreven in hoofdstuk 4, 
is in 49 klinische E. coli isolaten onderzocht of een verhoogde expressie van het 
AmpC enzym de oorzaak is van resistentie tegen cefoxitin en of dit van invloed is 
op de activiteit van 3e generatie cefalosporinen. 
Negen van 33 (27,2%) cefoxitin-resistente isolaten (minimaal remmende concentratie 
(MIC) > 8 mg/L) toonde hyperproductie van chromosomaal AmpC (c-AmpC) op 
basis van (i) ten minste twee positieve fenotypische testen met AmpC-remmers, 
(ii) mutaties in de promoter/attenuator gebieden en (iii) een 6,1 tot 163-voudige 
toename van c-AmpC expressie door kwantitatieve RT-PCR. In de ESBL-negatieve 
isolaten waren de MICs van ceftazidim en cefotaxim meestal boven wildtype 
niveau, maar onder het S/I breekpunt (EUCAST richtlijn), met uitzondering van 
één isolaat met MICs van 4 mg/L. Er werden geen plasmidaal gecodeerde AmpC 
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genen aangetoond. Periplasmatische extracten (uit de ruimte tussen de binnenste 
celmembraan en buitenste membraan) van 9 c-AmpC hyperproducerende isolaten 
werden vooraf geïncubeerd met of zonder cefuroxim of ceftazidim en met behulp 
van SDS-PAGE geanalyseerd. Cefuroxim en ceftazidim waren bestand tegen 
hydrolyse maar fungeerden als remmers van het enzym. Geen van deze isolaten 
toonde verlies van buitenmembraaneiwitten. 
Uit deze studie is gebleken dat resistentie tegen cefoxitin niet specifiek is voor 
c-AmpC hyperproducerende stammen. c-AmpC hyperproducerende E. coli isolaten 
zijn meestal nog steeds gevoelig voor de 3e generatie cefalosporinen, maar wel 
minder gevoelig dan wildtype E. coli. Monitoring van cefoxitin-resistente E. coli 
op de ontwikkelingen in de resistentie tegen de 3e generatie cefalosporines wordt 
aangeraden.
Hoofdstuk 5
Nederlanders reizen steeds meer naar verre bestemmingen waar relatief veel 
resistente bacteriën voorkomen. In deze prospectieve cohortstudie is onderzocht in 
hoeverre resistente darmbacteriën worden opgelopen tijdens deze verre reizen, hoe 
lang men deze bacteriën bij zich blijft houden en of deze ‘import-bacteriën’ zich ook 
verspreiden onder niet-reizende huisgenoten. Het gaat hierbij om dragerschap van 
carbapenemase producerende Enterobacteriaceae (CP-E) en extended-spectrum-
ß-lactamase producerende Enterobacteriaceae (ESBL-E) en de geassocieerde 
risicofactoren. Er werden bij 370 Nederlandse reizigers van de Travel Clinic van het 
LUMC en de GGD Hollands Midden vragenlijsten en rectumuitstrijken afgenomen 
vóór en na terugkeer van een buitenlandse reis. De ESBL-enzymen werden 
gekarakteriseerd met behulp van een micro-array (Check-Points BV). Bovendien zijn 
alle E. coli isolaten getypeerd. Van 370 reizigers waren 32 (8,6%) gekoloniseerd 
met ESBL-E voor de reis, 113 (31%) verwierf een ESBL-E en 26 reizigers waren 
zes maanden na terugkeer nog gekoloniseerd. Er werden geen CP-E gevonden 
in deze studie. Onafhankelijke risicofactoren voor ESBL-E dragerschap waren 
reizen naar Zuid- en Oost-Azië. Typering van de E. coli isolaten toonde uitgebreide 
genetische diversiteit. CTX-M enzymen waren het overheersende ESBL-type, dat 
werd gevonden. Het percentage ESBL-E dragerschap na een buitenlandse reis in 
Nederlandse reizigers was hoog (31%). Actieve surveillance van ESBL-E en CP-E 
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en minimaal contactisolatie voorzorgsmaatregelen worden aanbevolen bij opname 
van patiënten, die in de afgelopen 6 maanden naar Azië hebben gereisd.
Hoofdstuk 6
De nieuwe generatie sequencing-technologieën, de zogenaamde ‘next-generation 
sequencing’ (NGS) technieken, zijn in staat grotere stukken DNA tegelijkertijd te 
sequencen en dus geschikter voor het ontrafelen van hele genomen. Hierdoor kan 
binnen korte tijd een enorme hoeveelheid DNA-sequentie worden geproduceerd. 
In hoofdstuk 6 zijn 10 goed gekarakteriseerde klinische E. coli isolaten geselecteerd 
voor sequentie analyse met behulp van de Ion Torrent bench-top sequencer. 
In deze isolaten is de aanwezigheid van antimicrobiële resistentie mechanismen 
voor ß-lactam antibiotica, fluoroquinolonen, aminoglycosiden en co-trimoxazol 
onderzocht. Bovendien werd Ion Torrent sequentie analyse gebruikt om de isolaten 
te typeren en de aanwezigheid van 13 virulentiegenen te bepalen. Resultaten 
werden vergeleken met conventionele PCR en sequenties voor 18 antimicrobiële 
resistentiegenen. Voor 17 antimicrobiële resistentiegenen waren de NGS resultaten 
vergelijkbaar met conventionele PCR en sequentieanalyse. Alleen de SHV genen 
waren moeilijk te identificeren vanwege een lage dekkingsgraad van dit gen. 
Daarnaast is met behulp van NGS de aanwezigheid van 13 virulentiegenen 
geïdentificeerd. Tenslotte kon met deze techniek ook in alle gevallen het correcte 
sequentietype worden vastgesteld. NGS met behulp van de Ion Torrent sequencer 
van klinische isolaten maakt het mogelijk om het hele genoom van een bacterie te 
onderzoeken in één test.
Conclusie
Zoals weergegeven in alle hoofdstukken van dit proefschrift toont moleculaire 
karakterisering van antimicrobiële resistentie mechanismen de heterogeniteit aan 
van antimicrobiële resistentiemechanismen in multiresistente Enterobacteriaceae. 
Naast de belangrijke overdraagbare ESBL-enzymen, CTX-M, SHV, TEM, plasmidaal-
gemedieerde AmpC ß-lactamasen en carbapenemases zouden multiresistente 
isolaten in elk geval ook onderzocht moeten worden op de aanwezigheid van 
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andere resistentie genen, zoals de plasmidaal-gemedieerde resistentie genen qnr 
en aac-6’-Ib-cr.
Zoals beschreven in hoofdstuk 2, 3, en 4 is met moleculaire karakterisering gebleken 
dat chromosomaal gecodeerde resistentie, zoals de mutaties in GyrA, ParC, ParE, 
chromosomale efflux activiteit, c-AmpC met zijn promoter/attenuator regio ook 
een belangrijke rol spelen. Hoewel verschillende technieken als multiplex PCR en 
sequentieanalyse, qRT-PCR en microarrays zijn gebruikt in verschillende hoofdstukken 
van dit proefschrift, is het gebruik hiervan niet toereikend om alle betrokken genen 
te kunnen onderzoeken. In het huidige tijdperk van multiresistente bacteriën zijn 
moleculaire technieken nodig, die het hele genoom kunnen onderzoeken in één test. 
 
De toepassing van NGS in een klinisch microbiologisch laboratorium zal alle 
informatie verstrekken: de identificatie van de species, de gevoeligheid voor 
antibiotica, de virulentie kenmerken en typering en tenslotte ook de hoeveelheid 
van de aanwezige species. Mogelijk kan NGS uiteindelijk de meeste, zo niet alle 
huidige fenotypische microbiologische methoden vervangen. Als NGS aan deze 
verwachtingen kan voldoen, zal dit een revolutie betekenen in de microbiologische 
diagnostiek en de klinische praktijk. Naast het gebruik van snelle en gevoelige 
detectie van resistentiemechanismen door niet-fenotypische testen, zal actieve 
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Louis Kroes, mijn promotor, voor de nuchtere kijk op de zaak, het einddoel helder 
krijgen en de ruimte die jij me gaf om onderzoek te doen. Vooral je ondersteuning 
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ik erg gewaardeerd.
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Anne-Marie van Welzen, Jouraima Ras, Ivo Kors, Yi Li, Anouk Tengeler en Romy 
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Onze samenwerking heeft veel voor me betekend. In november 2012 had ik de eer 
om naast je te staan bij jouw promotie. Bedankt dat jij nu mijn paranimf wilt zijn. 
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Een goede werksfeer is belangrijk, maar vriendschap buiten het vak mogelijk nog 
meer. Dus daarom wil ik ook mijn vrienden en vriendinnen bedanken voor alle 
ondersteuning en meeleven, gezellige etentjes en ontspannende gesprekken.
Elise, Bernard en Norbert: bedankt voor al jullie steun en vertrouwen tijdens de 
afronding van mijn proefschrift.
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Er is zoveel meer dan alleen opleiding, werk en onderzoek. Onze dochters Jiya 
(2009) en Jahnavi (2013) maken het leven waard om geleefd te worden.
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